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Summary
Phosphodiesterase 4 (PDE4) is a family o f around 20 cyclic AMP (cAMP) hydrolysing 
enzymes. Expression o f each isoform is regulated in a tissue and developmental specific 
manner. Such regulation suggests as yet undefined functions for each isoform. 
Understanding these functions will highlight likely therapeutic targets. I have employed 
various methods to identify possible functional roles for various PDE4 iso form s.
PDE4B4 is a novel enzyme cloned from a rat brain cDNA library. By characterising the 
biochemical properties o f this isoform in comparison to known, previously characterised 
members o f the PDE4B family, I highlighted similarities and differences within this sub­
family. Recombinant PDE4B4 was characterised in a COS-1 cell, temporary expression 
system. 1 demonstrated that PDE4B4 has a molecular weight lying between PDE4B1 and 
PDE4B2, is largely cytosolic, has a relatively low Km cAMP and is highly sensitive to 
inhibition by rolipram. As it has a UCRl region it conforms to long form structure and is 
activated by PKA. It has an extreme N-terminal region homologous to PDE4D3 and 
behaves in a similar way in response to PKA phosphorylation.
Development o f macrophages from monocytes involves differential expression of various 
biochemical mediators. I developed a cell line model using the U937 pro-monocytic cell 
line and compared it against ex-vivo monocytes cultured in plastic. Using this model 1 
identifies developmental changes in PDE4 isoform expression. PDE4A activity increased 
dramatically which was due in part to novel expression of PDE4A10. PDE4D isoform 
expression was entirely lost with no im munologically detectable enzyme present in 
macrophage like cells. PDE4B2 expression more than doubled in the mature cell. Loss of 
PDE4D and gain o f PDE4B2 represents a shift from long to short form PDE4 dominance. I 
demonstrated a resultant switch in PDE4 response to extracellular signal related kinase 
(ERK) activation. Thus in monocytic cells EGF resulted in a decrease in total PDE4 
activity, while in macrophage like cells PDE4 activity increased.
To demonstrate a role for PDE4 in regulating macrophage function I stimulated the RAW 
264.7-macrophage cell line with EPS in the presence o f rolipram. 1 demonstrated a PGE2 
dependent increase in iNOS expression and a PGE2 independent increase in C 0X 2 
expression. Such differential effects, suggests a compartmentalisation o f rolipram’s action. 
Inhibition of T N F a production was not dependent on PGE2 production. 1 then found that 
LPS activates PDE4 in an ERK dependent manner, but inhibits PDE3, highlighting further
compartmentalisation o f cAMP regulation. PDE4 activation was in part due to ERK 
dependent activation of the short form PDE4B2, downstream of LPS stimulation of RAW 
cells. Such activation may be associated with physical interaction between members o f the 
ERK signalling cascade and PDE4B2.
Next I demonstrated that crosstalk between ERK signalling and cAMP occurs in the 
opposite direction as rolipram leads to an early and elevated activation of ERK 1/2 in LPS 
stimulated RAW 264.7 macrophages. In an attempt to explain this effect I used rap 1 
activation and PKA phosphorylation mutants, transfected into RAW cells to interfere with 
normal inflammatory signalling. No significant changes were observed in these studies.
Finally I attempted to develop HIV-tat, PDE4 N-terminal, fusion proteins to inhibit 
individual PDE4 isoforms. I used primers encoding the HIV-tat peptide and PDE4 
sequence to produce a cDNA fusion. This was cloned into a GST-expression vector and 
transformed into E-coli. Recombinant protein was expressed and purified using sepharose 
beads. Various problems were encountered in the course o f this project, including the 
development o f appropriate cloning primers and the production o f proteins in inclusion 
bodies. The strategies employed to resolve these difficulties are discussed.
Two further experiments are discussed. Firstly rolipram was found not to affect tritiated 
thymidine incorporation into proliferating HEK cells. This work argues against a role for 
PDE4 in regulating cell cycle in these cells. I also attempted to characterise PDE4 activity 
from the induced sputum of normal subjects. While PDE4 activity was found to survive the 
isolation process the intra-subject variability meant that useful interpretation o f fluctuations 
based on therapeutic intervention would be impossible.
In conclusion I have characterised a new member o f the PDE4B family. It shares many 
characteristics with other members o f the sub-family and long form PDE4 enzymes in 
general. I have shown upregulation o f PDE4A10 and PDE4B2 in the maturation o f 
macrophages and the loss o f long form PDE4D3 and PDE4D5. This was found to have 
biochemical significance. PDE4B2 was shown to be important in the regulation o f LPS 
activation o f RAW cells and ERK/PDE4 crosstalk was found to occur in both directions. 
Rolipram was demonstrated to influence the behaviour of stimulated macrophages in a 
compartmentalised fashion, while LPS was found to activate PDE4 and inhibit PDE3. 
Finally I was unsuccessful in the development o f a novel strategy for inhibiting individual 
PDE4 isoforms, by developing an HIV-tat fusion protein.
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........................to reflect that these elaborately constmcted forms, so different from each
other, and dependent on each other in so complex a manner, have all been produced by 
laws acting around us.
........................................................................................................................................ There is
grandeur in this view o f life, with its several powers, having been originally breathed into a 
few forms or into one; and that, whilst this planet has gone cycling on according to the 
fixed law o f gravity, from so simple a beginning endless forms most beautiftil and most 
wonderful have been, and are being, evolved.
Charles Darwin 
(fi'om The Origin of Species)
Chapter 1 Introduction
1.1 Biological diversity
Darwin identified species diversity as the stimulus to scientific investigation that 
eventually led to our modern understanding o f evolution. Careful cataloguing inspired 
observation, thoughtful interpretation and the willful incorporation o f  ideas from different 
scientific disciplines all led to the theory. Appreciating the similarities and differences 
between species has led to greater understanding o f animal behavior and interaction in 
nature. Recently similar methods have been applied across biological science disciplines. 
Understanding molecular diversity offers the modern investigator the keys to unlocking the 
complexity o f the cell, as species diversity did for nature 150 years ago. That it takes just
30,000 genes to produce a fully mature human suggests there is little redundancy in the 
expressed genome and that each transcribed gene serves a specific or multiple defined 
purposes. Understanding the purpose o f each gene or protein product will eventually lead 
to a fuller understanding o f biological life. One means o f achieving these insights is to 
compare proteins with a high level of sequence homology and to identify how they differ. 
Just as Darwin observed with Galapagos finches such differences might reveal structural 
adaptations designed to fulfill specific purposes.
Families of molecules generated by gene duplication exist abundantly within the genome. 
The phosphodiesterase (PDE) family o f cyclic nucleotide hydrolysis enzymes is such a 
family. This thesis represents work performed to observe the characteristics of one sub­
family of this group, the PDE4 family, within the context o f inflammation and specifically 
with reference to macrophage function. By observing differential behavior o f PDE4 
isoforms I hope to gain insights into the overall role o f these moleeules in regulating 
inflammation.
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This introduction will begin by describing the molecular diversity o f cAMP signaling 
apparatus before focussing on the PDE4 family itself. I will describe previous insights into 
PDE4 in inflammation generally and then discuss macrophages in detail. Finally I will 
describe work that has looked at PDE4 and cAMP regulation o f some key macrophage 
mediators that I will later expand on in the experimental sections.
1.2 Cyclic amp signaling
Cyclic AMP (cAMP), signalling can be considered in three phases, synthesis, detection 
and hydrolysis. Enzymes involved at each step o f this process exist as multiple isofoims. 
Figure 1.1 illustrates the different levels of diversity.
1.2.1 An Overview
Cells reeeive inform ation from extracellular signals that m ust be transformed into 
intracellular information to produce behavioural change. The discovery in the late 1950’s 
of cyclic AMP by Sutherland et al, introduced the era o f the second messenger [1]. These 
are a diverse family o f molecules allowing signal amplification and refinement. Cyclic 
AMP and its relative cyclic GMP are cyclic purine nucleotides synthesised from their 
respective triphosphate preeursors by cyclase enzymes. In response to various ligands, G sa 
coupled receptors activate adenylyl cyclase which produces cAMP. Due to the high 
availability o f its substrate ATP, adenylyl cyclase (AC) operates at Vmax when active. 
Therefore the levels of cAMP generated by a signal depend partially on adenylyl cyclase, 
but also on the rate of degradation.
The sole means o f degrading cyclic nucleotides and thus signal limitation are hydrolysing 
enzymes called phosphodiesterases [2]. These enzymes form a family of cAMP specific, 
cGMP specific or dual specificity 3 ’,5 ’cyclic nucleotide hydrolysing enzymes [3]. 
Normally they function at less than Vmax and can be up or down regulated in activity to
Membrane associated 
Soluble GPCR: eg EPI g PCR: eg (32 receptor
Adnylyl 
Cyclases
cAMP specific PDE
Dual specific PDE
EPAC/Rapl Pka
Fig 1.1 Multiple signalling proteins involved in regulating cAMP signal transduction
Many proteins that influence cAMP signals exist as multi-member families. Illustrated 
above are the PDE and Adenylyl cyclase families and some o f  the factors that influence 
their activity.
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limit or enhance a cyclic nucleotide signal and can therefore influence both the magnitude 
and the duration of a signal [4].
I will describe the molecular diversity o f each level o f cAMP regulation and attempt to 
demonstrate functional significance for this molecular variation.
1.2.2 Adenylyl Cyclase
At least 9 adenylyl eyclase (AC) genes exist encoding AC types 1-9 [5] with differential 
splicing of the inRNA products o f AC5, AC6 and ACS, increasing molecular diversity [6]. 
Each AC contains 2 membrane-spanning units called Mi and M 2 and 2 catalytic units Cj 
and C2 . Each M unit consists of 6 transmembrane domains with an ion channel like 
structure [5]. Further complexity exists due to splice variation of the C sub-units resulting 
in CiA  and CiB isoforms and C 2 A and C2 B isoforms [7] with CiB containing many 
regulatory domains[8]. Significant degrees o f molecular diversity therefore exist at the 
point of cAMP synthesis.
Molecular diversity underlies differential AC activation and regulation [8]. Thus while 
most AC enzymes are activated by the GTP bound form o f G-protein S a  (GTP-Gsa) and 
Forskolin, AC 9 is not, [9, 10]. AC isoforms are under specific regulatory control. For 
example, inhibition o f AC by Mn^"" occurs to different degrees in different AC isoforms 
[11]. Inert purine rings can inactivate AC by P site inactivation. AC iso forms are 
differentially regulated by such P site inhibitors, [12]. The G protein G ia  selectively 
inhibits AC5 and AC6, while PKC can specifically activate AC2 [8] [13]. Finally, while 
the G protein complex G^y inhibits the function of AC 1 it synergises with G sa, in the 
activation o f AC2 and AC4 [14]. Molecular diversity therefore translates into isoform 
specific biochemical regulation.
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Granneman et al demonstrated the physiological significance o f molecular differences in 
brown adipose tissue where a variety o f AC isoforms are expressed. Cyclic AMP 
production was increased by {32 agonists, but only AC3 activity was increased [15]. 
Diversity o f the molecular structure o f AC isoforms has therefore been shown to have 
biochemical and functional significance.
1.2.3 Cyclic AMP detection
Until recently it was believed that the sole means of propagating a cAMP signal was to 
activate protein kinase A (PKA). This remains an important downstream target, but has 
been joined by a small G-protein Effector Factor (GEF) molecule called EPAC.
1.2.3.1 Protein Kinase A
Protein kinase A (PKA) is a heterotetramer composed of two regulatory and two catalytic 
subunits termed R and C, forming a holoenzyme term ed R 2 C2 [16, 17] for which the 
crystal structure has been solved [18, 19]. PKA is activated by cAMP binding to the R 
subunit leading to a conformational change and release o f the active C [18, 20]. PKA C 
subunit is a serine threonine kinase and targets domains containing X-Arg-Arg-X- 
Ser/Thre-X m otifs [21]. Targets for C subunit kinase range from ion channels to 
transcription factors, [22-24]. Elevated cAMP can increase or decrease gene transcription 
by virtue o f PKA dependent phosphorylation of cAMP response element binding protein 
(CREB) [6, 25, 26]. Therefore functional diversity exists at a cellular level by virtue o f the 
range o f substrates expressed by a cell.
The molecular diversity o f PKA was initially identified by DEAE elution of 2 isoforms 
[27] corresponding to 2 isoforms of the R subunit R1 and R ll. Genetic analysis has 
revealed further complexity by demonstrating four isoforms R la , Rl(3, R lla  and Rll(3 [16, 
28]. Three C subunit isoforms have been identified C a , C(3 and Cy. C subunits express
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tissue specificity with C(3 being enriched in brain [29] and Cy being exclusively expressed 
in testis [30]. Tissue specific expression o f R subunit isoforms suggests important 
functional differences. For instance RI(3 is highly expressed in brain, while responses of 
certain regions o f the brain to cAMP correlates with the expression o f RIIp subunit [31, 
32]. Differences between the classes o f R subunit also exist in terms o f intracellular 
distribution, with RI being predominantly cytosolic and RII occurring mainly in the 
particulate fraction[33]. Kondrashin et al took this analysis further and found R lla  
enriched in the golgi and mitochondria o f cells fractionated in sucrose gradients [34]. The 
R subunit thus serves to target the holoenzyme to specific subcellular locations.
The nature of this targeting has recently been illuminated by the discovery of a new family 
of proteins known as A Kinase Anchoring Proteins (AKAP) [35]. These structurally 
diverse proteins are targeted within the cell by protein-protein and protein-lipid 
interactions. Tissue specific AKAP expression may refine the response o f a particular 
tissue to an adenylyl cyclase activating hormone [36]. AKAP proteins bind PKA R 
subunits at their N-terminal and target the PKA holoenzyme within the cell.
Finally the sensitivity of different R subunits to cAMP is known to vary. Thus R Iip is 
relatively insensitive to cAMP, and the regions o f rat brain rich in RIip are those areas 
known to be less responsive to cAMP [32].
Variations in intracellular targeting, tissue specific expression and sensitivity to cAMP 
concentration all regulate the PKA mediated response, allowing the cell to precisely 
control its response to cAMP by differential protein expression.
1.2.3.2 Rap-1 a novel cAMP signal transducer
The discovery o f the cAMP sensitive, Rap-1 activating GEF, EPAC added to the 
complexity o f cAMP signaling [37, 38]. Rap-1 is a GTPase sharing 50% sequence
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homology with Ras, particularly at the Ras protein interaction domain [39]. Rap-1 has 
significant homology to a drosophila gene which when Imocked out led to a lethal mutation 
[40], suggesting that its function is non-redundant despite significant homology to othei 
proteins. Cyclic AMP, calcium (Ca^"") and diacyl glycerol (DAG), can all activate Rap-1 
[41, 42]. Cyclic AMP was shown to phosphorylate Rap-1 in a PKA dependent manner m 
prostacyclin treated neutrophils [43] and it was believed that cAMP activation of Rap-1 
was due to this effect. The only Rap-1 PKA target sequence is at the C-terminal some 
distance from the sites of GTP binding, however and it may be that PKA phosphorylation 
affects targeting rather than activity [44]. Kawasaki et al demonstrated that a PKA 
deficient CHO cell could activate Rap-1 in response to cAMP [45]. Finally EPAC was 
discovered to directly activate Rap-1 in a cAMP dependent manner and PKA was shown to 
reduce Rap-1, raf binding activity [38, 46].
Evidence for two separate mechanisms of cAMP detection and downstream signaling have 
therefore been found. Cyclic AMP signaling thus displays molecular diveisity at synthesis, 
sensing and substrate levels, leading to variable functional outcomes as I have desciibed. It 
is essential that the cell can limit the “dose” o f cAMP to which it is exposed. This 
limitation is provided by the cyclic nucleotide phosphodiesterases. I will next outline some 
of the salient features of this family, and deal with PDE4 in detail in the next section.
1.2.4 Phosphodiesterases
1.2.4.1 Homogeneity and heterogeneity
Sutherland described cyclic nucleotide hydrolysing activity from heart extract in 1970 [47]. 
It soon became apparent by anion exchange chromatography that this activity existed in 
different forms, suggesting the existence o f a family o f enzymes with similar biochemical 
properties [48, 49]. The development o f advanced molecular biological techniques has
confirmed this assumption and shed light on the enormous degree o f complexity within 
this family [50]. Nineteen genes encode members o f the eleven PDE families suggesting 
some degree o f differential function. Differential tissue and developmental expression, 
different kinetic properties and specific affinities for substrate and inhibitors supports the 
notion that individual PDEs exist to serve specific functions [4].
Two major classes o f PDE have been described. Class I enzymes share homology over a 
region o f approximately 300 amino acids, o f which 56 amino acids are identical between 
the drosophila dunce gene product, the slime mould dictyostelium reg-A gene product, the 
putative c. elegans PDE and human PDE4s [51]. This highly conserved region correlates to 
the catalytic domain and points to a single ancestral gene. Class II PDEs are a group o f 
enzymes conserved in yeast, bacteria and slime moulds. They lack the catalytic domain as 
in class I and are secreted proteins. To date no mammalian homologue of class II PDEs has 
been identified [51].
The PDE4 family will form the focus of this thesis, but some important aspects o f PDE 
biology are learned from studying the shared or divergent characteristics o f the other 
members o f this superfamily. The agreed convention on nomenclature grouped PDE 
families by functional characteristics, based on substrate specificity and inhibitor 
sensitivity, PDE characteristics are summarised in table 1.1. Important functional aspects 
are outlined below.
P D E Defining Substrate Number of Chromosomal Number ofCharacteristic specificity genes locations isoforms
Ca“'/CaM CAMP PDEIA A-? A - 2
activated CGMP PDE IB B-12ql3 B -  1
PDE 1C C-7 C - 5
t o E 2  4 cGMP activated CAMP 7
CGMP
cGMP inhibited CAMP PDE3A
PDE3B
l l pl S. l
l l p l 5
A - 3  
B -  1
M Ë R Rolipram CAMP PDE4A 19pl3.2 A - 6
inhibited PDE4B lp31 B - 3S PDE4C 19pl3.1 C - 3PDE4D 5ql2 D - 5
CGMP PDE5A
PDE5B
Photoreceptor CGMP PDE6A
PDE6B
PDE6C
Rolipram CAMP PDE7A A - 2
resistant PDE7B B - 1
IBMX resistant CAMP PDE8A
PDE8B
IBMX resistant CGMP
CGMP
t o E i  c CAMP PDEl l A A - 3
-U - ------ a CGMP
Table 1.1 Characteristics o f  mammalian PDE families
Cyclic nucleotide phosphodiesterase activity exists as a multi-member family o f  
enzymes each with specific characteristics. Three groups o f  enzymes are
family is further subdivided into gene products and mRNA splice variants, resulting 
in multiple isoforms.
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1.2.4.2 Structural organisation
Phosphodiesterase enzymes share a common modular structure with different domains 
encoding different biochemical properties [50]. Figure 1.2 details the important domains.
L Catalytic domain
The highly conserved region described above encodes the catalytic legion located towards 
the C-terminal o f PDE proteins. Analysis o f the conserved regions within the catalytic 
domain demonstrates further modular organisation with 10 putative functional regions 
[51]. These regions regulate the activity of the enzyme and have been studied in a variety 
o f PDE families. For example domains II and IV encode regions homologous to zinc 
binding domains in other zinc binding hydrolases. M utations o f charged amino acids in 
these domains reduce or abolish PDE activity in PDE3, PDE4 and PDE5 [52]. Zinc has 
been shown to support PDE3 and PDE5 activity [53]. Other catalytic domains of interest 
are I and II which regulate rolipram binding to PDE4, whereas mutation of regions VIII 
and IX abolish rolipram inhibition o f PDE4, but do not affect binding [51, 54]. The 
modular organisation o f the entire molecule is therefore mirrored in the conserved catalytic 
domain. Less structural homology exists between PDE isoforms over the non-catalytic 
regions.
II. Carboxyl Terminus
The extreme C terminus contains an hydrophillic region in which conserved regions of 
acidic amino acids exist [50]. The role of these amino acids is not known. With the 
exception o f PDE 1, PDE C-terminal regions are shared by PDE gene products. This allows 
the immunological identification o f PDE4 gene families by raising antiserum against the 
C- terminal regions. Thus PDE4A, PDE4B, PDE4C and PDE4D can be differentiated on 
immunological grounds.
11
III. NH3 terminus
The PDE N -terminal region lies up stream of the catalytic core and is known as the 
regulatory domain (Figure 1.2). It is in this region that molecular modifications regulate 
PDE activity. For example it is in this region that the calmodulin (CaM) binding site on 
PD El is found [55]. Ca^VCaM binding to this domain increases PD El activity and 
individual PDE 1 isoforms are structurally distinct at this domain suggesting differential 
regulation by Ca^VCaM [56]. A protein module known as GAF (cGMP binding proteins, 
anabaena adenylyl cyclase and E. Coli flilA ) has been found on PDE 2, PDE5, PDE6, 
PDE 10 and PDEl 1 [57, 58]. Each family expresses two GAF domains in close proximity 
that bind cGMP increasing the enzyme activity (Fig 1.2).
Further regulatory domains are to be found in the N termini o f other PDE families. These 
include PDE4 enzyme regulated kinase (ERK) substrate domains at which phosphorylation 
influences activity described in more detail in a later section. Thus molecular diversity of 
the N -term inals results in enzymes with the same catalytic function with specific 
regulatory properties.
1.2.4.3 Genetic Organisation
Early studies carried out on the drosophila dunce gene complex were the first to give 
insight into the complexity o f PDE gene organisation [50]. Dunce gene deletion gave rise 
to learning difficulties and sterility in fruit flies [59]. Each problem could be produced 
alone or together by differential mutation o f the various promoters in the notch complex 
upstream o f the dunce gene itself. Thus it was clear that different tissue expression of the 
dunce gene product was under the control of different promoters regulating specific
12
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transcriptional units [50], Further studies on slime moulds demonstrated that different 
promoters regulated PDE genes at different stages of maturation.
Similar differential regulation o f PDE expression between tissues and at different stages of 
maturation is seen in mammalian tissues. Rat brain provides a rich source o f PDE 
isoforms, which are not found elsewhere in the body e.g. PDE4A1, and various models of 
cellular differentiation have demonstrated stage specific expression o f PDE in a manner 
reminiscent of the drosophila dunce gene [60, 61].
1.3 Phosphodiesterase 4 a study in biological diversity
It is outwith the scope o f this review to detail all the structure-function relationships that 
define specific PDE4 isoforms. In summerising these relationships I will select specific 
domains within the molecules and attempt to show how these produce functional diversity 
based on molecular difference. Table 1.2 details specific characteristics of each PDE4 
isoform, PDE4 is a family o f cAMP specific, rolipram  sensitive cyclic nucleotide 
hydrolysing enzymes. The family is encoded by 4 genes A, B, C and D and splice variation 
provides additional complexity [50]. As described for PDE enzymes in general significant 
homology exists at the catalytic domain between all PDE4 isoforms. Gene families are 
defined at the molecular level by sharing an extreme C-terminal, while N-terminal regions 
have varying degrees o f homology between specific PDE4 isoforms. Finally isoform 
specificity is defined at the extreme N-terminal.
1.3.1 PDE4 structure
PDE4 genes each code for multiple forms o f their enzyme product. This occurs by mRNA 
splicing at specific splice domains.
14
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1.3.1.1 Splice Junctions -  "Long form " and ” Short form " distinction
All PDE4 genes encode two splice junctions [62], the first lies immediately upstream of 
the sequence of the conserved region upstream conserved region 2, (UCR2). Splicing of 
mRNA at this site produces "short-forms" with N -term inal sequence im mediately 
following UCR2 and "long forms" with common sequence including U C R l. Long forms 
have N-terminal sequence after UCRl [63]. Every PDE4 gene except PDE4C encodes both 
long and short form enzymes. In addition to this distinction the PDE4A gene encodes two 
' super-shorf enzymes known as PDE4A1 and PDE4A8 [64]. The former has N-terminal 
sequence extending from approximately half the UCR2 region while the latter, recently 
shown to exist in vivo, lacks any UCR domains and encodes the ‘core’ catalytic 
domain[64].
By aligning different long form PDE4 sequences Bolger et al identified two regions of 
sequence homology [63], conserved within PDE4 isoforms but not found in other PDE 
families. The 33 residue linker region 1 (LRl) separates U CRl and UCR2. The net polarity 
o f U C R l is +1 m aking it an attractive site for conform ational regulation by 
phosphorylation. This has been demonstrated by Mackenzie et al [65] who demonstrated 
ERK2 phosphorylation o f PDE4D3 led to inhibition by the UCR1/UCR2 module. This 
confirmed the work o f Hoffman et al [6 6 ]], who demonstrated that EGF treatment o f cells 
overexpressing PDE4D3 reduced PDE4 activity. Further confirmation was provided by 
Baillie et al [67] who showed that short form PDE4 isoforms, lacking U C R l, were 
activated by ERK2 phosphorylation of the catalytic region.
16
‘ Long-torms ‘Super-short
PDE4A Splice variation
Long-forms” “ Short-forms” 
3 2
HuPDE4B splice variation
‘Long-forms” “Short-forms
HuPDE4D splice variation
Upstream conserved 
region (UCR)
Linking 
region (LR)
A /
Catalytic domain COOH
Splice
junctions
Unique N- 
terminal
F/g 1.3 The variability between PDE4 iso forms is governed by mRNA splice 
variation. Each PDE4 gene codes for a variety of isoforms in which size (long or 
short form), number of regulatory regions (UCR) and site of unique N terminal 
region, is governed by differential use of splice junctions. PDE4A, PDE4B and 
PDE4D are schematically represented. Conserved regions are colour coded, 
unique regions are black.
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U CRl contains a substrate site for phosphorylation by PKA (serine target residue, STR), 
[6 8 ]. In PDE4D3 this is Ser54, although this isoform also contains a PKA STR at S e ri3. 
Sette et al demonstrated that it was Ser54 that was responsible for the rapid activation of
PDE4D3 in FRTL-5 TSH sensitive cells [6 8 ]. PKA phosphorylation o f PDE4D3, also 
prevents the inhibitory effect o f ERK2 phosphorylation [65]. This is likely to be due to 
uncoupling o f the protein-protein interaction between U CRl and UCR2 demonstrated by 
Beard et al [69].
N-terminal regions o f PDE4 isoforms therefore limit the activity o f the enzymes. This is 
probably due to interaction o f UCR1/UCR2 modules altering substrate access to the 
catalytic domain. It follows that enzymes lacking these regions should have enhanced 
activity. A synthetic enzyme containing the core o f the PDE4A enzyme, (the catalytic 
region and the extreme C-terminal) known as met^^-RDl was shown to have significantly 
higher activity than its progenitor PDE4A1 or other PDE4A enzymes [70, 71]. Indeed I1 6 .I 
an N-terminal truncation o f PDE4A4, had a Vmax relative to its progenitor enzyme 11.5 
times greater.
The region o f most variability between PDE4 isoforms therefore dictates functional 
regulation of each isoform.
L3.1.3 Targeting
!. S u b -c e l lu la r  d is t r ibu t ion
Analysis of the characteristics of met^^-RDl described above found it to be entirely soluble 
[70, 71] suggesting that the N-terminal region was involved in targeting PDE4 isoforms to 
sub cellular locations [72]. The addition o f the PDE4A1 23 N-terminal residues absent from 
met^^-RDl to make a chim era with the norm ally soluble chloram phenicol acetyl
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transferase (CAT) resulted membrane binding [73, 74]. This is due to N-terminal 
tryptophan residues in PDE4A1 that allow the Ca^ "  ^ dependent association with 
phosphatidic acid enriched domains in the cell membrane. This region of PDE4A1 has 
been term ed TA PA S-1 [75]. In comparison to PDE4A1 the long form PDE4A4 co- 
distributes between particulate and soluble compartments [76]. The long form PDE4D 
isoforms (PDE4D3, PDE4D4 and PDE4D5) which are co-distributed between particulate 
and cytosolic compartments o f disrupted cells, differ from their short form counterparts 
(PDE4D1 and PDE4D2) which are exclusively cytosolic [77, 78].
The N-terminal variable region therefore also regulates subcellular targeting o f PDE4 
isoforms.
11. P ro te in  -  p ro te in  in te ra c t io n
Protein-protein interaction domains on signalling proteins allow incorporation into macro- 
molecular signalling complexes and association with scaffold proteins. SH3 domains bind 
to proline rich regions o f other proteins [79, 80]. Analysis o f PDE4A5 reveals two class 1 
SH3 binding domains in the N-terminal region [81]. These were shown to confer 
association with the SH3 domains of the src family kinases lyn, fyn and src [81, 82]. This 
interaction reduced PDE4A5 activity suggesting that association with Lyn kinase leads to 
an increase in the local cAMP concentration. Analysis o f PDE4D4 revealed SH3 binding 
domains, and src family association is therefore not exclusive to PDE4A5 within the PDE4 
family [83].
PDE4D5 has been shown to bind the protein RACK 1 [84]. RACKl was originally 
deseribed as a protein able to bind and translocate activated PKC-(3 [85, 86]. It has since 
been shown to be a scaffold protein binding other signal transduction proteins including 
Integrins, c-src and the common |3 chain o f the interleukin receptor [87-89]. PDE4D5
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interacts with RACKl via an N-terminal domain and the last 3 WD repeats of R A C K l’s 7 
WD repeat structure [90].
The N-terminal regions o f PDE4 isoforms have therefore been shown to be important in 
both localisation and regulation o f activity.
1.3.1.4 Catalytic domain
The sequence o f the PDE4 catalytic domain has excited considerable interest, as it 
eorresponds to the site o f rolipram binding and governs the therapeutic potential for PDE4 
inhibitors. Two conformations o f this site have been described, high affinity for rolipram 
binding site (HARBS) and a low affinity site (LARBS) [91]. HARBS binding by rolipram 
appears to oceur with an affinity that relates closely to rolipram’s ability to induce emesis. 
LARBS binding affinity conforms to anti-inflammatory and bronchodilator properties [92, 
93]. Torphy et al demonstrated that histidines 506 and possibly 505 were required for 
cAMP binding to the catalytic core o f PDE4A but were not required for rolipram binding 
[94]. Mutational analysis o f other histidine sites at amino acids 433, 437, 473 and 477 
demonstrated decreased rolipram association. The same group later demonstrated that two 
conserved histidine containing domains HNXXH (m otif I), and HDXXH (motif II), were 
essential for cAMP hydrolysing activity [52]. M otif I inactivity mutants lost all activity 
while m otif II mutants lost 50% activity. Each domain proves to be a ligand for divalent 
cations such as Z n ^  or Mg^^ suggesting that full activity and rolipram binding activity 
depends on structural conformation dependent on metal ion binding. Thus structural 
analysis demonstrates that different PDE4 isoforms may interact with both substrate and 
inhibitors differentially depending on the ability of regions o f the catalytic domain to form 
particular conformations. The importance o f overall molecular structure influenced by N- 
terminal domain binding becomes apparent.
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A second level o f regulation based on molecular structure lies in two sequences found in 
the catalytic core o f PDE4D3. These ERK2 docking domains provide the necessary sites 
for ERK2/PDE4D3 interaction to allow phosphorylation o f the Ser residue at 579. 
Phosphorylation results in inhibition o f long form PDE4 isoforms. Figure 1.2 highlights 
these important regions o f the catalytic core [66].
1.3.1.5 COOH-domain
The biological purpose o f the extreme C-terminal remains obscure. This region is shared 
between all members o f a gene family and thus allows immunological identification. 
Separation o f immunologically related PDE4 isoforms by migration on SDS-PAGE allows 
discrimination between family members. The purpose o f this domain is not understood.
1.3.2 Biological diversity - consequences
The existence o f a large family o f enzymes with the same or closely related biochemical 
properties begs the question why do we need so many? The differences in regulation and 
expression outlined above suggest that each PDE and PDE4 in particular may serve 
specific functions. This in turn would suggest that cAMP though pluripotent is strictly 
regulated to perform specific tasks under certain conditions.
1.3.2.1 Compartmentalisation o f  cAMP signalling
The hypothesis o f com partmentalisation suggests that functional pools o f signalling 
chemicals and proteins exist in discrete "compartments" within the cell [95, 96]. By 
regulating the mix o f proteins within these eompartments cells ean regulate the specific 
response to any given signal. By varying the enzymes, substrates and ehemicai messengers 
in different compartments at the same time a cell could generate multiple responses to a
21
given signal. This hypothesis waits rigorous testing, but offers a neat explanation for the 
diversity o f PDE4 isoforms.
L 3.2.1.1 Evidence fo r  compartmentalisation
Keely et al, demonstrated that epinephrine and PGE2 elevated myocardiocyte cAMP 
causing the PKA phosphorylation o f a range o f proteins, but isoprotenolol caused the 
phosphorylation o f approxim ately 16 more PKA targets [97]. Further examples o f 
functional compartmentalization exist. O f interest in the context o f this thesis is the work 
of Dousa et al, who demonstrated in renal mesangial cells, a distinction between PDE3 and 
PDE4 regulation o f cellular behaviour despite equivalent increases in intracellular cAMP, 
[98].
Compartmentalisation would require physical localisation o f the elements of cAMP 
signaling within the cell and such targeting was shown by Jiirevicus and Fischmeister 
when they treated frog ventricular myocytes with isoprotenolol [99]. They found that 
although L-type Ca channels were widely disseminated in cells only those close to |32 
receptors were phosphorylated by PKA. Initial attempts to localise cAMP within cells were 
hampered by the tendency for cAMP to diffuse or leach out o f areas. Using microwave 
fixing technology Barsony and Marx demonstrated discrete pools of cAMP forming after 
stimulation with different ligands [100]. More recently fluorescent RII subunits of PKA 
has allowed FRET analysis to be used by Tsien et al [101]. They demonstrated 5-HT 
induced pools o f cAMP within neuronal dendrites. Thus evidence has accumulated that 
non-random distribution o f cAMP occurs within cells.
Finally evidence supporting the functional compartmentalization o f cAMP signaling in 
inflammation was provided by Ahmad et al [102]. This group observed a distinction 
between the PDE isoforms activated by different pro-inflammatory agents. Thus while IL- 
3 activated both PDE4 and PDE3, IL-4 selectively activated PDE4.
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Thus considerable evidence exists, from diverse experimental fields supporting the concept 
o f compartmentalization.
1.3.2.1.2 The molecular basis o f  compartmentalisation
For compartmentalization of a second messenger to occur certain prerequisites must be met 
[4]. First both a synthetic and a sensing device must exist that can be targeted within the 
cell. In the case o f cAMP these criteria are met. I have described multiple forms of 
Adenylyl cyclase targeted by 6 transm embrane helices. The strongest evidence for 
targeting however exists for the cAMP sensing system PKA and its binding partner AKAP 
described above. Neurone post-synaptic densities are enriched in AKAP79 [103], AKAP 15 
is associated with skeletal muscle Ca^^ channels [104] and S-AKAP84 expression is 
developmentally regulated in male germ eells [105]. Therefore PKA targeting can be 
regulated in a subcellular and developmental fashion. If  discrete pools o f cAMP can be 
synthesised, targeting PKA to these pools regulates whieh of the various R2C2 enzyme 
modules is activated.
The second requirement for Compartmentalisation o f signaling molecules, is a means to 
prevent ‘spillage’ that could result in random activation o f sensing molecules. This 
requires cAMP hydrolysing activity targeted within the cell. PDE is the only means of 
hydrolysing cAMP and I have already deseribed the accumulating evidence for PDE4 
targeting.
PDE targeting may explain why such a diversity of molecules exists. An elegant study by 
Juilfs et al, looked at PDE distribution in olfactory neurones, by immunofluoresence [106]. 
They demonstrated that PDE1C2 co-localised with AC3 in the cilia that protrude into the 
nasal mucosa and respond to odorants. It is believed that this complex regulates the early 
phase o f odorant receptor signaling. While PDE 1C is absent from the axon and cell body, 
PDE4A can be found. These studies suggest that within the complex structure of a neurone
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PDE isoform distribution is not random. Like the studies described above for individual 
PDE4 isoforms, the PDE3 family has been intensively investigated with regards to 
intracellular targeting. PDE3A1 and PDE3B have each been isolated from membrane 
structures including ER and SR o f myocardiocytes and adipocytes [107]. The N-terminal 
region o f these isoform s contains a hydrophobic rich region believed to form 6 
transmembrane helices. Deletion analysis shows loss o f membrane association when these 
regions are removed. A third PDE3 species, PDE3A2 has been identified recently. 
Sequence analysis demonstrates alternative splicing to provide a short N-terminal highly 
polar region [108]. As expected, recombinant expression of this molecule yields a mainly 
cytosolic distribution.
1.2.2A. 2 Compartmentalisation  -  summary
All the requirements for compartmentalisation can be met by the molecules involved in 
cAMP signal transduction. This theory may therefore partially explain the requirement for 
such a large degree o f m olecular diversity w ithin the PDE4 family. A lternative 
explanations for the evolutionary persistence o f such a large family, however include the 
concept o f inter-molecular crosstalk.
1.3.2.2 Molecular Crosstalk
Integration of multiple signalling pathways allows refinement o f these pathways to take 
account of additional intracellular messages. This concept is known as crosstalk. [96].
1.3.2.2.1 Evidence fo r  crosstalk
Evidence for crosstalk between the cAMP signalling cascade and other pathways is 
accumulating. Lin et al demonstrated in RAW murine macrophages, that activation o f PKC 
potentiated the prostaglandin E2 activation o f AC [109] and Dowd et al found cAMP
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potentiation o f Ca^^ induced gene transcription en route to apoptosis [110]. Another group 
examined the integration o f PKA and ERKl and ERK2 activation [111] and demonstrated 
PKA phosphorylation at the Kinase Interaction M otif (KIM) o f ERK isoforms prevented 
the dephosphorylation by phosphatase. Therefore multiple examples o f other signalling 
pathways feeding into eAMP signal transduction have been deseribed.
1.3.2.2.2 PDE4 and molecular crosstalk
Both the cAMP cascade and the ERIC 1/2 MAPKinase signalling pathways regulate PDE4. 
PDE4B, PDE4C and PDE4D families have an ERK 1/2 KIM domain in the catalytic region 
[65, 66]. This allows phosphorylation o f Ser579 (named as for PDE4D3) and the inhibition 
of long form PDE4 aetivity, the short form PDE4B2, however is aetivated by ERK 1/2 [67]. 
PDE4A isoforms appear to be insensitive to ERK 1/2 phosphorylation. PDE4A4 however, 
is sensitive to PI-3 kinase and may integrate a different series o f signalling pathways [112]. 
Varying PDE4 isoform expression will alter the overall PDE4 response to a specific 
signalling environment.
1.3.2.2.3 Summary molecular crosstalk
PDE4 isoforms may thus play an important role in the integration o f signalling cascades. 
By altering their activity in response to different environments the level o f cAMP can be 
tightly regulated.
1.3.3 PDE4 Diversity -  Conclusions
PDE4 isoforms are a diverse group of enzymes, each of which has the same catalytic 
activity. Such a multitude of isoforms in spite o f evolutionary pressure to economise the 
expressed genome implies specific functions for each. I have demonstrated that molecular 
diversity exists at every level o f cAMP signalling from synthesis by adenylyl cyclase,
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sensing by PKA and Rap-1 and most impressively degradation by PDE. Clues to the 
specific function can be made from analysis of the molecular sequence for each PDE4 
isoform. Thus KIM domains in the catalytic region allows crosstalk between ERK 1/2 and 
cAMP. PKA phosphorylation complicates molecular crosstalk by abolishing the effects of 
ERK 1/2 inhibition. Finally targeting o f PDE4 isoforms could allow compartmentalisation 
o f cAMP signal and provide a mechanism for large macromolecular complexes to be 
formed.
Differential expression o f PDE4 iso forms at different stages o f development and in 
response to specific signalling environments would allow refinement of the response to a 
cAMP signal. Thus understanding the molecular diversity o f PDE4 has offered insights 
into the complex organisation o f cell signalling.
1.4 PDE4 in inflammation
1.4.1 Introduction
Since the description of coffee as a useful treatment for bronchospasm in the mid-ninteenth 
century [113] non specific PDE inhibtiors have been used to treat airway disease. The 
appreciation  tha t m ethyl xanth ines such as caffine and theophylline had 
immunomodulatory activity came from the work o f Lichtenstein in the early 70’s [114, 
115]. Significant volumes of work have been produced looking at the role o f PDE 
inhibitors in inflammatory cells and these have been collected in a Series o f review articles 
[50, 116-118]. I will summarise the main concepts to be gleaned from this work and 
concentrate in a later section on the work pertaining to macrophages, which is the cell of 
particular interest in this thesis.
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1.4.2 PDE content of immune cells
An understanding of the PDE expression profile of inflammatory cells offers insights into 
spécifié roles for these molecules. In summary PDE3 and PDE4 appear to be the main 
cAMP PDE species expressed in inflammatory cells. Some interesting work suggests that 
in monocytes at least compartmentalisation o f PDE species occurs with PDE4 being the 
main soluble species and PDE3 being particulate associated [119].
1.4.2.1 Mast cells and Basophils
Basophils isolated from human blood contain PDE3, PDE4 and PDE5 [120, 121]. PDE3 
and PDE4 account for the majority o f cAMP PDE activity in these cells. Mast eells are 
significantly more difficult to harvest and as such the studies o f these cells are more 
circumspect [117]. Notwithstanding this however PDE3 and PDE4 have been identified in 
mast cells isolated from guinea pig and human lung [121].
1.4.2.2 Eosinophils
Significantly more work has looked into eosinophil PDE expression profile [122-124]. By 
far the largest cAMP PDE activity expressed is PDE4. In eosinophils this activity co- 
distributes in both the particulate and the soluble fractions. PDE3 and PDEl are present in 
small amounts, but no independent functional activity has been found for these.
1.4.2.3 B lymphocytes
Suzuki et al have demonstrated PDE4 in B lymphocytes, but little more work in this 
important cell type was reported until Gantner et al compared cells from atopic and non- 
atopic donors [125]. They demonstrated that the greatest cAMP PDE activity represented 
was cytosolic PDE4 followed by cytosolic PDE7. Small amounts o f PDE3 were also
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present. RT-PCR was used to further define the PDE4 isoform expression profile, and they 
demonstrated PDE4A, PDE4B2 and PDE4D were represented.
L4.2.4 Monocytes and Macrophages
I will review the work relating to macrophages in more detail later, however a significant 
body o f work has investigated the expression o f PDE isoforms in monocytes and 
macrophages [119, 126, 127]. In monocytes significantly more PDE4 activity is expressed. 
With the differentiation to macrophages however this balance is rectified [127]. In both 
cell types PDE4 is mainly soluble while PDE3 associates with the particulate fraction.
1.4.2.5 Summary
PDE4 is widely expressed in cells o f the immune system. As inhibiting PDE4 leads to 
elevated intracellular cAMP it would be expected that PDE inhibitors would have anti­
inflammatory properties. I will discuss the evidence for this next.
1.4.3 Immunomodulation by PDE4 inhibitors
Many studies have confirmed that cAMP derived from PDE4 inhibition has anti­
inflammatory activity. Again I will summarise the main focus o f this research for each cell 
type and deal with macrophages in more detail in a later section. Table 1.3 details the 
major effects o f PDE4 inhibitors in inflammatory processes.
1.4.3.1 M ast cells and Basophils
Inhibition of PDE4 prevents IgE stimulated histamine release and platelet activating factor 
(PAF) stimulated Leukotriene (LTC4) production from human basophils
28
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[120, 121, 128, 129]. Although these effects were dose dependent on intracellular cAMP 
concentration, some functional compartmentalisation was seen by the absence o f an 
inhibitory effect o f PDE3 or PDE5 inhibition [120]. Although PDE4 inhibition was 
capable of elevating cAMP in mast cells conflicting evidence exists for its role in mast cell 
regulation. W eston et al have found no effect on mast cell mediator release with IgE 
challenge in the presence o f PDE4 inhibitors, while Anderson et al suggest inhibition is 
achieved [121].
1.4.3.2 Eosinophils
PDE4 accounts for almost all eosinophil cAMP PDE activity, thus it is not surprising that 
PDE4 inhibition has profound effects on eosinophil function. Table 1.3.2 details these 
effects. M ediator release, surface molecule expression, oxygen radical release and 
chemotaxis have all been shown to be reduced by PDE4 inhibitors in a concentration 
dependent fashion. Again compartmentalisation o f function is suggested by the lack o f 
effect o f PDE3 and PDEl inhibitors. It must be noted however, that the effect on cAMP of 
either one o f these inhibitors is small given their relative low expression. [122-124, 130- 
134]
1.4.3.3 B Lymphocytes
Inhibition of PDE4 in B lymphocytes appears to have conflicting effects depending on the 
context. [135] This group demonstrated that PDE4 inhibition increased IgE production in 
the presence o f low IL-4, however if  IL-4 concentration is higher IgE was inhibited. 
Another group demonstrated that EPS stimulated proliferation o f B lymphocytes was 
increased in the presence o f rolipram [125] This effect was mimicked by a lipid soluble 
analogue of cAMP (db cAMP) and inhibited by H89, an inhibitor of PKA.
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1.4.3.4 T Lymphocytes
PDE4 inhibitors prevented the antigen, mitogen and MHC class I stimulated proliferation 
o f T lymphocytes, while PDE3 inhibition did not [136, 137]. This distinction lends more 
weight to the theory of compartmentalisation as PDE3 and PDE4 are fairly evenly 
represented in T cells. PDE4 inhibitors also reduced the stimulated production of cytokines 
from T cells [138]. The combined effect of PDE3 and PDE4 inhibitors failed to mimic 
completely the effect of non-specific PDE inhibitors such as[139] Theophylline. Thus it 
may be that PDE7 may play a significant role in the regulation o f T cell cAMP. PDE7 has 
since been shown to be important in the activation of T cells [140]. Another explanation 
for the differences in aetivity between both groups of drugs could be non-PDE effects of 
theophylline such as adenosine agonism.
1.4.3.5 Monocytes and Macrophages
Due to the relative abundance of monocytes a wealth o f information demonstrates a role 
for PDE4 in regulating pro-inflammatory activity. Most significantly TN Fa production by 
EPS stimulated macrophages is profoundly inhibited in the presence o f PDE4 inhibitors.[, 
[141, 142]]. Other pro-inflammatory effects are inhibited by PDE4 inhibition such as 
fMLP induced arachadonic acid release and calcium ionophore stimulated leukotriene 
production [143].
1.4.3.6 Summary
Thus non-specific and specific PDE4 inhibitors have anti-inflammatory properties across 
most o f the cells involved in inflammation and immunity. This makes PDE4 iso forms 
attractive therapeutic targets. A large volume o f pharmaceutical research is dedicated to 
developing new agents with PDE4 inhibitory properties.
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1.4.4 Development of new PDE4 inhibitors
Unfortunately just as non-specific PDE inhibitors such as theophylline are limited by 
toxicity, PDE4 inhibitors are also limited by their side effect profile. The main side effects 
experienced are nausea and headache, both o f which are believed to be due to an effect on 
the CNS due to the high affinity binding site (HARBS) [91]. As PDE4 itself is a complex 
family with different isoforms possibly regulating different cellular processes it is not 
surprising that side effects are seen with relatively non-specific agents.
Many new PDE4 inhibitors are in development, some o f which may offer relative isoform 
specificity [118]. To further understand the role o f each PDE4 isoform in cell function it 
will be necessary to investigate a cell type in more detail. I have selected the 
macrophage/monocyte cell to address phenotype specific roles for PDE4 isoforms. I will 
discuss the macrophage in terms o f development, pathogenesis in inflammation, its role in 
asthma and cAMP signalling. Asthma is discussed as increasing interest in PDE4 
inhibition in this disease is leading to considerable research into cAMP molecular 
mechanisms. It should be noted however that to date PDE4 selective inhibition has proven 
therapeutically disappointing in asthma as opposed to in COPD where it has been found to 
be therapeutically efficacious [144].
1.5 Alveolar Macrophages
Macrophages are a useful model to study PDE4 regulation o f inflammation. They represent 
a highly differentiated mature cell with a defined progenitor, the monocyte. Comparison of 
these cells can offer insights into the im portant biochem ical changes involved in 
maturation. M acrophages also have well defined and m easurable pro-inflammatory 
behaviour which is useful for studying biochem ical m odulation. Finally alveolar
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macrophages (AM) are important in the development o f lung disease and offer a potential 
therapeutic target.
1.5.1 Lung Macrophage - a heterogeneous population with 
specific developmental phenotypes
Macrophages are tissue specific accessory cells derived from circulating peripheral blood 
monocytes (PBM) both constitutively and in response to inflammation [145]. Alveolar 
macrophages (AM) are mobile phagocytic cells that reside on the surface of the alveoli and 
small bronchi o f normal lung and represent approximately 3-5% o f all lung cells [146]. 
Given that the lung is the largest interface of internal and external environment AM have a 
fundamental role in host defence by surveying airborne particles along this surface. AM 
are more adherent, less phagocytic, morphologically distinct and have increased capacity 
to produce cytokines than either peritoneal macrophages or PBM. [147]. Thus AM 
represent a phenotypically defined stage of differentiation. This differentiation is a 
biochemically regulated process.
1.5.1.1 Maturation and migration
Migration from blood to the alveolus is a process o f adherence to and passage through 
vascular endothelium, extracellular matrix and the alveolar epithelium. This requires the 
sequential interaction o f  monocyte surface receptors w ith selectins expressed on 
neighbouring cells. Transendothelial migration involves (32 integrins (GDI 1/CD 18) VLAg 
4 and 5, P-ECEL, PEC AM and I cam 1 and Vcam 1 [148]. Rosseau et al demonstrated the 
importance o f (32 integrins CDl la, b, c and d, VLA 4, 5 and 6 and CD47 in transalveolar 
migration [149]. Cell recruitment and adhesion molecule expression is biochemically 
controlled by the monocyte chemokines M CP-l and RANTES [150, 151]. Both of which 
are produced by resident cells in the lung including alveolar type II cells in response to
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TN Fa, IL-1, ÏL-2 and TGF|3 [149]. Galactin 3 is a recently described lectin involved in 
monocyte migration and macrophage development and has been shown to be specifically 
expressed in lung tissue [152].
1.5.1.2 Intermediate macrophages may represent stage specific development
A  second population o f macrophages have also been described accounting for -2%  of lung 
cells or 40% of lung macrophages [146]. These cells are found in the interstitium of lung 
tissue and are known as interstitial macrophages (IM). W hether these represent maturing 
maerophages or a separate population o f active macrophages is not clear.
Thus distinct developmental regulation of alveolar macrophages takes place in lung tissue. 
U nderstanding the biochem ical changes governing this process may increase our 
understanding o f the cells involved.
1.5.1.3 Cell line models as surrogates fo r  macrophage development
While AM are relatively abundant their isolation remains difficult and yields are often 
insufficient for biochemical analyses. Investigators have thus developed models o f 
macrophage differentiation based on leukaemic cell lines. Huberman and Callahan 
demonstrated that a granulocytic cell line HL-60, could be made to develop macrophage­
like features by treating with the phorbol ester PMA [153]. Subsequently other related cell 
lines including the premonoeytic cell U937 have also been similarly shown to respond 
[154]. Such cells when treated become adherent to plastic, develop phagocytic capability 
and change their surface markers to a more mature display including the expression of (32 
integrins (C D lIP ) and MIF [155, 156], Monocytes isolated from the circulation and 
cultured on plastic develop in a similar fashion a model laiown as the “ex-vivo” model.
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L 5 .1.4 Biochemical regulation o f  development
Two studies have shown the importance o f biochemical regulation in the control o f 
macrophage development using the cell line U937. Firstly Kim et al found that the 
inhibition o f ERK 1/2 prevented the full expression of the macrophage phenotype [157]. 
Secondly, Frudovsky used CD l lb  antisense to reduce the expression o f this (32 integrin, 
previously discussed as important in monocyte migration, and prevented the expression of 
the macrophage phenotype [156]. Therefore biochemical systems control the development 
o f mature cellular phenotypes. W hat can be learned by comparing mature cells with 
progenitor cells?
1.5.1.5 Biochemical changes with macrophage development
PKC is a large family o f Ca dependent and independent kinases. Monick et al, mapped the 
changes in isoform  expression between im m ature PBM s and AM [147]. They 
demonstrated that monocytes have a relatively high level o f PKC activity with the Ca 
dependent isoforms PK C pi and PKCp2 being dominant. In AM however Ca independent 
isoforms PKC6 and PKCÇ were relatively over expressed. PKC subcellular location was 
also different in AM with a greater proportion o f PKC being membrane associated than in 
monocytic cells a distribution which is associated with activation o f the kinase [158]. To 
determine if  functional changes matched the PKC profile M onick et al, demonstrated 
reduced PMA stimulated ERK activation in AM compared to PBMs and suggested that 
this could impact significantly on a number o f macrophage specific functions. It is 
interesting that many groups have shown that EPS activate two different PKC iso forms ie 
PKC E and PKC P [159, 160#].
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1.5.1.6 Summary
Thus macrophage development is accompanied by biochemical changes with potentially 
important functional outcomes. Equivalent changes in PDE isoform expression will be 
discussed in a later section. What relevance to disease do AM have?
1.5.2 Function of Alveolar macrophages
Alveolar macrophages are capable o f secreting a large variety o f inflammatory mediators 
and cytokines that are implicated in the pathogenesis o f lung disease. The overall role of 
the AM in resting lung is believed to be immunosuppressive [161] [145] partly related to 
inhibition o f T lymphocytes [145] in which they are able to induce apoptosis. Although 
poor antigen presenting cells, IL-10 a cytokine active in asthmatic lungs, promotes this 
activity [162]. IL-10 is an important product o f cAMP treated macrophages and has been 
shown to be increased by PDE4 inhibition [163].
1.5.2.1 Alveolar macrophage in disease
The important role played by AM in resolving inflammation through recognition and 
phagocytosis o f apoptotic neutrophils is becoming clear [164]. The role of pulmonary 
based macrophages in ARDS, shock lung and pulmonary fibrosis has long been accepted. 
Their role in obstructive lung disease and especially asthma is more contentious. Evidence 
is accumulating, however that activated macrophages at least participate and may initiate 
the chronic inflammation that underlies both allergic and smoking induced obstructive 
airways disease [165]. Asthma is o f particular interest to this thesis given the weight of 
research aimed at producing asthmatic therapies based on PDE4 inhibition. It should be 
noted that AM are heavily implicated in the pathogenesis o f COPD and that novel PDE4 
inhibitors have proven more effective in this disease than in asthma.
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1.5.2.2 Mediator release
Many o f the chemical mediators and chemokines implicated in asthma pathogenesis are 
produced by AM. These include T N Fa [166], IL-1(3 [167, 168], leukotrienes, and nitric 
oxide and their production is limited by inhaled corticosteroid use in asthma [169-171]. 
Conversely AM are known to express reeeptors for pro-asthmatie mediators eg LTD4 
[172]. In this study pre-treatment o f AM with LTD4 was shown to enhance stimulated 
cytokine production. Therefore AM ean produce and respond to inflammatory mediators 
important in asthma.
1.5.2.3 Functional differences in atopic macrophages
Some functional differences exist between AM isolated from healthy and asthmatic 
subjects. AM from patients with pulmonary fibrosis were capable of producing IL-4 and 
IL-5 which are known to be important cytokines in the Th2 response [173]. Furthermore 
AM isolated from atopic asthmatics were capable o f causing enhanced IL-5 production 
compared to non-asthmatic atopies. AM isolated from asthmatic lungs have an “activated” 
phenotype defined by the expression o f ICAM-1 and LFA-1 suggesting that they were 
actively participating in the inflammation [168]. Viksman et al found that activation 
marker expression on AM from asthmatic lungs was greater than normal donors [174] and 
when stimulated with LPS, AM from asthmatic subjects produced more GMCSF, TN Fa, 
IL-8 and LTB4. Finally Lensmar et al, compared AM from atopic asthmatics before during 
and after chronic low dose exposure to pollen [175]. They demonstrated increased 
macrophage content o f broncho-alveolar lavage from exposed patients and found a shift in 
surface marker expression from a CD 16 and C D l la  bias to a CD 14 and CD l lb  
dominance. CD 14 expression in particular correlated closely with the drop in FEV l. CD 14 
is more classically considered to be a monocyte marker and overall it appears that AM 
eells were developing a more immature phenotype [176, 177].
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1.5.2.4 Mechanisms by which macrophages may support airway inflammation
It may be that in the background of an active inflammatory process such as asthma where a 
Tli2 dominance has already been asserted then cells o f the innate immune response can, by 
producing general lymphocyte growth factors such as IL-2, promote and maintain 
inflammation [178]. Indeed IL-10 produced by macrophages is loiown to support a TH2 
profile preferentially. There are other possible mechanisms.
Firstly, AM are capable o f suppressing immune activity partly by the production o f NO 
which inhibits T lymphocyte proliferation, AM are twice as good at this inhibition than PM 
[161]. It has been noted that ThI cells are more sensitive to such inhibition than Th2 cells, 
and thus selective expansion o f Th2 cells may result from activated AM producing 
NO[179]. Secondly it has been suggested that IM, by virtue of their close proximity to DC 
may influence accessory cell function and thus regulate the adaptive immune response. 
Thirdly AM and DC are the only lung cells capable o f phagocytosis and thus functioning 
as antigen presenting cells to T and B lymphocytes. In a recent study o f pollen starch 
granule (PSG) phagocytosis, it was found that AM bound and internalised PSG in a lectin 
and p2-integrin dependent fashion, [165]. Uptake o f PSG in this study was associated with 
the expression of iNOS and nitric oxide production from the AM cells studied. Thus the 
AM in the lung and bronchus may serve to screen inspired air for allergens and by 
internalising them become activated and promote the inflammatory response.
A final mechanism by which AM may promote airways inflammation is by responding to 
airbourne bacterial wall products such as LPS. LPS and other bacterial proteins are 
recognised by microbial recognition receptors on AM such as CD 14. By stimulating the 
production of cytokines and mediators these molecules can influence the behaviour o f the 
adaptive immune response. Endotoxin (LPS) has been found associated with aeroallergens 
such as pollen and house dust mite and asthma symptoms have been reported to correlate
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with the level o f household endotoxin. Macrophages from asthmatics express increased 
levels of CD 14 when compared with non-asthmatics [168]. Direct inhalation o f endotoxin 
in both mouse and human subjects causes acute inflammation, bronchoconstriction and 
airways hyper-responsiveness [180]. In other studies intravenous LPS resulted in 
bronchoconstriction mediated by COX-2 expression [181] and CD 14 +ve cells exposed to 
inhaled LPS cells have been shown to prolong eosinophil survival [182]. GM-CSF 
treatment o f isolated lungs significantly increased the sensitivity to the LPS induced 
bronchoconstriction [183]. This was believed to be due to prim ing o f lung cells and 
probably AM to produce COX-2. Finally Schwartz etal dem onstrated that topical 
application o f synthetic inhibitors o f LPS into the airway could block inflammation and 
subsequent AHR [180]. Thus by virtue o f their sensitivity to airborne LPS, AM can 
activate and perpetuate an inflammatory response in the airway that has many o f the 
hallmarks o f asthma. This model not only supports the use o f AM as a model for 
therapeutic manipulation but suggests that understanding the complex biochemistry 
associated with LPS stimulation could also aid our understanding.
1.5.2.5 Alveolar macrophages may induce bronchoconstriction by eicosanoid  
production
Accumulating evidence suggests that AM influence airway inflammation resulting in 
AHR, but it is also possible they are involved in producing bronchoconstriction. The 
molecular mechanisms prom oting bronchoconstriction lie in the chemical mediators 
released from activated macrophages. Martin et al [184] demonstrated in precision cut lung 
sections that COX-2 inhibition reduced the constrictive response to asthmatic airway 
milieu. COX-2 and the bioactive lipids that it produces including PGE2 and TXA2 are 
pathogenic for both asthma and COPD [185]. Studies comparing lung cells found that IM 
expressed most COX-2 mRNA in non-inflammatory lung closely followed by epithelial
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cells. It is interesting to speculate that in the asthmatic airway where AM may undergo a 
monocytic “de-differentiation” that COX-2 may be more active in the AM.
Finally as has already been discussed the capacity for AM to produce leukotrienes is 
enhanced by maturation. The enhanced activity is related to the nuclear localisation o f 5- 
LO the synthetic enzyme o f LTA4. This molecule is the precursor o f LTB4, which acts as 
a neutrophil chemoattractant and the cysteinyl leukotrienes (LTC4, LTD4 and LTE4). 
These chemicals promote bronchial smooth muscle contraction and vascular permeability. 
Interestingly Fuller et al found that while agents which indirectly elevate cAMP in AM, 
such as PDE inhibitors could prevent the release of TXB2, the ^2 agonist isoprenaline was 
ineffective[186]. This was thought to be due to a lack o f responsive (32-adrenoceptor.
1.5.3 Conclusions
The alveolar macrophage is an attractive model to study the role of PDE4 isoforms in the 
regulation o f inflammation. Defined developmental stages and a clear progenitor cell allow 
analysis o f isoform expression as seen for PKC isoforms. Biochemical regulation is 
important in the development and it is likely therefore that distinct PDE4 isoforms will be 
expressed at specific stages. Finally macrophages are important cells in airway disease and 
PDE4 inhibition is likely to result in significant therapeutic interventions.
1.6 Cyclic AMP in the macrophage
Cyclic AMP regulation of macrophage function and macrophage control o f cAMP signal 
transduction will provide the final topic for this discussion. Cyclic AMP is largely 
inhibitory to macrophage function thus PDE4 promotes inflammation. The effect of cAMP 
on pro-inflammatory functions is cell specific and I will limit the discussion to monocytes 
and macrophages as these form the subject of investigation in this thesis.
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1.6.1 Cyclic AMP Signalling in Macrophages
It is clear that cyclic AMP signalling can regulate important inflammatory functions of 
macrophages. The outcome of a cAMP signal depends on the range o f proteins involved in 
signal transduction expressed at a cellular level. What is known o f these molecules in 
macrophages?
1.6.1.1 Adenylyl cyclase and receptors
Cyclic AMP is generated by adenylyl cyclase in response to ligand binding to various 
receptors. Multiple AC coupled receptors are expressed by macrophages with endogenous 
ligands ranging from bioactive lipids such as prostanoids to amino acid hormones such as 
adrenaline.
1.6.1.1.1 Adrenergic Receptors
O f particular significance to respiratory disease is the expression of a range of adrenergic 
receptors. These are receptors for the endogenous catecholamine hormones adrenaline and 
nor-adrenaline. |3l, P2 and a  adrenergic receptors are expressed on alveolar and peritoneal 
macrophages [187]. Regulation o f macrophages during sepsis is mainly mediated through 
the (32 receptor [188]. The (32 receptor is a classical G-protein coupled receptor that 
activates AC upon ligand binding. Therapeutic manipulation of this receptor using agents 
such as isoprotenolol have proven effective in reducing LPS stim ulated cytokine 
production from macrophages, including T N Fa [189] and IL-12 [190]. This does not 
represent a general suppression of macrophage function however as IL-6 production is not 
inhibited [189] and the production o f IL-10 can be increased [191]. Hasko et al however 
reported a widespread suppression o f multiple cytokines from isoprotenolol treated RAW 
264.7 macrophages [192].
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L 6.1,1.2 Prostaglandin receptors
Prostaglandin receptors are also coupled to AC. Prostaglandins are important macrophage 
derived mediators o f inflammation and have autocrine effects on their cells o f origin. 
Hubbard et al dem onstrated regulation o f expression o f prostaglandin receptors with 
isoforms EP2, EP3 and EP4 being expressed in resting RAW 264.7 macrophages with a 
preponderance o f EP4 [193]. LPS treatm ent caused increased EP2 production while 
interferon y resulted in a reduction in EP2 and EP4 expression. PGE2 a macrophage 
derived ligand for both EP2 and EP4 exerts significant inhibitory effects over macrophage 
activity. For example exogenous PGE2 reduces T N Fa and IL-12 production in response to 
LPS [194]. Prostaglandins have also been shown to inhibit phagocytosis of apoptotic cells 
by macrophages [195].
1.6.1.1.3 Cytokine receptors
Cytokines represent intercellular messengers signalling between inflammatory cells. GM- 
CSF is an important macrophage growth factor and cytokine controlling proliferation and 
activation. Coleman et al found that treatment o f macrophages with GM-CSF led to 
increased AC activity in membrane preparations of isolated macrophages with a resultant 
increase in cAMP [196].
Therefore a range o f chemical mediators o f inflammation are ligands for AC coupled 
receptors. While the majority result in supression o f activity, others such as GM-CSF are 
important in the full expression o f macrophage dependent inflammation.
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1.6.1.2 Signal transduction
Cyclic AMP dependent signals can be communicated by both PKA and the cAMP 
dependent GEF, EPAC, via Rap-1 activation. Both of these cascades have been found to 
regulate important macrophages processes.
1.6.1.2.1 PKA
The role o f PKA in regulating macrophage activation is generally thought to be inhibitory. 
Cyclic AMP prevents macrophage apoptosis [197] and probably explains AC activation by 
GM-CSF. Interestingly in the context o f this thesis agents that elevate cAMP by PDE 
inhibition show diverse effects. Thus while theophylline at therapeutic concentrations 
causes apoptosis and reduces IL-5 or GM-CSF inhibition o f o f apoptosis, PDE4 selective 
agents do the opposite [198]. Rolipram was found to prevent apoptosis induced by Fas 
ligand in eosinophils and increase the anti-apoptotic effects o f IL-5 and GM-CSF. 
Otherwise PKA activation by IL-I3 activates arginase reducing nitric oxide production 
[199], inhibits T N F a production [200] and is involved in cyclic AMP prevention of 
phagocytosis [195]. Among the PKA targets expressed by macrophages is the cyclin B 
protein, cDc2 kinase. PKA phosphorylation o f this protein leads to delayed progression 
through cell cycle during proliferation and a G2 phase delay [201]. This might partially 
explain the inhibition o f macrophage proliferation by PGE2 described by Banner et al 
[202]. Finally Delgado et al found that vasoactive intestinal peptide (VIP) and pituitary 
adenylyl cyclase activating peptide (PACP), both enhanced the expression o f B7.1 co­
stimulatory molecule in a PKA dependent manner [203]. This had the effect of enhancing 
macrophage stimulated T cell proliferation and may reflect accessory cell function in vivo.
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L 6 .L 2 .2  E P A C -R a p l
The discovery o f the small cAMP activated GEF, EPAC, has recently offered an 
alternative pathway for cAMP dependent signalling [38]. No studies have yet been 
published demonstrating EPAC in macrophages, but its partner Rap-1 has been found to 
regulate macrophage behaviour. Caron et al have found constitutively active Rap-1 mimics 
the effects of (31 integrin activation [204]. Rap-1 and Ras express competitive behaviour 
and constitutively activated Ras did not have the same effect. It appears that R ap-1 may 
regulate macrophage binding and therefore chemotaxis and phagocytosis.
Signal transduction o f a cAMP signal can therefore be accomplished in macrophages in a 
complex fashion. Understanding the roles o f cAMP signal transduction has therefore 
expanded our understanding of cAMP regulation o f macrophage function.
1.6.1.3 Transcription factors
Ultimately cellular regulation is achieved by gene transcription and cAMP response 
elements (CRE) are present in the promoters o f various macrophage expressed proteins. 
Cyclic AMP response elem ent binding protein (CREB), is activated by PKA by 
phosphorylation at S e r i33 [22]. CREB can promote or repress gene transcription. For 
example Parry et al demonstrated activated CREB competed with N F kB for a binding 
protein (CBP) thus reducing its potential for gene transcription [26] whereas Proffitt et al 
found CREB dependent expression of MIP-1(3 in murine macrophages [205]. O f particular 
interest to macrophage function, Delgado et al found that VIP and PCAP decreased LPS 
induced T N Fa production by CREB activation and NFkB repression [206].
Cyclo-oxygenase and i-NOS represent two im portant macrophage derived proteins 
regulated by cAMP. I will now discuss these enzymes in some detail as they form 
important subjects in the work to be described.
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1.6.1 A  Cyclooxygênase 2
Cyclooxygenase (COX) is the prostaglandin synthase, which converts arachadonic acid to 
PGH, the substrate for the more specific prostaglandin synthase enzymes [207]. Two COX 
isoforms are recognised, COX 1 and C0X 2 the latter being an inducible form found at sites 
o f inflammation [207]. COX2 is capable of producing a variety o f lipid mediaters of 
inflammation including prostaglandin E2 (PGE2), PGD2 and thromboxane A2 (TXA2). 
While macrophage expressed PGE2 is believed to promote a healing phenotype by the 
production o f the fibroblast growth factor IGF-1 [208], PGD2 is thought to support a more 
tumourocidal pattern of behaviour[209]. TXA2 on the other hand is capable of inducing 
bronchospasm in asthmatic airways [210]. COX-2 products exist therefore in a complex 
balance in the pathogenesis of asthma [211].
Fournier et al demonstrated that at sites of high T N F a production such as asthmatic 
airways COX-2 was most likely to produce PGE2 supporting the hypothesis that COX-2 
expression is protective in airways disease [209]. PGE2 is im portant in macrophage 
biology by virtue o f its capacity to maintain a specific phenotype. PGE2 promotes the 
expression o f the LPS receptor CD 14, which I have described as being increased in 
macrophages in asthmatic airways. This would be expected to enhance LPS sensitivity of 
these cells, which itself increases COX-2 and therefore PGE2 production [212]. Finally in 
the presence o f LPS, PGE2 enhances its own production ensuring that in a state o f LPS 
induced inflamm ation positive regulation o f receptor and COX-2 enzyme promotes 
phenotypic stability [213].
Studies using exogenous cAMP and AC activators have shown cAMP to cause and 
enhance LPS induced COX-2 expression [214, 215]. The role o f PKA is more contoversial. 
While zymosan stimulation, a model o f phagocytosis caused H89 resistant COX-2 
production, T N Fa induced COX-2 was reduced by H89 co-stimulation. Caivano et al 
warned that H89 was capable o f inhibiting M SKl and MSK2, as well as PKA and that this 
may interfere with post LPS signalling [216]. Examination o f COX-2 promoter regions
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suggest that cAMP can upregulate expression. Miller et al found co-stimulation o f AP-1 
and the CRE sites in the COX-2 promoter to explain the synergism between LPS and 
cAMP stimuli [217]. Gorgani et al found that mice deficient in C/EBP, an important 
transcription factor binding protein involved in cAMP response elements (CRE) in 
promoter regions, were unable to produce COX-2 in response to multiple stimuli [218]. 
Finally Wadleigh et al made multiple deletions o f the COX-2 promoter and found that 
while both cAMP response elements and NFkB response elements are present, only the 
CRE box was essential for LPS induced activation o f COX-2[212].
COX-2 therefore represents an important macrophage enzyme, promoting an asthmatic 
airway and lies under the control of cAMP.
1.6.1.5 Inducible nitric oxide synthase
Inducible nitric oxide synthase (iNOS), represents another macrophage product under 
cAMP control. Three NOS enzymes exist of which iNOS is inducible at sites o f 
inflammation including the asthmatic airway [219]. The role o f macrophage derived NO is 
not clear but some evidence points to an anti-inflammatory bronchodilatory activity [179].
Cyclic AMP can increase or decrease the expression o f iNOS in activated macropahges 
and the precise outcome appears to depend on the cell type examined and the stimulus 
applied. Nusing et al found that both db-cAMP and PGE2 applied to mesangial cells 
caused enhanced LPS stimulated iNOS production [220], while Delgado found that 
vasoactive intestinal peptide prevented LPS and interferon y (IFNy), stimulated iNOS 
production from RAW  264.7 m acrophages. Thus another im portant prom oter o f 
inflammation and macrophage regulation is regulated by cAMP signalling pathways.
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L 6.1.6 Summary
It appears therefore that the molecular apparatus for activating and transducing a cAMP 
dependent signal are available in macrophages. These molecules regulate macrophage 
function and the degree o f complexity and the molecular variety suggests a high degree of 
control can be exerted by manipulating cAMP signals. The limiting factor to any cAMP 
signal is cAMP phosphodiesterase.
1.7 Phosphodiesterase isoforms in macrophages and 
monocytes
1.7.1 PDE Profile
In 1976 Thomson et al found that the greatest cAMP phosphodiesterase activity in human 
inflammatory and immune cells correlated with PDE4 [221]. Many subsequent studies 
looking at lymphocytes and monocytes have confirmed this analysis. Interest in the field 
was generated by studies demonstrating that PDE4 inhibitors prevent proinflammatory 
behaviour in these cells. Mapping the PDE profiles and changes in response to stimuli in 
inflammatory cells has developed into a major research interest.
1.7.1.1 Ex-vivo monocytes
Many groups have shown a PDE4 dominance in the cAMP PDE profile o f monocytes 
isolated from human blood and found PDE4 to represent between 60-75% of the total 
activity [119, 126, 222, 223]. While Thompson in the original work on monocytes found 
very little PDE3 represented, subsequent studies have recorded between 9 and 40% of the 
total cAMP PDE activity to be inhibited by cGMP. While the majority of PDE3 is found in 
the particulate fraction o f  disrupted monocytes, all studies that have looked have shown
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90-100% of PDE4 to be cytosolic [223, 224]. This suggests specific isoform targeting in 
these cells.
1.7.1.2 Alveolar macrophages
Investigating the PDE profile of AM is much harder due to the lower abundance of these 
cells and the complexity in acquiring them. Tenor et al looked the PDE isoforms expressed 
in isolated alveolar macrophages and found PDE3 and PDEl to represent 45% each of 
total PDE activity while PDE4 was significantly less [127]. Again PDE4 was entirely 
soluble, while PDE3 was membrane associated. Due to the difficulties in acquiring 
macrophages Gantner et al investigated the PDE activity o f peripheral blood monocytes 
cultured on plastic and found a profile very similar to AM. PD El activity rose from 
approximately 0 to 55% of total PDE activity and PDE3 increased to 55%. PDE4, however 
fell to between 15-20% [119]. In contrast to this Kelly et al have found AM isolated from 
guinea pig lungs express significant amounts o f PDE4 [225].
It appears therefore that the maturation of macrophages from the monocyte progenitor cell 
is accompanied by a change in the mechanisms of cAMP control. This suggests that each 
PDE family is important for regulating functions specific for each type of cell.
1.7.1.3 PDE4 isoforms
Although changes in the contribution o f PDE4 to the total cAMP activity have been 
described less work has been reported on the changes in PDE4 iso form expression. 
Attempts have been made to profile PDE4 isoforms in monocytes and macrophages using 
RT-PCR and western blot analysis. Manning et al demonstrated mRNA transcripts for 
PDE4 A, B and D in resting ex-vivo monocytes, but little detectable protein [222]. After 
treatment with the P2 adrenergic receptor agonist salbutamol, for 4 hrs increases in total 
PDE4 activity, increased levels o f PDE4A and B mRNA and detectable PDE4 protein were 
recorded. Souness et al found PDE4A and PDE4B mRNA in monocytes, but also 
identified a faint band corresponding to PDE4D [223]. Studies using the U937 cell line
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have confirmed the presence of three PDE4 isoforms and demonstrated an increase in 
enzyme expression with salbutamol [226]. McKenzie and Houslay have shown that PDE4 
A, B and D are present in resting U937 cells and by im m unoprécipitation have 
demonstrated that these contribute approximately 1%, 20% and 80% respectively. No 
work specifically reporting the PDE4 isoform profile o f macrophages has been reported to 
date. This may represent a combination o f the difficulty in acquiring sufficient cells to 
identify members o f a low abundance enzyme family.
1.7.2 Functional Importance of FDE4
Regulation o f PDE4 during cell specific maturation suggests important functional roles in 
cellular control. Evidence for such important roles is hard to provide. If  dysregulation of 
PDE4 function was shown to cause a disease state then the significance of PDE4 could be 
implied.
1.7.2A  PDE4 in disease
Early studies o f PDE activity in disease found that peripheral blood monocytes from 
patients with atopic dermatitis had greater PDE4 activity than the same cells from normal 
donors [227]. Other groups have not found a similar difference however [126] Gantner et 
al went further and mapped the PDE4 isoforms and found no significant differences in 
expression between normal donors and patients with atopic dermatitis. No significant 
differences have been found in any cell type from atopic donors including B lymphocytes 
[125] and eosinophils [228]. Studies on cells purified from asthmatic subjects have been 
similarly unrewarding [229].
Inhibitors o f PDE4 on the other hand suggest that this family might have a role to play. 
While in vivo studies make it difficult to tease out the cells responsible for a therapeutic 
response. Studies o f isolated cells or cell line models allow careful cell identification.
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1.7.2.2 PDE4 inhibitors in monocyte and macrophage regulation
PDE4 inhibition potently reduces TN Fa production from LPS stimulated monocytes [223], 
and to a lesser extent macrophages [163]. Gantner et al looking at ex-vivo monocytes 
demonstrated that rolipram was capable of preventing T N Fa release at levels where cAMP 
increases were undetectable [119]. Souness et al also found that while low levels of 
rolipram were capable of inhibiting T N Fa release, to measure a significant increase in 
cellular cAMP PGE2 had to be added to activate AC [223]. That this combination 
increased cAMP over PGB2 alone demonstrates the functional importance o f PDE4 in 
monocytes as the main cAMP hydrolysing enzyme. Seldon et al found (32 adrenergic 
receptor agonists had the same effect as PGE2 with rolipram by generating an excess o f 
cAMP over the presence o f inhibitor alone [142]. Thus PDE4 is capable of altering pro- 
inflammatory behaviour at concentrations below that which result in measurable cAMP. 
This suggests that while dysregulation may not cause disease the normal functioning of 
PDE4 is permissive for inflammation to progress. What of other PDE isoforms?
Inhibitors o f PDE3 do not have the same effects on TN Fa production as PDE4 inhibitors 
[141]. This may simply reflect the smaller contribution o f PDE3 to total cAMP PDE 
activity seen in many inflammatory cells. The capacity for rolipram to inhibit T N Fa 
without substantial changes to cellular cAMP argues against a dose effect as do equivalent 
studies in macrophages where PDE3 is found in greater quantities than PDE4. Gantner et 
al found rolipram to have a weak inhibitory effect on T N F a production in monocyte 
derived macrophages while PDE3, now representing a greater proportion of the total PDE 
activity had no effect whatsoever [119]. If cAMP production was augmented by the 
addition o f PGE2 then the effect o f rolipram was significantly enhanced, as was, to a lesser 
extent that o f PDE3.
Thus the functional importance o f PDE4 in macrophages and monocytes is seen when 
inhibition o f pro-inflammatory behaviour is investigated. PDE4 inhibition can prevent
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T N Fa production at very low inhibitor concentrations. This effect can be enhanced by 
exogenous stimulators of AC and an equivalent effect is not found with PDE3 inhibitors 
even though PDE3 represents an major cAMP PDE in macrophages.
1.7.3 Compartmentalisation / crosstalk
The apparent ability o f rolipram to inhibit cellular function at concentrations less than are 
required to generate cAMP requires explanation. The principle behaviour o f rolipram is 
PDE4 inhibition and it is this behaviour that has been shown to cause immunomodulation. 
Rolipram may alter intracellular cAMP concentration to levels below the sensitivity o f 
experimental testing. Could such small changes in cAMP have demonstrable effects on 
cellular behaviour however?
One other explanation may lie in the principle of compartmentalisation described in section
1.1.3 [96]. The generation o f localised pools o f cAMP contained by targeted PDE4 
isoform s im plies that very low levels o f cellular cAMP could mask high local 
concentrations. In this case inhibitors causing a relatively small total increase in cellular 
cAMP could have significant influence over a signalling cascade in the same cellular 
compartment by the principle of crosstalk. The principle o f compartmentalisation remains 
to be rigourously tested in inflammatory cells, however several lines o f evidence support 
the concept.
1.7.3.1 Functional specificity o f  PDE isoforms
Firstly studies mentioned above describe a frmctional distinction between PDE3 and PDE4 
inhibitors in terms o f T N Fa inhibition from LPS stimulated macrophages. Chini et al 
describe a similar distinction between proliferation and superoxide release by PDE3 and 
PDE4 inhibitors in renal mesangial cells [98]. They found cAMP suppressed both 
proliferation and superoxide radical release but while PDE3 inhibitors prevented cell 
division, PDE4 inhibitors prevented superoxide radical production. M onocyte ROM
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generation has also been shown to be reduced by PDE4 inhibitors. Further evidence for 
functional compartmentalisation comes from work carried out in a myeloid cell line 
FDCP2 cells [102]. This cell line was reported to have roughly equal amounts of PDE3 and 
PDE4 but they were shown to be under different control. Total cAMP PDE activity was 
increased by treatment with IL-3, IL-4 and GM-CSF and the PKC activator PMA each 
PDE isoform responded differently. While all 4 stimulants activated PDE4 activity only 
IL-4 activated PDE3. IL-4 was shown to activate total PDE activity by PI-3 kinase 
dependent system, but while PDE4 was activated by E R K l/2  activation o f PDE3 was 
ERK l/2 independent. ERK signals were also shown to be responsible for the activation of 
PDE4 by IL-3 and PMA. Thus different PDE isoforms are under different control 
mechanisms which are functionally relevant as they represent the signalling moieties o f 
different pro-inflammatory cytokines. It is interesting from the pathological perspective 
that IL-4 a classical Th2 cytokine activates PDE3 while other cytokines do not.
1.7.3.2 Targeting o f  PDE4
While this work supports functional compartmentalisation of PDE3 and PDE4 it does not 
suggest that PDE4 isoforms are similarly distinct. Some circum stantial evidence does 
suppo rt PDE4 isoform s com partm entalisa tion . It has been suggested  tha t 
compartmentalisation implies certain prerequisites must exist [4]. A regulated source o f 
signal, a detector for that signal and a destroying activity are required. Adenylyl cyclase, 
PKA and PDE4 are all present in macrophages as described above. Another requirement is 
that these molecules are all targeted in the cell. Evidence for targeting o f PKA and AC is 
accumulating from other tissues, although little work has been done in inflammatory cells. 
Circumstantial evidence from non-inflammatory studies supports the targeting o f PDE4 
isoforms in general and suggests possible means o f targeting in inflammatory cells 
specifically.
The PDE4D5 binding partner RA CKl is important in macrophage function [84]. For 
example, impaired T N F a production due to ageing was overcome by replacing RACK
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1[230], RACK 1 has also been shown to associate with the intracellular portions of 
cytokine receptors [89] and (3 integrins [88]. Lyn kinase, a binding partner of PDE4A4, is 
only expressed by haem opoietic cells and has been im plicated in LPS activation of 
macrophages [82] [231]. Huston et al showed that PDE4A was a substrate for caspase3 a 
regulator of apoptosis and was cleaved to produce a more active enzyme [232]. The region 
found to be removed was the SH3 interaction domain implying a possible role for protein 
protein interactions as controlling cAMP in normal cells.
Thus Targeting of PDE4 isoforms within inflammatory cells has a theoretical basis, but the 
concept o f compartmentalisation dependent on differential targeting of PDE4 isoforms 
requires further testing.
1.7.4 Conclusions section 1.7
I have described the molecular basis for cAMP signalling in macrophages. The variety of 
molecules involved in the regulation of this single compound suggest that its control is 
important to the cell and that it may play a number o f roles in cell function. PDE4 
inhibitors, by virtue o f their capacity to elevate cAMP, influence pro-inflammatory 
behaviour. This behaviour has been taken advantage of by the pharmaceutical industries 
who require to address a number o f outstanding questions before rational therapeutic 
manipulation o f PDE4 can be achieved. These questions and possible means o f answering 
them will form the conclusion to this introduction.
1.8 Conclusions and hypotheses
Cyclic AMP signalling depends on a cascade of events and at every level of this cascade 
nature has provided a selection o f molecules from which effectors can be chosen. The 
pressure on nature for efficiency suggests that these choices are not random and that 
redundancy in these families o f signalling molecules is unlikely. Individual PDE4 isoforms 
are therefore likely to provide specific control over cAMP governing specific outcomes
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and in specific circumstances. Considerable circumstantial evidence suggests that sub 
cellular compartmentalisation and inter molecular crosstalk explains the roles o f each 
molecule in a given setting.
M acrophages are im portant cells in the inflamm atory response producing important 
mediators and responding to foreign agents and toxins. They are also regulated to a high 
degree by intra cellular cAMP. Cell line models offer a useful tool for examining the 
control of macrophages in vitro.
I hypo thesised that individual PDE4 isoforms would regula te specific macrophage 
functions. I tested these hypotheses by isolating individual PDE4 iso forms from LPS 
treated macropahges and measuring their activity. I further hypothesised that macrophage 
development from monocyte progenitors would be accompanied by a change in the PDE4 
isoforms expressed. These changes would suggest which isoforms are im portant in 
regulating macrophage functions. Due to the difficulty in acquiring sufficient tissue 
macrophages to measure these low abundance proteins I aimed to develop a cell model of 
macrophage development. I selected the U937 model previously described due the high 
level of characterisation already reported.
Alongside these aims I wished to measure macrophage responses to inhibition of PDE4. I 
used LPS as a stimulus for activation and rolipram as a specific inhibitor of PDE4. I also 
hypothesised that PDE4 engaged in m olecular crosstalk w ith signalling cascades 
downstream of LPS receptors. In particular I aimed to identify a crosstalk model between 
ERK l/2 and PDE4 via Rap-1. I tested this hypotheses by measuring ERIC2 activation in 
the presence and absence o f rolipram.
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Chapter 2 Materials and Methods
2.1 Materials
Unless otherwise stated all chemicals were from Sigma-Aldrich (Gillingham UK, SP8 
4XT) or Fischer Scientific (Loughborough, UK) and were of analytical grade. All solutions 
were prepared in de-ionised and filtered w ater and sterilised where appropriate by 
autoclave or filter.
2.1.1 Bioactive Reagents
The following cell signalling reagents were used. From Sigma Aldrich UK. (Gillingham 
UK SP84XT); Phorbol 12 M yristate 13-Acetate (PMA, Cat No 79346); Salmonella 
Minnesota Lipopolysaccharide (LPS y irradiated and phenoli extracted for cell culture, Cat 
No L4641); Human recom binant Epidermal Growth Factor (EGF, Cat No E9644); 
Salbutamol (Cat No S8260); Wortmannin Pénicillium Funiculosum (Wortmannin, Cat No 
W1628); Cilostamide (Cat No C7971); Tumour Necrosis Factor Alpha (TN Fa, Cat No 
T7539); A ctinom ycin D (Cat No A4262) and Protein K inase A Inhibitor Fragment 
Myristilated (PKA Inhib Myr, Cat No P9115). From Promega UK (Southampton UK, 
S016 7NS): U 0126 (Cat No V I 121) and SB203580 (Cat No V I 161). From Calbiochem 
(San Diego, CA, USA); Indomethacin (Cat No 405268) and H89 dihydrochloride (H89, 
Cat No 371963).
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2.1.2 Antibodies
Name/No Target Source Application Dilution 2°
Schering B Muman
g e n e r ic
isoforms
and rat 
PD E 4B
Schering-plough WB,ELISA,IP 1/1000 R
270 H um an
g e n e r ic
isoforms
and rat 
PD E 4A
S cottish  antibody 
produc tion unit ( 
SBTS. Lanark UK)
WB, IP 1/2000 R
93 H um an
g e n e r ic
isoforms
and ra t 
P D E 4D
S cottish  antibody 
produc tion unit ( 
SBTS. Lanark UK)
WB, IP 1/2000 R
Anti-IntegrinaM
(SC6612)
CD-11 Santa Cruz Biotech. 
(Santa Cruz. CA 
95060. US)
WB 1/5000 G
Anti-PKC(3 Protein 
isoform P
K inase C Transduction 
Laboratories 
(Lexington, KY, US)
WB 1/5000 M
Anti-COX-2
(C22420)
Cyclooxygenase 2 Transduction 
Laboratories 
(Lexington, KY, US)
WB 1/10,000 M
Anti-ERKl/2 
(El 7120-050)
Pan -ERK 1 and 
ERK 2 Mitogen 
activated protein 
kinase
Transduction 
Laboratories 
(Lexington, KY, US)
WB 1/5000 M
Anti-P-ERKl/2
(T202/Y206,
612358)
Phosphorylated 
(activated) ERKl/2
Transduction 
Laboratories 
(Lexington, KY, US)
WB 1/1000 R
Anti-RACK-1 
(TLR20620-050)
RACK-1 Transduction 
Laboratories 
(Lexington, KY, US)
WB 1/10,000 M
Anti-iNOS
(N39120)
Inducible nitric oxide 
synthase
Transduction 
Laboratories 
(Lexington, KY, US)
WB 1/10,000 M
Anti- m ouse/rat 
TNFa (mo46423)
Turn ou r 
factora
necro sis Pharmingen ELISA M
Anti-CREB 
(scl86)
C am p
e lem en t
protein
re sp o n se
b in d in g
Santa Cruz Biotech. 
(Santa Cruz. CA 
95060. US)
WB 1/400 R
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Anti-P-CREB
(sc7978)
Anti-rap 1 
(R22020)
Phosphorylated Santa Cruz Biotech. WB
(activated) CREB (P- (Santa Cruz. CA
Serl33) 95060. US)
Human and mouse Transduction
Rap] Laboratories 
(Lexington, KY, US)
Anti-rabbit HRP Rabbit IgG (Horse Amersham
(A6154) rad ish  perox idase  Pharmacia
conjugated antibody)
Anti-mouse FIRP Mouse IgM (Horse Amersham
WB
WB ELISA
WB ELISA
(NA-931V)
An t i  -B 
(sc9002)
Anti C Raf
rad ish  peroxidase Pharmacia 
conjugated antibody)
R a f  Human B Raf
Human C Raf
Santa Cruz Biotech. IP, WB 
(San ta Cruz. CA 
95060. US)
Santa Cruz Biotech. IP, WB 
(San ta Cruz. CA 
95060. US)
1/400
1/5000
1/5000
G
1/10,000 M
1/10,000 N/A
1/10,000 N/A
M
M
Table 2.1 A ntibodies used in the follow ing research. (WB, Western Blot; IP, 
Immunoprécipitation; ELISA, Enzyme-linked Immunosorbant Assay; 2 ,^ species o f secondary 
antibody used; M, Mouse; G, Goat; R, Rabbit)
2.L3  Primers
The following oligonucleotides were used in the following research.
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PDE4 Isoform Forward primer Reverse
Primer
Fragment 
size (bp)
Cycling 
conditions: 
Dn An Ex
PDE4A4B -  specific N- 
terminal region
CGGAAAGGAGCCTGTCT
CTG
AGTGCCATG
GAAGGACGA
GG
257 94 "C 
30 s
60 ”C 
30 s
72°C 
1 m
PDE4A10 -  specific N- 
terminal region
AGATCTGTCAGCTTCGAG
GCAG
AGTGAGAAG
TTGCTACGG
ACGGC
281 94 "C 
30 s
60 T  
30 s
72°C 
1 m
HIV-tat-PDE4B2 -  
specific N-terminal 
region
GAGCTCTATGGCAGGAA
GAAGCGGAGACAGCGAC
GAAGACGGCGGCGGCGG
CGGCGGCGGATGCCTTG
AGATGGCAAAGCACTC
AATCACAGT
GGTGCTCTG
CCTGAGCTC
270 94 T  
Im
68 °C
45 s
72V  
1 m
HIV-tat-PDE4B2 -  full 
length
GAGCTCTATGGCAGGAA
GAAGCGGAGACAGCGAC
GAAGACGGCGGCGGCGG
CGGCGGCGGATGCCTTG
AGATGGCAAAGCACTC
TTATGTATCC
GAGCTC 1861 94 °C Im
52 T  
45 s
72V  
1 m
HIV-tat-PDE4D3- 
specific N- terminal 
region
GAGCTCTATGGCAGGAA
GAAGCGGAGACAGCGAC
GAAGACGGCGGCGGCGG
CGGCGGCGGATGATGCA
CGTGAATAATTT
TGGCCAAGA
CCTGAGCAA
ATGAGCTC
358 94 °C 
Im
68 °C 
45 s
72°C 
1 m
HIV-tat-PDE4D3-full
length
GAGCTCTATGGCAGGAA
GAAGCGGAGACAGCGAC
GAAGACGGCGGCGGCGG
CGGCGGCGGATGATGCA
CGTGAATAATTT
GATCTACAT
CATGTATTG
CACTGGCGA
GCTC
2088 94 “C 
Im
52 T  
45 s
72V  
1 m
Table 2.2 Primers used in the following research. Oligonucleotides were ordered from 
Interactiva©, Cycle conditions are as follows: Dn, dénaturation; An, annealing; Ex, 
Extension; S, seconds; M, minutes
2.1.4 Plasmids
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Clone
(name)
Plasmid/ 
Restriction site
Description: Source: Reference:
PDE4B1 
(pcDNA R89)
PcDNA 3 .0 / 
Notl
Native PDE4B1 G Bolger [233]
PDE4B2 PcDNA 3 .0 / 
Notl
Native human PDE4B2 G Bolger [233]
PDE4B3 PcDNA 3.0/ 
Notl
Native human PDE4B G Bolger [233]
PDE4B4 PcDNA 3.0/ 
Notl
Native Rat PDE4B4 G Bolger (326)
PDE4B4-
S56D
PcDNA 3.0 / 
Notl
PDE4B4 with Ser56 mutated to 
Asp, mimicking the 
phosphorylated conformation.
G Bolger (326)
PDE4B4-
S56A
PcDNA 3 .0 / 
Notl
PDE4B4 with Ser56 mutated to 
Ala preventing the phosphorylation 
at this site.
G Bolger (326)
PDE4B4-
S14D
PcDNA 3 .0 / 
Notl
PDE4B4 with Seri 4 mutated to 
Asp, mimicking the 
phosphorylated conformation.
G Bolger (326)
PDE4B4-
S14A
PcDNA 3 .0 / 
Notl
PDE4B4 with Seri4 mutated to 
Ala preventing the phosphorylation 
at this site.
G Bolger (326)
PDE4B4-
FLAG
PcDNA 3.0 / 
Notl
Native Rat PDE4B4 tagged with 
FLAG peptide sequence
G Bolger (326)
PDE4B4-
S56D
PcDNA 3 .0 / 
Notl
PDE4B4 with Ser56 mutated to 
Asp, tagged with FLAG peptide 
sequence.
G Bolger (326)
PDE4B4-
S56A
PcDNA 3 .0 / 
Notl
PDE4B4 with Ser56 mutated to 
Ala tagged with FLAG peptide 
sequence.
G Bolger (326)
PDE4B4-
S14D
PcDNA 3 .0 / 
Notl
PDE4B4 with Seri 4 mutated to 
Asp, tagged with FLAG peptide 
sequence.
G Bolger (326)
PDE4B4-
S14A
PcDNA 3.0 / 
Notl
PDE4B4 with Seri4 mutated to 
Ala tagged with FLAG peptide 
sequence.
G Bolger (326)
PDE4A4 PcDNA 3.0 Native human PDE4A4 sequence In house [76]
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PDE4A10
PDE4D3
Rap 11A
Rap IA­
SI 80A
Rap 1A- 
S180D
RaplA-
Serl2-Val
RaplA-
T17N
PcDNA 3.0
PcDNA3 / Notl
Native human PDE4A10 
sequences
In house
PcDNA 3.0 Native human PDE4D3 sequence In house
Native RaplA
PcDNA3 / Notl RaplA with Seri 80 mutated to Ala
preventing PKA phosphorylation
PcDNA3 / Notl RaplA with Seri 80 mutated to 
Asp mimicking PKA 
phosphorylation
pEXV3 RaplA with Seri2 mutated to Val
resulting in a constitutively active 
conformation
pEXV3 Rap 1A with Thr 17 mutated to Asn
resulting in a dominant negative 
conformation.
In house
In house
In house
J Bos et al
J Bos et al
[234]
[66]
[235] 
[235]
[235]
[204]
[204]
Table 2.3 Plasmids used in the following research. Various plasmids were used in the 
course o f this project. Some were cloned sequences generated in our laboratory, while 
some were gifts from kind collaborators. P rof G Bolger provided many o f the PDE4 
constructs in particular the PDE4B4 constructs. The R aplA  activation mutants were kind 
gifts from Prof J Bos.
Plasmids were transformed into E Coli bacteria and stored as glycerol stocks at -70 C.
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2.2 Buffers and Solutions
2.2.1 Cell Culture
2.2.1.1 Cell Culture Medium  
DMEM
Dulbecco’s modified Eagles Medium (GibCo Life technologies, Paisley, UK. Cat No 
11965). This medium supports the growth of a broad range o f mammalian cell lines.
RPMi 1640
Roswell Park Memorial Institution 1640 (GibCo Life Technologies, Paisley, UK. Cat No 
11875). This medium supports mammalian cell lines and was originally developed to 
support growth o f leukaemic cells.
Complete medium
Cell culture medium with the addition o f 10% (v/v) fetal calf Serum, 2mM L- 
Glutamine, 1 unit/ml penicillin and 1 mg/ml streptomycin.
Serum free medium
As complete but excluding fetal calf Serum
Transfection medium
5ml Complete medium (replacing fetal calf Serum newborn calf
Serum.)
1 OOpM Chloroquine
6 i
2,2.1.2 Cell culture buffers 
Wash Buffers
Phosphate Buffered Saline (PBS)
2.7mM KCl
137mM NaCl
4mM NaiPOq
Tris Buffered Saline (TBS)
137mM NaCl
20mM Tris pH 7.6
Transfection Buffers
T E Buffer
lOmM Tris-HCl pH 7.2
IniM EDTA
DNA adhesion buffer
lOOmg DEAEDextran
10ml PBS
Shock Buffer
10%(v/v) DMSO/PBS
Lysis Buffers
KHEM lysis Buffer
50mM Hepes KOH, pH7.4
50mM KCl
lOmM EGTA
1.92mM MgClz
3T3 -  Lysis Buffer
50mM HEPES, pH 7.2
lOmM EDTA
lOOmM NaH 2P 0 4 ,2 H 2 0
1 % (v/v) Triton X -100
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Nuclear Buffer A
lOmM Hepes pH 7.5
1.5mM M gCb
lOmM KCl
0.5mM DTT
Nuclear Buffer B
20mM Hepes pH 7.5
20%(v/v) Glycerol
0.2mM EDTA
0.5mM DTT
Protease Inhibitors
Protease inhibitors were included in all lysis buffers and were added immediately 
before use to a final concentration o f 40p,l/ml. Complete EDTA free protease 
inhibitors were from Boheringer Mannheim, and made up as 2ml HzO/tablet.
2,2.2 Biochemical Techniques
2.2.2.1 Lactate dehydrogenase (LDH) reaction buffer 
150mM Tris HCl pH 7.4
2.2.2.2 LD H  reaction mix:
Washed fraction mix;
186pl LDH reaction buffer 
7|il lOmM Pyruvate
7ji.l Lysate sample
Occluded fraction mix:
17 2jil LDH reaction buffer 
7pi 1 OmM Pyruvate
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7pi Lysate sample
14pl Triton X -100
2.2 .23  PDE4 Assay buffer
lOmM M gC li
20mM Tris/HCl, pH 7.4
2.2.2.4 PDE4 Assay Dilution Buffer 
20mM Tris/HCl, pH 7.4
2.2.2.5 Protein Kinase Assay Bujfer (2X)
lOOmM Tris
3 OmM MgCl:
3 OmM P-mercaptoethanol
20% (v/v) Glycerol
2.2.2.6 Kinase Assay Reaction Mix
500pl 2X KAB
lOpl [32p]y-ATP
490pl H2 O
2.2.2.7
O.IM Na2P04 (pH 9.0)
2.2.2.8 ELISA Blocking Buffer
10% fetal bovine serum in western blot wash buffer
2.2.2.Ç ABTS Substrate Solution
150mg 2,2’-AzinO“bis-(3-ethylbenzthiazoline-6-sulfonic acid)
500ml O.IM anhydrous citric acid in dH20
2.2.2.10 5X  SDS loading buffer
0.26M Tris/HCl (pH 6.7)
55.5% Glycerol
8.8% SDS
11.1% b-mercaptoethanol
2.2.2.11 2X S D S  loading buffer
0.125M Tris/HCl (pH 6.7)
25% Glycerol
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4% SDS
5% b-mercaptoethanoi
2.2.2.12 Acrylamide resolving gel (6-8%)
6-8% 29:1 Acrylamide:N,N’-methylenebisacrylamide mix
0.375M Tris/HCl pH8.8
0.1% SDS
0.1% Ammonium Persulphate
0.06% N ,N ,N hN ’-tetramethylethylenediamine (TEMED)
2.2.2.12 Acrylamide resolving gel (10-15%)
10-15% 29:1 Acrylamide:N,N’-methylenebisacrylamide mix
0.375M Tris/HCl pH8.8
0.1% SDS
0.1% Ammonium Persulphate
0.04% TEMED
2.2.2.14 Acrylamide stacking gel
5% 29:1 Acrylamide:N,N’-methylenebisaciylamide mix
0.125M Tris/HCl pH8.8
0.1% SDS
0.1% Ammonium Persulphate
0.1% TEMED
2.2.2.15 Tris-Glycine running buffer
192mM Glycine
25mM Tris
0.15% SDS
2.2.2.16 Transfer Buffer
192mM Glycine
25mM Tris
20% Methanol
2.2.2.17 Western Blot Wash Buffer
137mM NaCl
2OmM Tris pH 7.6
0.05% Tween
2.2.2.18 Blocking Buffer
137mM NaCl
20mM Tris pH 7.6
0.05% Tween
5%(w/v) Skimmed milk protein
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2.2.2.19 Antibody Dilution Buffer
137mM NaCl
20mM Tris pH 7.6
0.05% Tween
l%(w/v) Skimmed milk protein
2.2.2.20 Ponceau S  stain
0 . 1%
3%
Ponceau S 
Trichloroacetic acid
2.2.2.21 Coomassie stain
0,025% Coomassie brilliant blue R 250
40% Methanol
7% Acetic acid
2.2.2.22 Destain
40%
7%
Methanol 
Acetic acid
2.2.3 Molecular Biological techniques
2.2.3.1 Tris Acetate Electgrophoresis (TAE) Buffer
2M Tris
IM Acetic acid
0.05M EDTA
2 PCR Reaction mix
50mM KCl ( 1 OX in Taq polymeRase buffer)
1 OmM Tris HCl (lOX in Taq polymeRase buffer)
200pM dATP
200pM dCTP
200pM dTTP
200pM dGTP
1.5mM M gCb
> ln g Template DNA
5 units Taq polymeRase
0.5pM sense/antisense primer
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2.23 .4  cDNA synthesis mixture (all solutions from  kit)
llpl
Ipl
Ipl
20pl
“Bulk first strand cDNA mix” 
DTT solution
N otl-d(T)10 (0.2pg/pl) primer 
heat-denatured RNA
2.2.3.5 L-Broth
170mM 
0.5%(w/v) 
1 %(w/v)
+ /-
NaCl
Bacto-Yeast extract
Bacto-Tryptone
Antibiotic
2.2.3.Ô LB-Agar
170mM
0.5%(w/v)
l%(w/v)
2%
NaCl
Bacto-Yeast extract
Bacto-Tryptone
Agar
lOmM 
15 OmM 
ImM
Tris pH 8.0
NaCl
EDTA
2.2.3.8 Bacterial lysis reagents stoc/cs
Lysozyme 
Sarkosyl 
Triton X-100
lOmg/ml in STE 
10% in STE 
10% in STE
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2.3 Mammalian cell culture
All solutions used in the manipulation of cell culture were heat sterilised by autoclave.
2.3.1 Cell lines
COS 1 cells are an African green monkey renal cell line immortalised with an origin 
defective mutant simian virus 40 (SV 40). The expression o f the SV 40 T antigen in COS 
cells facilitates the transcription o f plasmid DNA containing the SV 40 origin o f 
replication. This characteristic means that COS cells provide an excellent vehicle for 
transient transfection for analysis o f over expressed proteins. COS 1 cells were maintained 
in com plete DMEM unless being prepared for transfection or Serum starved for 
stimulation. Trypsin EDTA (Sigma Aldrich T4299), solution is required to passage COS-1 
cells as they are firmly adherent to plastic.
23.7.2 C/937 (EC4CC3307/4(4(0)
U937 cells are derived from a human histiocytic lymphoma and continue to express many 
monocytic markers. U937 is a useful tool to investigate the mechanisms of monocyte 
inflammatory signalling. They are a suspension cell and were maintained in RPM I 
medium. U 9 3 7 p m a  were U937 cells treated with 4nm PMA for 4 days. Medium was 
replaced after 2 days.
23.7.3 TCmv 2W. 7 cgZ/j- (EC4CC 97002707;)
Raw 264.7 monocyte macrophage cells were isolated from a murine lymphoma caused by 
the Abelson leukaem ia virus. They are capable o f phagocytosis and have many
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charateristics o f macrophages. They are adherent and were m aintained in complete 
DMEM.
2.3.1.4 Human Monocytes
Human monocytes were collected to compare with a model based on the U937 cells.
I D o n o r  S e le c t io n
Normal healthy volunteers were selected and full ethics approval was obtained from the 
local ethics committee.
II M o n o c y t e  Iso la t ion
Heparanised whole blood was collected and centrifuged over Ficoll-Hypaque at 350 X G 
for 30 mins. The mononuclear cell layer was removed and washed in Ca^^ and Mg^ "^  - free 
Hanks salt solution and resuspended in RPM I (Section 2.2.1.1). Monocytes were isolated 
by incubation with paramegnetic beads conjugated to anti-CD 14 antibodies (Dynabeads 
M-450 CD -14) and magnetic separation according to manufacturer's instructions.
III M o n o c y t e  C u l tu re
Monocytes were cultured under standard conditions (Section 2.3.2) in plastic lOOcm^ 
culture plates. Culture was allowed to proceed for varying lengths of time ( 0 - 7  days) with 
frequent changes in culture medium.
2.3.2 Culture Conditions
All mammalian cell culture was performed in incubators maintaining ambient temperature 
at 37°C and a 5%C02 enriched atmosphere. COS and Raw 264.7 cells were grown in 
continuous culture as a monolayer. U937 cells were grown as a continuous suspension.
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Cells were passaged at approxim ately 90%, confluence and were split 1:5. This 
necessitated passage every 4 days.
2.3.3 Pharmacological treatment
Unless otherwise stated cells were Serum-starved for 4 -1 2  hours prior to the addition of 
pharmacological agents. Signal transduction inhibitors were added 30 minutes prior to 
further stimulation or manipulation. Pharmacological agents were stored at -20°C as 10 X 
stock solutions. Lipopolysaccharide was used both in the presence and absence of Serum to 
allow for the presence of LPS binding proteins.
2.3.4 Transfection
Plasmid DNA was prepared for bacterial hosts and diluted in TE buffer (2.2.1.3.1).
2.3.4. ID EAE Dextran transfection
24 hours prior to transfection 90% confluent COS 1 cells were split 1:2. They were grown 
overnight until 50-60% confluent. lOpg plasmid DNA per 79cm^ cells was diluted to 
40ng/ml in sterile TE buffer (2.2.1.3.1), then further diluted in DNA adhesion buffer 
(2.2.1.3.2) to 40ng/ml. This mixture was incubated at room temperature for 15 min and 
5ml transfection medium (2.2.1..1.5) at 37°C was added. This was mixed then added to 
flasks from which medium had been freshly removed. Following 3-4  hours incubation, 
DNA solution was aspirated and cells were shocked by the brief (2 min) addition of 2 ml 
shock buffer (2.2.1.3.3). Cells were washed once with 10 ml PBS and complete DMEM 
added. Cells were incubated for 72 hours before being harvested.
Where mock transfections were run in parallel all steps were followed, but DNA was 
omitted.
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23 .4 .2  Superfect transfection (Qiagen)— as per manufacturer's instructions
24 hours prior to transfection Raw 264.7 cells were split to 50% confluence and grown 
over night. 5|ng/ 60mm dish DNA was dissolved in 10|ul TE buffer. 130|Ul Non enriched 
DMEM was added, followed by 30|ul superfect reagent. The solution was mixed then 
incubated at RT for 10 minutes. 1ml complete DMEM was added to the DNA solution and 
this was added to cells. Cells were incubated for 3 hours under normal conditions, then the 
solution was removed and cells washed once with PBS at 37°C. Complete DMEM was 
added and incubated for 72 hours prior to harvest.
2.3.5 Cell counting
Cell number was calculated using a standard haemocytometer. Suspension cells were 
diluted in trypan blue 1:1 (v:v), and injected under a cover-slip on an haemocytometer. 
Cells deemed viable by their ability to exclude trypan blue were counted in 5 defined areas 
in two regions o f the haemocytometer and the mean calculated. This figure was then 
adjusted for dilution and volume. Where adherent cells ( U 9 3 7 p m a )  were counted these 
were grown on gridded cover-slips and counted in the same way.
2.3.6 Disruption
Prior to disruption cells were either washed 3 times in PBS and scraped (adherent cells) or 
collected from suspension by centrifugation and washed 3 times in PBS.
2.3.6.1 Non-detergent based lysis
Cells were homogenised in KHEM buffer with 0.5mM DTT and pro tease inhibitors by 
passage through a 26 gauge needle 10 times. The homogenate was then fractionated by 
centrifugation at 2,000 rpm for 5 minutes and the supernatant (SI)  was removed. The
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resulting pellet (P I) was washed in KHEM buffer and kept on ice until resuspension. The 
SI was further fractionated by high-speed centrifugation (55,000rpm for 30 minutes), 
producing a supernatant (S2) and pellet (P2). The P2 fraction was washed in KHEM buffer 
and both pellets were resuspended in a volume equal to the final volume o f the S2 fraction. 
Lactate dehydrogenase assay was performed to confirm the integrity o f each fraction.
23 .6 .2  Detergent based lysis
Washed cells were either scraped into (adherent cells), or added to 3T3 lysis buffer and 
incubated end over end for 30 minutes before separating the detergent insoluble fraction by 
centrifugation at 13,000 rpm for 5minutes. The detergent soluble supernatant was reserved.
2.3.6 .3 Nuclear fractionation
Preparations of enriched nuclei from RAW 264.7 cells were prepared as follows. Washed 
cells were resuspended in 500 |ll1 nuclear buffer A to which the detergent NP40 (0.1%v/v) 
had been added. Cells were mixed and gently pipetted on ice for 10 minutes before being 
separated by centrifugation at 12,000rpm for 5 minutes. Pellet was retained and 
resuspended in 300pl nuclear buffer B. Enriched nuclei were lysed by sonication on ice at 
40W, for 5 seconds. Sonicate was separated by centrifugation at 12,000 rpm for 5 minutes 
and the supernatant was retained.
2.4 Biochemical Techniques
2.4.1 Sample preparation and storage
Protein samples for western blot analysis were diluted in 5X SDS loading buffer and 
heated to 100° C for 5 minutes to denature the proteins.
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Protein samples for enzyme assay analysis were frozen in liquid nitrogen and stored at 
-70°C until use.
Protein samples for other forms o f analysis were frozen in liquid nitrogen and stored at 
-20°C.
2.4.2 Protein quantification (Bradford's assay)
Lysate protein content was measured in 96 well microtitre plates against a standard curve 
derived from known concentrations o f bovine Serum albumin (BSA) 0-5p,M. A series o f 
dilutions o f test lysate were made in 50jul volumes and 200|ul 1:5 B radford’s reagent was 
added to these and the standard curve protein. Light absorbance at 590nM was measured 
on a MRX microtitre plate reader (Dynex teehnologies). All samples were measured in 
triplicate.
2.4.3 Lactate Dehydrogenase (LDH) Assay
To confirm the integrity o f high speed fractionation the activity o f the cytosolic enzyme 
lactate dehydrogenase (LDH) was measured in each fraction. The following reaction 
allows quantification o f NADH oxidation to be measured spectrophotemetrically in 96 
well microtitre plates using a MRX microtitre plate reader at 340nm wavelength:
Pyruvate + NADPLI ----- ► Lactate 4- NAD
The activity o f washed and occluded fractions were measured by setting up pre-reaction 
solutions and the reaction was started by the addition of lOfil 2mM P-NADH. Readings 
were taken at 20 second intervals for 10 minutes. The rate o f extinguishing was 
proportional to the LDH activity in the sample, and the difference between washed and 
occluded fractions represented contamination o f pellet fractions by intact cells or S2. 
(appendix 2  demonstrates the integrity of fractionation measured in this way).
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2.4.4 Phosphodiesterase assay
Cyclic AMP was stored at -20°Cas a lOmM stock and diluted to ImM  immediately prior
to use. Substrate solution was prepared by further diluting the stock cAMP to 2pM in assay
1 -1 buffer supplemented with 8 - H cAMP (O.OOSjnCi pi ). The reaction was performed in
lOOpl volume consisting o f 50pl cAMP (final concentration IpM ) and 40pl sample lysate. 
Rolipram or assay buffer contributed the remaining lOpl. The solution was mixed by 
vortexing and the reaction was performed at 30°C for 10 minutes. Where PDE4 activity 
was less abundant a longer reaction period was used after ensuring this remained in the 
linear range o f the reaction. Placing in boiling water for 2 minutes stopped the reaction and 
tubes were cooled on ice.
25pl of 1 mg/ml snake venom (Crotalus atrox venom) was added to the reaction and mixed 
by vortexing. This was then incubated for 10 minutes at 30°C and cooled on ice. 400 pi of 
a 1 :1 : 1  solution o f activated dowex : water : ethanol was then added, and thoroughly 
mixed. This was then incubated on ice for a minimum of 15 minutes with regular agitation 
before being vortexed and separated by centrifugation at 13,000 rpm for 3 mins. 150pl of 
the top soluble layer was then removed and added to 1 ml o f scintillation fluid and counted 
on a Wallac 1409 liquid scintillation counter.
Data was processed using the following calculation where X is the mean o f the PDE 
activity measured in triplicate with a value o f non-metabolised cAMP subtracted.
(X/ (total activity o f 50pl 2pM  cAMP solution)  ^ 391.67/150 (representing the proportion 
o f total reaction supernatant sampled) * (1*10'^-10 / 10) (representing moles of cAMP in 
solution divided by the time of the reaction) \ 0 3 2  (converting to picomoles)) / quantity 
o f protein in pg tested. This equation produces an activity in terms o f velocity
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pmol/min/pg. W here activity is expressed as pmol/min/mg the figure is multiplied by 
1000 .
2.4.5 Kinetic analysis o fP D E 4 isoforms
When characterising the activity o f PDE4B4 I modified the asssay as follows.
2.4.5.1 Transfection specific activity
For each transfection o f active PDE4B4, a mock transfection and a comparison PDE4B 
isoform were included as controls. To calculate the specific activity for each PDE4B4 
assay mock activity for a given [cAMP] was subtracted from the transfected activity under 
investigation.
2.4.5.2 Relative transfection efficiency
Comparison o f relative activities between two transfections requires assessment of enzyme 
expression for each. Quantative analysis was performed by ELISA using antisera raised 
against the C-terminal region o f PDE4B iso forms or by semi-quantitative western blot 
analysis. In the latter analysis increasing quantities o f protein from two transfection lysates 
were western blotted beside each other. Densitometry using Kodak 2.0 software was then 
used to construct protein Vs density plots. The gradient o f these plots reflects the amount 
of transfected protein present. The ratio o f these gradients was used to adjust activities 
against each comparative experiment.
2.4.5.3 Relative activity determination
To define the K ^  o f PDE4B4, data from PDE assays over a range of cAMP concentrations
0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 4, 6 , 8 , 10, 15, 20, 25, 30pM, were plotted and analysed using
15
computer m odelling o f the parabolic form of the M ichaelis-M enton equation. This 
equation (y=(M l*M 0)/M 2+M0, where y = V obs, M l = V max, MO = [cAMP] and M2 =
Km), was used to calculate the Km- Each assay was performed in triplicate and each
experiment was performed on three transfected samples. Equal amounts o f enzyme were 
used to generate Kobs and V max was calculated for IpM  cAMP. Relative V max 
calculations were calculated by comparing V max for PDE4B4 and comparing it against V 
max for a known PDE4B control.
2.4.5A I C 50 Rolipram
IC50 o f an enzyme for its inhibitor is calculated by measuring the activity of an enzyme at a 
set substrate concentration in this case 1 pM cAMP, in the presence o f varying amounts of 
inhibitor. I used 10, 5, 2, 1, 0.5, 0.2, 0.1, 0.05, 0.02, 0.01 and 0 pM rolipram and 3pg lysate 
protein. IC50 was then calculated by using a least squares log fitting algorithm.
2.4 . 6  Preparation and running o f  Tris-Glycine gel
Both mini-gels and standard 25cm gel kits (Bio-RAD, Hemel hempsted) were used for 
SDS-Poly-acrylam ide gel electrophoresis (SDS-PAGE) during this work. The gel 
apparatus was assembled as per the manufacturer’s instructions. A resolving gel (2.2.2.11, 
2 .2 .2 . 1 2 ) appropriate for the molecular weight of the protein under investigation (see table 
2.4) was prepared and poured between the plates. A protective layer o f deionised water 
was poured on top to exclude oxygen during polymerisation. The gel was left for a 
minimum o f 30 minutes at room temperature. One hour before use a stacking gel was 
prepared and poured on top o f  the resolving gel (2.2.2.13). Once poured a comb was 
inserted to make wells in the stacking gel. Running buffer was used to clean the individual 
wells o f non-polymerised gel solution. Samples prepared in SDS sample buffer (2.2.2.10) 
were warmed to 40°C prior to being loaded into wells. The gel was then immersed in a
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tank containing tris-glycine running buffer (2.2.2.14). A hood connected to an electrical 
supply was connected and electrophoresis was performed for 1-4 hours (40 V / gel) or 16 
hours ( 8  V/gel).
Acrylamide content (%) Molecular weight (kDa)
8 40-200
1 0 2 1 - 1 0 0
1 2 10-40
Table 2.4 Range of protein separation on SDS PAGE
2.4.7 Transfer to nitrocellulose
Once SDS-PAGE was complete the gel was removed and layered on a pre-soaked 
nitrocellulose membrane (Bio-RAD XjUiM). This was then immersed in transfer buffer and 
sandwiched between two protective non-insulative plates bound by 3mm blotting paper 
(Whatman, UK). This assembly was slotted in a transfer tank and proteins were electrically 
transferred to nitrocellulose at 1 A, for 1 hour. To confirm adequate transfer and equal 
loading o f lanes, membranes were washed in Panceau red stain to visualise proteins 
(2.2.2.19).
2.4.8 Immunostaining o f  proteins
Membranes were blocked in 5% milk protein blocking buffer (2.2.2.17), for 1 hour and 
washed in wash buffer three times (2.2.2.16). Proteins were visualised by incubation with 
antibodies raised against the proteins selected, at the pre-determined concentrations in 1 % 
blocking buffer. Incubations were performed for 4 hours at room temperature or o/n at 
4°C. Membranes were washed 3 times in wash buffer and incubated with peroxidase- 
conjugated secondary antibody (0 .0 0 0 0 1 %), appropriate for the species o f the primary 
antibody in 1% blocking buffer (see table 2.1). After 1 hour membranes were washed and
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treated with ECL-reagent (Amersham ltd) prior to development on blue light sensitive film 
(KODAK, UK).
In all cases positive controls were recombinant proteins expressed in COS cells (SAPU, 
PDE4 isoform antibodies) or well characterised cell conditions supplied with antibodies 
(commercial antibodies).
2.4.9 Quantification o f  western blot analysis
Where quantification of expressed protein was required radiographs were scanned on and 
densitometry o f expressed band was performed using kodak ID software. A control band o f 
recombinant sample, fi'om transfected COS cells was used as a blank value and different 
quantities o f cell lysate were compared to generate a range o f values. A mean of these 
values was used for comparison with a similarly calculated mean for an opposing set of 
conditions.
In the specific case o f phospho-ERK antibodies, the ratio o f P-ERK band density was 
compared with total ERK band density and ratios are expressed.
2.4.10PDE4B2 Back Phosphorylation
Six confluent flasks o f RAW 264.7 cells were treated with LPS for a range o f time 
intervals. Cells w ere w ashed in ice cold PBS and lysed in 3T3-lysis buffer. 
Immunoprécipitation of PDE4B isoforms was performed as described below. After 2 hours 
incubation with antibody captured PDE4B was isolated on protein A-beads, beads were 
collected and washed 3 times in 3T3-lysis buffer containing protease inhibitors. Beads 
were then washed once in PBS and once in kinase assay buffer (2,2.15).
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To Im l o f kinase assay reaction buffer, lp,l 0.2mM ATP-P^^ was added. W here 
phosphorylation was to be performed, l|al (21.4mU) recombinant ERK kinase was added 
to the immunoprecipitates in a micro-tube, followed by 50|O.l reaction buffer. These were 
mixed and incubated for 30 minutes at 30°C. Beads were collected by centrifugation, and 
supernatant removed. Beads were then boiled in 2X sample buffer collected and 
supernatants were loaded onto an SDS-poly acrylamide gel.
Following SDS-PAGE, proteins were transferred to a nitrocellulose and incubated on a 
phosphoimage plate and images were quantified on a phosphoimager (Bio-Rad LTD, UK).
2.4.11 Immunoprécipitation and Co-immunoprecipitation
Immunoprécipitation was performed using antisera, raised against cell signalling molecules 
in non-immune animals. Pre-immune serum is serum from the animal used to raise the 
antisera, prior to exposure to the antigenic portion of the molecule. Ranging experiments 
were performed to assess the optimum ratio of cell protein to antisera to immunoprecipitate 
all active target molecule.
Cells lysates were prepared in 3T3-lysis buffer and protein content quantified. A volume 
of cell lysate equivalent to the required amount o f protein was incubated with a volume of 
preim m une serum  equal to the volum e o f im m une serum  to be used for 
immunoprécipitation. Incubation was allowed to continue for 1 hour at 4°C end over end. 
During incubation, 60jil o f protein A beads per immunoprecipitate sample were prepared 
by repeated centrifugation at 13,000rpm and washed in lOOjul 3T3 lysis buffer with 
protease inhibitors. Immediately prior to use these beads were washed again, distributed to 
micro-tubes and immunoprecipitate samples were added. Protein A binds to the Fc portion 
o f IgG antibodies allowing these to be isolated from solution. Further incubation was 
allowed to continue for 30mins at 4°C.
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Preimmune antibodies bound to protein A coated beads were removed by centrifugation, 
and antiserum was added to the resulting precleared lysate. Incubation with antiserum was 
allowed to continue for 2 hours at 4°C, before being added to protein A beads prepared as 
above. Further incubation was allowed to continue for 30 mins at 4°C and beads were 
collected by centrifugation at 13,000rpm.
Protein A beads were washed in PBS with IpM  DTT, and protease inhibitors, twice and 
transferred to a new microtube. Where immunoprecipitates were to be analysed by western 
blot, beads were washed once more in 3T3 lysis buffer with protease inhibitors, collected 
by centrifugation and resuspended in IX SDS loading buffer. These samples were boiled 
for 5 mins and the bead free supernatant was collected and loaded onto polyacrylamide gel. 
Where immunoprecipitates were to be analysed by phosphodiesterase4 assay, beads were 
washed once in PDE4 assay buffer with IjiM  DTT and protease inhibitors, before being 
resuspended in I20p.l PDE4 assay buffer and distributed evenly between three microtubes.
2.4.12Enzyme-linked Immunosorbant Assay (ELISA)
ELISA was performed to quantify the amount o f protein in cell lysate or cell culture 
medium. All ELISA was performed with test samples in parallel with standards o f known 
quantity, by which a standard curve was generated. Four different quantification protocols 
were followed. Where cell culture medium was being assayed, standards were prepared in 
the culture medium used. Where cell lysate was prepared all samples were diluted in lysis 
buffer to a range o f protein concentrations (Appendix 1, presents the standard curves 
prepared).
2.4A 2.1 "In -  house ” TN Fa assay
Anti- T N Fa capture antibody, was diluted in ELISA binding buffer to 2pg/ml and 50|Ll1 of 
the resulting solution was added to each well of a 96 well ELISA plate. Plates were sealed
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with wax paper and incubated for 1 Shours at 4°C. Plates were warmed to room temperature 
and excess capture antibody removed by washing twice with PBS. Non-specific peptide 
binding was blocked by incubating each well for 2 hours at room temperature with 1 OOpl 
ELISA blocking buffer. Blocking buffer was removed by 3 washes with western blot wash 
buffer.
Samples and standards were prepared in DMEM lOOpl. T N Fa standards were prepared by 
multiple dilutions from 200ng/ml to 0.195ng/ml. lOOjil samples and standards were added 
to each well the plate was sealed with wax paper and incubation was allowed to continue 
overnight at 4°C. Following incubation plates were allowed to rewarm to room temperature 
and wells were washed 4 times with western blot wash buffer.
Biotinylated anti- T N Fa was diluted to Ifig/ml in western blot wash buffer, and lOOpl was 
added to each well. Incubation was allowed to continue for 1 hour at room temperature and 
plates were washed with lOOpl wash buffer per well 4 times. Avidin-horse radish 
peroxidase conjugate (Av-HRP) was diluted to 2pg/ml in ELISA blocking buffer and 
lOOpl was added to each well. Incubation at room temperature was allowed to continue for 
30 minutes before each well was washed in western blot wash buffer 4 times.
ABTS substrate solution was thawed immediately prior to use and 1 00|il H 2 O2 added to 
1 Imls solution. lOOpl o f prepared substrate solution was added per well and incubated at 
room temperature in the dark until colour change occurred. Plates were read in a micro- 
titre plate reader at 405nm over a range o f time. Standard curves were calculate from the 
standards and samples were measured by reference to this standard curve. Appendix 1.2 
presents a typical example of a cytokine standard curve.
81
2.4.12.2 Commercial TN Fa ELISA (Chemicon International, Inc, CA, USA)
For T N F a assay in RAW 264,7 cells transfected with Rap-1 mutants the commercial 
mouse T N Fa enzyme immunosorbant assay (EIA) kit (Chemikine, mouse TN Fa EIA kit, 
Cat CYT140) was used. This kit is a competitive EIA using wells precoated with T N Fa 
antiserum to which samples and standards were added. Following washing biotinylated 
TN Fa was added to occupy free antibody sites. Streptavidin-alkaline phosphatase was 
bound to the biotin and colour reaction was achieved with commercial solutions and 
quantified by absorption at 490nm. In contrast to the in-house T N F a ELISA, a high 
reading indicates free antibody and therefore a low TN Fa content in the test solution.
2.4.12.3 Recombinant Protein ELISA
Where relative transfection efficiencies were compared by cell lysate ELISA for PDE4 
isoforms the volumes of cell lysate representing a range of protein quantities, prepared in 
KHEM were allowed to bed in 96 well ELISA plates at 4°C overnight. PDE4B content of 
this embedded lysate was detected by incubating each well with PDE4B antiserum diluted 
1/5000 in ELISA blocking buffer. Incubation was allowed to continue for 1 hour at room 
temperature and antibody was removed by washing 4 times with western blot wash buffer. 
HRP conjugated anti-rabbit antibody was diluted to 0.5jig/ml in ELISA blocking buffer 
and lOOjil was added to each well. Incubation was allowed to continue for 1 hour at room 
temperature and antibody was removed by washing 4 times in ELISA wash buffer.
ABTS substrate solution was prepared as for cytokine detection, and 100|ul was added to 
each well and incubation was continued for a range o f time periods at room temperature in 
the dark. Protein was quantified by optical density measurement at 405nm and relative 
protein quantities were plotted by O.D. against protein quantity. A representative assay is 
presented in appendix 1.2 (p249).
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2.4.12.4 Prostaglandin E2 (PGE2) EIA
PGE2 production from RAW264.7 cells was quantified using the commercial EIA kit from 
Cayman chemicals CO, USA. This competitive ETA uses 96 well ELISA plates coated 
with goat anti-mouse antiserum to which a mixture of sample or standard, mouse anti- 
PGE2 antiserum and alkaline phosphatase conjugated PGE2 is added and incubated at 
room temperature for 2 hours. This mixture is washed and colour reagent added. The 
resulting colour change is quantified by light absorption at 490nm and a plot o f known 
standard against OD 4 9 0nm was used to generate a standard curve. Test samples were 
calculated from this standard curve (appendix 1.3, p250).
2.5 Molecular biology techniques
2.5.1 Plasmid /  DNA preparation
Glycerol stocks of E Coll transformed with plasmids encoding recombinant proteins were 
maintained at -70 °C. Prior to bulk preparation a sample o f stock was smeared on antibiotic 
selective agar plates, and grown o/n at 37 °C. One colony was selected to innoculate a 10 
ml (mini-prep) or a 400ml (maxi-prep) flask o f L-Broth with appropriate antibiotic added. 
A fter incubation for 24 hours, bacteria were collected by centrifugation. Plasmid 
preparation was performed using either Qiagen’s QIAprep maxiprep kit or QIAprep spin 
miniprep kit. Manufacturer’s instructions were followed at all times.
Recovery o f cDNA from agarose gels was achieved using Q iagen’s Q IAquick gel 
extraction kit following manufacturer’s instructions.
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2.5.2 RNA extraction
Cells were collected by centrifugation and homogenised in Tri-reagent (1m l/10'^7 cells) 
using a 12 guage needle. Homogenates were incubated at room temperature for 5 minutes, 
transferred to sterile eppindorph tubes and centrifuged at 13,000rpm for 5 minutes to 
remove cell debris. Supernatants were transferred to fresh tube, 0.2ml RNAse-free 
chloroform was added and solutions were mixed by vortexing for 15 seconds. RNA and 
DNA were phase separated by incubating the mixed solutions at room temperature for 3 
minutes, then centrifugation at 13,000 rpm for 15 minutes. The aqueous (clear) phase was 
removed to a sterile tube and 0.5ml isopropanol/ml o f Tri-reagent used was added to 
precipitate RNA. Incubation at room temperature for 10 minutes then centrifugation at 
13,000 rpm and 4 oC for 10 minutes collected precipitated RNA. The pellet o f RNA was 
washed with 75% ethanol and RNA stored before quantification immediately prior to use,
2.5.3 Quantification o f  DNA and RNA
A known volume o f dissolved RNA or DNA was quantified spectrophotometrically by 
m easuring absorbance at 260nm and 280nm on a Shim adzu UV-1201 UV-VS 
spectrophotometer blanked against distilled water. Estimates o f nucleic acid quantity and 
purity were made from the following assumptions:
1 . Absorbance o f 1 at 260nm (A2 6 0) is equivalent to:
50p,g/ml double stranded DNA 
37|Lig/ml single stranded DNA 
40|ig/ml RNA
2. A2 6o:A2 8o ratio of pure DNA equals 1.8
A 2 6o:A2 8o ratio o f pure RNA equals 2
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2.5.4 First strand cDNA (Pharmacia kit)
First strand cDNA synthesis uses poly dT primers to amplify poly adenylated niRNA from 
total cell RNA. 5fig total RNA is diluted to 20|ul in DEPC treated H 2O, heated to 65 °C for 
10 minutes and transferred to ice. This was added to first strand cDNA mix (section) and 
gently mixed by pipetting. The solution was incubated at 37 °C for 1 hour then stored at - 
70 °C.
2.5.5 Polymerase chain reaction (PCR)
Where the PCR template was cDNA from total cell RNA PCR is known as reverse 
transcriptase PCR. The PCR reaction subsequently is equivalent to that using plasmid 
DNA as a template. Briefly the PCR mix was assembled (section) and cycled through a 
Techgene therm ocycler PCR machine. Cycling conditions varied for different PCR 
reactions as determined by the melting temperature o f the specific primer used and ranging 
experiments where necessary.
2.5.6 Restriction digest
Restriction enzymes were used to digest plasmid DNA to isolate an incorporated fragment 
or to screen for a cloned cDNA. Restriction enzymes were purchased from promega along 
with the appropriate buffers. Restriction digest was performed in volumes of lOpl in 
diluted buffers with lp.1 enzyme at 37°C.
2.5.7 Agarose gel analysis
Agarose gels were used to resolve nucleic acids o f different molecular weight. Agarose 
content was selected based on the molecular weight o f the nucleic acid o f interest. The
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desired amount o f agarose was added to 20ml 1 X TAE and this mix was microwave 
heated until the agarose was dissolved. Once hand warm 1.7|al ethidium bromide was 
added and mixed by swirling. Molten agarose was poured into the gel mould and allowed 
to set. The tank was filled with TAE, and wells were filled with samples mixed with 
loading dye (promega), and the gel run at 75V until the desired distance was run out. Gels 
were now visualised under UV light by virtue o f ethidium bromide incorporated into 
nucleic acid flourescence.
2.5.8 Plasmid/insert Ligation
Ligation o f PDE4-HIV tat fusion cDNA into linearised PGEX 5.3 for synthesis o f a GST 
fusion protein was achieved using the rapid DNA ligation kit (Roche). M anufacturer’s 
instructions were followed. Briefly, DNA to be ligated ( XXX linearised pGEX-5.3 and 
insert cDNA) was purified from agarose gel quantified. Various molar ratios of vector 
DNA: insert cDNA were dissolved in DNA dilution buffer to a volume of lOpl. The 
optimum molar ratio was measured for each ligation reaction performed using the 
following ratios in ranging experiments 1:7, 1:5 and 1:3. lOpl o f 2 X T4 DNA ligation 
buffer was added and the solution was mixed. Ip l T4 DNA ligase was added, mixed and 
incubated at room temperature for 5 minutes. The ligation reactions were used immediately 
for transformation into bacterial hosts.
2.5.9 Bacterial Transformation
Cloned plasmids were transformed into either TO P-10 (Invitrogen) chemically competent 
E Coli for plasm id amplification, or BL 21 chemically competent E Coli for protein 
expression. In each case transform ation was carried out in the same manner. 50pl 
chemically competent bacteria were thawed on ice and l-5|al o f ligation reaction was 
added and gently mixed. Mixtures were incubated on ice for 30 minutes before heat
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shocking at 42°C for 30-45 seconds before removing to ice. 250pl o f pre-warmed SOC 
medium was added to the transformations, incubated for 1 hour at 37°C and spread on 
appropriate antibiotic selection agar plates. These were incubated inverted o/n at 37°C and 
sample colonies selected for screening by restriction digest and sequencing analysis.
2.5.10 Induction o f  recombinant proteins
Cultures o f E Coli (BL 21), transformed with a plasmid encoding a recombinant HIV-tat 
fusion protein were incubated o/n at 37°C in 10ml L-broth containing lOOpg/ml ampicillin 
(LB amp). These cultures were used to inoculate 400ml cultures o f LB amp, which were 
grown at 37°C with agitation and frequent sampling. Once the OD 600nm was 0.6-1.0 
protein expression was induced by addition o f 4ml lOmM isopropyl P-D-thiogalactoside 
(IPTG) (final concentration O.lmM). Incubation was continued at temperatures ranging 
from 37°C to 4 °C for between 4 hours and 18 hours respectively (see text chapter 6 ). 
Finally bacteria were harvested by centrifugation at 2500g for 5 minutes. Harvested 
bacteria were resuspended in PBS containing protease inhibitors and ImM  DTT and stored 
at -20 °C until use.
2.5.11 Protein purification PBS/sonification
Frozen bacteria were rapidly thawed and kept on ice. Where lysis buffers were used these 
were added to the bacterial solution to the desired dilution. Bacteria were lysed by 
sonication in 30second bursts separated by 30 second rests. The sonicate was separated by 
centrifugation at 13,000rpm for 1 minute and pellet P I, and lysate SI were reServed. These 
were sampled for recombinant protein by addition o f 2X SDS sample buffer heated to 40 
°C and subjected to SDS-PAGE analysis.
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2.5.12 Protein purification Lysosyme/ sarkosyl
Bacteria were prepared as above. Thawed bacteria were washed in STE buffe, resuspended 
in STE Lysosyme lOOjUg/ml and incubated on ice for 15 minutes. DTT was added to a 
final concentration o f 5mM, and cells lysed by addition o f Sarkosyl in varying 
concentrations (see chapter 6 ). Lysates were centrifuged at 10,000 rpm for 5 mins and the 
supernatant reServed. Triton X-100 was added to 2%(v/v) and protein isolation continued 
as below.
2.5.13 Sepharose isolation o f  GST-fusion proteins
Glutathione-sepharose beads equilibrated in the lysis solution required, containing protease 
inhibitors and ImM  DTT were added to solutions shown to contain GST-fusion protein. 
These were incubated end over end for 4-12 hours at 4°C, before beads were collected by 
centrifugation at 13,000 rpm in a bench top refrigerated centrifuge. Beads were held on ice 
and washed in PBS containing protease inhibitors and ImM DTT 3 times. Beads were then 
aliquoted and one aliquot was heated in 2X sample buffer and analysed for protein content 
by SDS-PAGE analysis, with coomassie blue identification.
2.5.14 Protein identification and preservation
Expressed proteins were resolved by SDS-PAGE on mini-gel apparatus as described 
above. Proteins were fixed and stained by incubation in 100ml Coomassie stain and gentle 
agitation at room tem perature for 2 hours. Proteins were visualised by subsequent 
incubation in destain for 1-4 hours at room temperature. Destained gels were rehydrated by 
incubation in 1% glycerol for 30 minutes with agitation.
Finally gels were dried for preservation. The stained gel was layered on the drying surface 
o f a gel drier (Bio-Rad, LTD). The cover sheet was sealed by a vacuum and the gel was 
dried at 65“C for 2 hours.
2.6 Statistical analysis
Statistical analysis was performed on studies where n=3 or more. When comparing the 
PDE4 profile between two cellular populations Student's paired t-Test was performed on 
measures o f activity or on densitometry derived from western blot analyses. Where the 
effect o f rolipram on a EPS driven effect was analysed, the significance of the difference 
between LPS alone and basal conditions and LPS + rolipram and basal conditions. In these 
studies o f TN Fa or PGE2 production, Student's paired t-Test was performed.
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Chapter 3 Characterisation of PDE4B4 
Introduction
PDE 4 genes encode a variety o f isoforms by virtue o f mRNA splice variation and 
differential use o f multiple promoters [4]. Each PDE4 gene family exhibit almost 100% 
sequence homology within regions downstream of their unique N-terminal regions. The 
conserved domains o f U C R l, UCR2 and the catalytic site demonstrate 95% sequence 
homology across mammalian species and to the drosophila dunce gene [50]. Each PDE4 
isoform is unique however at the extreme N-terminal region. Regulatory and targeting 
domains in this region allow individual PDE4 isoforms to exhibit non-conserved 
behaviour, [6 8 ] [73]. The human PDE4B gene has been localised to chromosome 1 and the 
rat PDE4B gene to chromosome 5,[236, 237]. To date, three gene products have been 
described in both species [233]. PDE4B1 and PDE4B3 are both long forms, distinguished 
Eom the short form PDE4B2 by the presence o f the N-terminal UCRl region [50].
A new member of the PDE4B family was recently discovered by our collaborator, Dr G 
Bolger. A rat cerebral cortex cDNA library obtained from Stratagene (La Jolla, CA, USA), 
was probed with cDNA corresponding to the PDE4B UCRl using a technique previously 
described [233]. A novel cDNA named rPDE90, reflecting the novel PDE4B4 isoform, 
was identified and cloned. As has been discussed, [4], the existence o f multiple isoforms of 
PDE4 suggests functional specificity and an understanding o f the physical and biochemical 
characteristics o f each isofoiin can be expected to give clues to its function and regulation
My aim in the work described in this chapter was to dem onstrate the biochemical 
properties, the physical distribution and the regulation o f PDE4B4. By comparing each 
characteristic against other PDE4 isoforms I will demonstrate how individual members of 
each PDE4 family are related and yet exhibit distinct characteristics from each other.
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Results
Section 1
3,1.1 Sequence Confirmation o f  plasm id and transfection efficiency.
PDE4B4 is a 659 amino acid protein containing both U CRl and UCR2, making it a “long 
form” PDE4. Fig 3.1.1 demonstrates the characteristic regions common to all PDE4 
isoforms. PDE4B4 has considerable homology to the other known long form PDE4Bs, 
namely PDE4B1 and PDE4B3, over the C-terminal 642 amino acids. The N-terminal 17 
amino acids o f PDE4B4 show no sequence homology to other PDE4B sequence. However 
remarkable similarity is seen between the unique N -terminal region o f PDE4D3 and 
PDE4B4, with 12 amino acids being conserved, including a PKA phosphorylation target 
domain. This domain includes S eri4 o f PDE4B4 which correlates with S e ri3 o f PDE4D3, 
Fig 3.1.1.
The transcript o f PDE4B4 was cloned from a rat {Rattus Norwegenesis; Sprague Dawley 
strain) cerebral cortex library (Stratagene) and inserted into the N o tl site o f pcDNA3 
mammalian expression vector (Invitrogen). This brings the ORF under the control of the 
cytomegalovirus immediate early promoter allowing, for example, expression in COS cells 
(Fig 3.1.2A). Plasmids were transformed into E.Coli and kept as glycerol stocks as 
described in the methods section. Plasmids were purified as described in and restriction 
digest analysis using S a d  and N otl restriction enzymes confirmed the integrity o f the 
clone (Fig 3.1.2B). N otl cut the insert coding PDE4B4 from the plasmid revealing a very 
high molecular weight band and a fragment o f 2Kba representing PDE4B4. Sac 1 cut the 
plasmid twice and the insert once resulting in one small 700 base fragment, a larger 
IKbase fragment and the plasmid remnant.
PDE4B1 PDE4B2
PDE4B3
CR 1 UCR-2 Catalytic
Domain
COOH
Linking
regionsUnique N-terminal o f PDE4B4
Splice Junction
Unique N-terminal o f PDE4D3
Fig 3 .L I Schematic representation o f  PDE4B4
This diagram (not to scale) represents the amino acid sequence o f  
PDE4B4 and illustrates the modular nature o f the protein. All 
domains other than the red shaded region are shared by the long forms 
PDE4B1 and PDE4B3. One o f  the two PKA phosphorylation sites 
(Seri4), o f  PDE4B4 is highlighted. The second at Ser53, lies within 
the shared long form common region. The splice junction shown 
marks the point o f  divergence between long form and short form 
PDE4B isoforms. Thus PDE4B2 lacks the region N-terminal o f  this 
junction containing UCRl and LRl. The long forms finally diverge 
after UCRl where distinct N-terminal sequence is under the control o f  
specific promoters. The extreme N-terminal sequence o f  PDE4D3 is 
presented beneath the sequence o f  PDE4B4, illustrating the sequence 
homology between these two molecules. Red letters represent shared 
residues while purple letters are non-conserved.
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Restriction enzyme 
target sites
B
1.5Kb
0.5Kb
2Kb
— 0.7Kb
Fig 3.1.2 Restriction digest o f  PDE4B4 confirms plasmid integrity
çPNA coding for PDE4B4 was cloned into pcDNA3 plasmid vector 
between the Notl sites in the poly-linker region. A; a schematic 
representation o f the subsequent plasmid, demonstrating the 
restriction enzyme sites. B; To confirm that the clone used to 
characterise the kinetic behaviour o f  PDE4B4 was intact a restriction 
digest using Notl and Sad  restriction enzymes was performed. Sad  
was used as restriction sites exist within both the plasmid and the 
sequence o f  the cloned insert. The predicted restriction map resulted 
with bands o f  0.7Kb and 1.4Kb following Sad  digestion, and an 
insert band o f 2Kb appearing after Notl digestion. The plasmid was 
thus proven to be intact.
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3.1.2 Specific activity o f  over-expressed PDE4B4
Our laboratory has employed over-expression o f PDE4 isoforms in COS cells as a useful 
means to analyse their biochem ical properties [76], This com pensates for the low 
abundance of these enzymes in nature and the difficulty in analysing a single PDE4 
isoform distinct from other endogenously expressed species. PDE4 activity was measured 
over a range o f protein quantities for transfected and mock transfected cell lysates.
Both Mock transfected and PDE4B4 transfected COS-1 cell extracts exhibited a linear 
relationship between protein content and PDE4 activity (Fig 3.1.3). PDE4B4 transfected 
cells, however exhibited considerably higher activity with a range o f 0-3.4 pmol/min, 
corresponding to between 0 and lOfXg of lysate protein. Mock transfected cells on the other 
hand achieved a maximum PDE4 activity of 0.09 pmol/min/pg over the same range of 
protein. As can be seen the activity/protein curve eventually forms a plateau, as no further 
substrate is available for hydrolysis. Using data from the steep, linear part o f the curve, 
PDE4B4 transfected lysate is shown to have an activity of 0.6 pmol/min/pg with a specific 
activity for PDE4B4 o f 0.58 pmol/min/pg.
To ensure kinetic analysis can be compared between experiments and previous reports, I 
performed all PDE4B4 characterisation at IpM  cAMP. I elected to perform all further 
kinetic analysis using 3pg o f protein lysate as this falls on the linear part o f the 
activity/protein curve measured at l|iM  cAMP. An equivalent time ranging experiment 
was performed to ensure that assaying PDE4B4 at IpM  cAMP for 10 minutes also fell on 
the linear part o f the activity/time curve.
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Fi^ 3.1.3 PDE4B4 protein ranging experiment
COS-1 cells transfected with plasmid coding for PDE4B4 protein and 
mock transfected COS-1 cells were lysed and PDE4 activity was 
calculated for a range o f protein concentrations at 1 pm cAMP. PDE 
activity was plotted against protein to find the linear range within which to 
analyse PDE4B4 activity. As can be seen 3 pg o f transfected protein lay 
within the linear part o f the curve and corresponded to 1.8 +/- 0,3 
pmol/min/pg. In contrast mock transfected COS-1 cells exhibited a cAMP 
PDE activity o f 0.05 4/- 0.01 pmol/min/ pg.
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Section 2
3.2.1 Calculation o f  molecular size
The predicted molecular size for PDE4B4 based on prim ary amino acid sequence is 
73kDa. The experimentally derived molecular weight is calculated from the distance 
migrated on SDS-PAGE gel compared to “markers” o f known molecular weight. This 
experimental determination gives an apparent molecular weight o f 85 +/- 3 kDa. (fig 
3.2.1).
3.2.2 Subcellular distribution ofPD E4B4
It has been shown that certain PDE4 isoforms expressed in COS cells are targeted to 
specific regions within the cell. For example while PDE4A1 is restricted to the cell 
membrane fraction, PDE4D1 and PDE4D2 exist in the soluble compartment [73, 77]. I set 
out to explore the localisation o f recombinant PDE4B4 in COS-1 cells lysed in KHEM 
buffer and subjected to high speed fractionation. The three subcellular compartments 
Pellet! (P I), Pellet2 (2) and Soluble (S2), were examined for PDE4B4 content by PDE4 
assay and western blot analysis.
Two methods of comparing PDE4B4 content can be used. In the first, the PDE4B4 content 
per unit protein of each fraction can be examined. This analysis allows the specific PDE4 
activity o f each fraction to be compared (Fig 3.2.2A). By this form o f analysis the greatest 
PDE4B4 activity in transfected COS-1 cells occurs in the S2 fraction. Different subcellular 
fractions may contain different quantities o f protein. This means that specific activities do 
not reflect proportional activities at a cellular level. Thus 3pg of PI protein is likely to be 
extracted from a different number o f cells than 3|ig o f S2 protein. To compare 
compartments that represent proportionally, a single cell, each fraction must represent the
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1 2.7 90
2 2.5 81
3 1.3 8 4
Figure 3.2.1 Molecular weight o f  PDE4B4
Recombinant PDE4B isoforms were expressed in COS-1 cells and resolved 
by 8% SDS PAGE fig 3.2.1 A. A typical western blot was probed with 
polyclonal anti-PDE4B antibody (Schering). (lane 1 PDE4B1, lane 2 + 3 
PDE4B4 and lane 4 PDE4B2). PDE4B4 migrates in a position between the 
long form PDE4B1 and the short PDE4B2. B. The loglO of the distance 
migrated by pre determined was markers plotted against molecular weight. 
A representative graph is presented. C. The line linking these distances was 
used to calculate the weight of recombinant PDE4B4 from the same blots. 
Three analyses from different transfections are presented. The average of 
these molecular weights was calculated. Thus the molecular weight of PDE 
4B 4 was calculated to be 85 +/- 3 Kda.
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Fig 3.2.2 Sub cellular distribution o f  PDE4B4 activity
Low speed fraction (PI) and high speed fractions (P2) and (S2) o f  
recombinant PDE4B4 expressing COS-1 cells were prepared in KHEM 
buffer as described. A; Specific cAMP PDE activity o f S2 and PI was 
calculated for 3pg o f protein. Specific activity o f P2 is estimated by 
adjusting the volume based distribution activity described below by mean 
protein content o f the fraction. B; Fractions were equalised for volume to 
represent equivalent cell numbers per lysate fraction. PDE4 activity was 
measured for a given volume representing 3pg o f  S2 lysate. The majority 
(68%), o f PDE4B4 activity was found in the S2 cytosolic compartment. 
With 23% in the PI. In each figure data represents three experiments and 
are expressed with standard errors.
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Fig 3.2.3 Sub cellular distribution o f PDE4B4 protein
Low speed (PI) and High-speed (P2 and S2) fractions of recombinant 
PDE4B4 expressing COS-1 cells were prepared as described. Each 
fraction was reconstituted to an equal volume. Equal volumes of lysate 
corresponding to 30pg S2 protein were resolved on 8% SDS PAGE gel 
and western blot analysis performed. (A, lanes 1 and 2 P2 fraction, 
lanes 2 and 4 S2 fractioniB lanes 1 and 2 S2 fraction lanes 3,4 and 5 PI 
fraction). The majority of PDE 4B4 was found in the cytosolic, S2 
fraction. The P2 fraction contains no PDE 4B4 while PI contains very 
little.
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same number o f cells. To achieve this, fractions prepared by high speed centrifugation 
were reconstituted in equal volumes o f PDE4 assay buffer. This volume was equal to the 
volume o f collected S2 and all kinetic analysis was performed on volumes o f cell lysate 
equal to that volume o f S2 lysate containing 3pg  o f  protein. This analysis allows 
proportional comparisons between subcellular fractions and using this method 62% of 
PDE4 activity was found in the S2 fraction with a further 23% in the PI fraction. 
Q uantifying LDH activity in each fraction estimates the degree of contamination 
(Appendix 2). Thus LDH is mainly cytosolic and if LDH activity is measured in PI in the 
presence o f detergent it suggests contamination with whole eells. Performing this assay 
suggested that around 30% of P I protein was from unbroken cells and adjusting the 
activities described above reduces the particulate bound proportion o f PDE4B4 still 
further. Little activity was found in the P2 fraction (fig 3.2.2.B).
Western blot analysis was performed in a similar way to the comparison described above. 
Equal volumes of fraction lysate, corresponding to 30|ag o f S2 lysate protein, were 
compared for immunological detection o f PDE4B. Figure 3.2.3 demonstrates that the 
majority of immunologically detectable PDE4B4 lies in the S2 fraction, while a small 
quantity is present in the P I and no band was resolved in the P2 fraction lanes.
Section 3
3.3.1 K,n value fo r  PDE4B4.
The Michaelis constant (Ki-q) represents the concentration o f substrate at which an enzyme
is half maximally active. Representative plots of the parabolic form o f the Michaelis- 
Menton equation are presented for the S2 and P I o f PDE4B4 (Fig 3.3.1). Using the
M ichaelis-M enton equation (V=Vmax*[cAM P]/ +[cAM P]), a plot o f PDE4B4
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activity/[cAMP] was generated, from which the Km was calculated. The Km was derived 
for three transfected lysates and the mean +/-1 standard error is presented. The Km value 
for cAMP of PDE4B4 S2 fraction is 5.4+/-0.7p,M, while that o f the P I fraction is 6.0 +/- 
0.5jaM. Figure 3.3.1 also presents the Km for recom binant PDE4B1 derived from 
experiments run in parallel to those described above. This produces a value o f 2.0 +/- 
0.1 pM, which serves as an internal control for my system.
3.3.2 Vmax value fo r  PDE4B4
Vniax represents the maximal activity for an enzyme measured at a saturating substrate 
concentration. I derived the Vmax by calculating the activity (Vobs) for a range o f protein 
quantities from COS-1 cells expressing recombinant PDE4B4. Using the mean o f these 
activities I derived the apparent Vmax for PDE4B4 from the Michaelis-Menton equation 
defined above. The apparent Vmax for recombinant PDE4B4 was 8.6pmol/min/pg and 
2.7pmol/min/pg for the S2 and PI fractions respectively. The apparent Vmax of an enzyme 
will depend on the quantity of enzyme present, thus the absolute Vmax for PDE4B4 would 
be expressed as pM cAMP/mol enzyme. Meaningful comparison between PDE4 isoforms 
thus requires some means o f quantifying the amount o f enzyme present. I wished to use 
PDE4B1 as a comparison as this has served as comparative enzyme in the past [76]. In 
order to compare enzyme quantities I performed ELISA on a range o f lysate volumes and 
identified recombinant enzyme using PDE4B antibody and a mock transfected cell lysate 
as a blank. Figure 3.3.3 illustrates one such ELISA, demonstrating that in each case a 
significant amount o f enzyme was present in transfected cell lysates, but that PDE4B1 
transfections contained more immunological enzyme than PDE4B4 transfections. The 
gradient o f the line connecting the linear part of the absorption/protein curve reflects the 
quantity of PDE4B isoform present and was used to adjust the apparent Vmax values for 
PDE4B4. This adjustment produces a relative Vmax ratio (relative to S2PDE4B1) for
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PDE4 Isoform /Fraction K hi(mM ) Std Error
PDE4B4/S2 5.4 0.7
PDE4B4/P1 6.0 0.5
PDE4BI/82 2.0 0.1
Fig 3 .3 .1 calculation PDE4B4.
Recombinant PDE4B4 expressing COS-1 cells were subjected to high speed 
fractionation in KHEM buffer. 3pg o f  cell lysate from both 82 and PI fractions 
were assayed against a range o f  cAMP concentrations. Representative plots 
from both 82 and PI are presented. This data was analysed using the parabolic 
form o f the Michalis plot. The equation y = ml*mO/(m2+mO) where ml = 
m2 = K,„and mO = [cAMP], defines the Michalis Menton equation, and can be 
used to interrogate enzyme activity data to calculate K,,^  for an enzyme. A mean 
K„, for these experiments (n=3), was calculated and is presented with standard 
error. Mean for PDE4B1 assayed in parallel is provided for comparison.
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F ig33.2  ICso Rolipram o f  PDE4B4
The cAMP PDE activity at IpM cAMP of 3pg cell lysate from Cos-1 cells 
expressing recombinant PDE4B4 was measured in the presence of a range of 
rolipram concentrations. Activity was plotted against the Log of the rolipram 
concentration interrogated using Kaleidograph, and ICso calculated. A; A 
sample ICso plot is presented. B; The mean inhibition of cAMP PDE activity 
from a number of transfections was used to calculate percent inhibition. This 
was then plotted against Log rolipram concentration. Presented is the plot 
representing the 82 fraction (n=3). C; This table summerises the ICso 
rolipram for Cox-1 cells expressing recombinant PDE4B4 in the PI and 82 
fractions.
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PDE4B4 o f 2.1 and 0.54 for the S2 and P I fractions of COS-1 cells expressing 
recombinant PDE4B4 respectively.
3 .33  Rolipram sensitivity o f  PDE4B4
A defining property o f PDE4 enzymes is their capacity to be inhibited by the compound 
rolipram. It has been proposed that two conformations o f PDE4 activity occur that can be 
detected by virtue o f their rolipram binding affinity. Thus “high affinity, (HARB) and 
“low affinity” (LARB) conformations are said to exist [91]. Combined to this variable 
property is the range o f IC 50 values observed for different PDE4 iso forms. These range 
from 1.2)llM rolipram for the particulate fraction o f RNPDE4A5 to 20nM for the soluble 
fraction o f PDE4B2 [50]. Therefore individual PDE4 isoforms are believed to interact with 
rolipram with isoform specific kinetics. The IC50 of an enzyme describes the concentration 
o f an inhibitor that causes 50% reduction in activity at a particular substrate concentration.
The value for IC 5 0  Rolipram inhibition was ascertained by incubating recom binant 
PDE4B4 expressing COS-1 cell lysates with increasing concentrations of rolipram and 
measuring PDE4 activity at IpM  cAMP as before. Fig 3.3.3 illustrates an example o f the 
IC50 rolipram curves generated by such an approach. A mean o f 4 experiments was used to 
calculate a final IC 50 value. The IC 50 value for the S2  fraction o f PDE4B4 was 0.08 V -  
O.OljaM, while for the P I fraction IC50 value was 0.16 0.04 jiM. Table 3.1 presents
previously described kinetic values for other PDE4 isoforms.
Section 4
3.4.1 PKA activation o f  PDE4B4
Long form PDE4 isoforms are characterised by the presence o f UCRl in their N-terminal 
regions. UCRl contains a PKA phosphorylation target site defined by RRESW, with Ser54
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Fi^ 3.3.3 PDE4B ELISA contrasting recombinant protein expression
In order to calculate the Vmax of PDE4B4 relative to a known standard 
(in this case PDE4B1), the apparent activity of each isoform was 
compared and adjusted for protein expression. To calculate relative 
enzyme expression ELISA was performed using anti-PDE4B antibody 
(Schering) to immunologically detect recombinant protein. Data is 
presented as optical density (arbitary units) against the Login of the 
quantity of protein. Presented is one ELISA demonstrating that while 
two separate PDE4B4 transfections result in similar enzyme expression, 
these differ considerably from PDE4B1.
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being the Serine Target Residue (STR) in PDE4D3 [238]. This sequence is present in 
PDE4B4 with the STR being Ser56. A second PKA target site is present in PDE4B4 
around SeiT4 as shown in figure 3.1.1, The context o f this site is very similar to that of a 
second PKA target site in the N-terminal region of PDE4D3, around S e r i3. While 
phosphorylation o f Ser54 of PDE4D3 appears to result in activation o f this isoform the role 
of S eri3 phosphorylation is not clear [68].
Phosphorylation o f an amino acid residue alters the charge o f  that residue by - I .  
Conformational changes resulting from this can lead to activity or functional alterations in 
proteins containing these residues. Substituting an aspartate or a glutamate residue for the 
STR at a PKA target site adds a -1  charge to the protein and can be used to mimic the 
conform ational changes resulting from phosphorylation. Conversely if  an alanine 
substitution is made for the serine residue, no phosphorylation is possible and a dominant 
negative phosphorylation mutant results. Mutations of the STR in U CRl in various long 
form PDE4 isoforms have been made and Ser-Asp mutants were found to be constitutively 
activated, while Ser-Ala mutants were resistant to PKA activation. [239]
I wished to examine the role o f PKA in the activation of PDE4B4. I used a combination of 
IBMX and forskolin to increase cAMP and thus activate PKA. I measured the activity o f 
PDE4B4 in the presence and absence o f this treatment and demonstrated a 57% increase in 
activity (Table 3.4.1). PDE4D3 has previously been used as a model of PDE4 long form 
activation by PKA and I included a parallel experiment using recombinant PDE4D3 in 
these studies [238]. I dem onstrated a doubling o f PDE4 activity in COS-1 cells 
overexpressing PDE4D3. A second property o f PKA phosphorylation o f PDE4D3 is an 
alteration o f mobility on SDS-PAGE. It is not clear why this change in electrophoretic 
mobility should occur, but it appears to be related to phosphorylation o f Seri 3 in the N- 
terminal STR o f PDE4D3. I hypothesised that PDE4B4 would behave in a similar fashion 
due to its N-terminal sequence homology with PDE4D3. Figure 3.4.1, is a representative
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FDE41sofoim Coitiol actiMty 
(nnDl/miVMS)
Foiskclin/IBMX Perceit Change
PDE4B4 10-f/-1.5 164/-3 +57 %
PDE4D3 4 8 +100%
Table 3 .4 .1 Effect o f PKA activation on PDE4B4
COS-1 cells over-expressing recombinant PDE4B4 or PDE4D3, were 
pretreated with IBMX lOpM for 20 mins before forskolin lOpM was added 
for 15 mins. Cells in each treatment group were taken from a single 
transfections and multiple transfections were used. PDE4 activity was 
measured in cell lysate representing 3pg of cellular protein prepared in 
KHEM buffer. Activity is presented with standard error. PDE4B4 activity 
was seen to increase by 57% under treatment conditions, consistent with 
positive regulation by PKA (n=3). A lso presented for comparison is a single 
experiment performed on recombinant PDE4D3. This isoform is known be 
activated by PKA and serves as an internal control.
PDE4B4
Fig3.4.1 PKA activation alters PDE4B4 migration on SDS PAGE gel.
Cell lysates prepared as described above were subjected to western blot 
analysis on 10% SDS-PAGE gel. Equal amounts of protein were loaded in 
each lane. Lane 1; Control (untreated) cell lysate, Lane 2; IBMX/Forskolin 
treated cell lysate. As has been previously described for PDE 4D3, migration 
of forskolin/IBMX treated PDE 4B4 is retarded leading to an apparent ‘band 
shift’ on western blot.
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western blot demonstrating that a change in electrophoretic mobility does occur when 
COS-1 cells over expressing recombinant PDE4B4 are treated with IBMX/forskolin.
To investigate this behaviour further PDE4B4 cDNA sequences were mutated to contain 
aspartate and alanine residues at both the STR sites described above. In order to allow 
comparison these constructs also had a FLAG sequence tag added to the C-terminal. 
Recombinant mutant FLAG tagged PDE4B4 were expressed in COS-1 cells and activity 
was measured in the presence and absence o f IBMX/Forskolin. In order to overcome 
differences in transfection efficiency when comparing between constructs and treatments, 
immuno-activity of PDE4B was measured by densitometry on western blot for a range o f 
protein amounts. Plots of densitometry against protein (pg), were constructed and the 
linear relationship was derived. The gradient of this line reflects the transfection efficiency 
of the recombinant protein and activity values were adjusted to allow for these differences.
3.4.2 S e r i4 - A la  substitutions
Mutant PDE4B4 containing a SeiT4-Ala mutation proved to be sensitive to PKA. PDE4 
activity in COS-1 cells overexpressing this mutant form o f the enzyme rose by 90% when 
treated with IBM X/forskolin (fig 3.4.2). U nfortunately expression o f the equivalent 
mutation o f Ser56 resulted in a dramatic reduction in cell viability, and cell extracts 
contained very variable quantities o f immunoreactive PDE4B. As a result no comparable 
experiments could be performed on the effect of Ser56-Ala mutation.
3.4.3 Ser -  Asp substitutions
As described above the effect o f Ser-Asp m utation at a STR for PKA reflects 
phosphorylation o f this residue. Asp mutations o f both S e ri4 and Ser56 were made and 
PDE4 activity was measured in COS-1 cell extracts overexpressing these mutants. Activity
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Fig 3.4.2 Effect o f Ser 14 
PDE4B4
Ala mutation on PKA activation o f
PDE4B4 cDNA was mutated by quick-change to produce an Ser 14- 
ALA mutation. This mutation prevents phosphorylation by PKA from 
taking place. This mutant protein was overexpressed in Cos-1 cells 
and the effect of IBMX/Forskolin treatment was compared to 
untreated (control) PDE4 activity. To allow for transfection efficiency 
western blot was performed on increasing quantities of lysate protein 
and densitometry was used to assess PDE4B isoform expression. A; 
table presenting change in PDE4 activity with IBMX/forskolin 
treatment (+/- Standard error). B; graphic representation of the same 
data (n=3). Control activity was less than wild type PDE4B4 
suggesting a role for Ser 14 in regulating latent activity. The effect of 
IBMX/Forskolin treatment was not altered by the A la l4  mutation, 
suggesting that Ser 14 is not involved in PDE4B4 activation by PKA.
PDE4B4 Mutant PDE4 Activity 
(pmol/min/jig)
Percent Wild Type
Wild T ype 10.3+/-1.5 100
Serl4 -  Asp 8.0+/-1.6 78
Ser56 - Asp 13.8+/-3.7 145
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F igSA J Effect o f Ser-Asp mutations in PKA activation sites in 
PDE4B4
Ser - Asp mutations were made using quickchange technology at both 
PKA phosphorylation sites (S erl4  and Ser56), in PDE4B4 cDNA with 
a “Flag” peptide tag. Aspartate substitution adds a negative charge to 
a protein reflecting a phosphorylation event. Cos-1 cells expressing 
recombinant PDE4B4 containing each of these mutations, were lysed 
and PDE4 activity was measured using wild type PDE4B4 as a 
control. To compare activities relative transfection efficiency was 
measured using densitometry of western blots probed with anti-FLAG 
antibody. A; Table showing the relative activity differences between 
both Asp mutants and wild type PDE4B4. B; Graphic representation 
of these differences. In each case three transfections were made using 
each mutation or wild type isoform. As can be seen a 
“phosphorylation” mutation at Ser56 resulted in increased PDE4 
activity.
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of SeiT4“Asp mutant PDE4B4 was 22% lower compared with wild type enzyme. The 
Ser56-Asp mutant PDE4B4 had an activity 45% higher than wild type enzyme.
Discussion
A novel member o f the PDE4B family was cloned from a cDNA library. Use o f  a 
complimentary probe based on the PDE4B UCR2 sequence confirmed the gene source of 
this novel clone. PDE4 isoforms can be classified by the presence or absence of UCRl into 
long and short forms [63]. This structural distinction is based on a mRNA splice junction 
near the N-terminal region o f UCR2 (fig 3.1.1). Splicing of mRNA at this site leads to 
short form PDE4 isoforms, o f which PDE4B2 is the only PDE4B representative [233]. 
Comparison o f the sequence o f the novel PDE4B4 and the two other long form PDE4B 
isoforms, PDE4B1 and PDE4B3, shows 100% sequence homology downstream of the N- 
terminal 17 amino acids. Thus PDE4B4 contains UCRl confirming its identity as a long 
form PDE4. The importance o f these structural distinctions can be inferred by the 
evolutionary conservation between mammalian PDE4 and the drosophila dunce gene [59, 
63]. Groups examining the regulation of PDE4 isoform activity have shown the functional 
significance o f long form and short form distinctions. Thus Baillie et al, demonstrated that 
ERK2 phosphorylation o f  PDE4 isoforms, increased the activity o f the short form 
PDE4B2, having previously shown reduction in the activity o f the long form PDE4D3 [66] 
[67]. PDE4B4 would be expected to share the regulatory properties o f long form PDE4 
isoforms.
Further examination of the cDNA sequence o f PDE4B4, PDE4B1 and PDE4B3 highlights 
divergence after U C R l. Thus the extreme N-terminal 17 amino acids are unique to 
PDE4B4 among the PDE4B family. Such unique N-terminal identity is common to PDE4
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isoforms [50]. N-terminal diversity is achieved by differential use o f multiple start sites 
regulating isoform specific transcription. Further analysis o f the 17 N-terminal amino acid 
residues o f PDE4B4 demonstrates remarkable homology to an equivalent region o f 
PDE4D3. 13 o f the 17 residues are conserved between these regions including the PKA 
STR S e r i3 (PDE4D3). Analysis o f the primary amino acid sequence thus identifies 
PDE4B4 as a long form PDE4 isoform, sharing sequence homology at the N-terminal 
region with PDE4D3.
Based on the primary amino acid sequence, predicted molecular weights o f PDE4B1, 
PDE4B2 and PDE4B3 are 84, 64 and 82 KDa while they been determined to be 104, 78 
and 103 KDa based on SDS-PAGE migration [233]. It is not surprising therefore that 
PDE4B4, with a predicted molecular weight o f 73KDa, migrates at 84+/-5KDa on SDS- 
PAGE. As proteins are fully denatured before electrophoresis is performed means that 
secondary structure is unlikely to affect electromobility. Whether interaction between SDS 
and regions o f charged amino acids in the primary sequence o f PDE4 isoforms results in 
retarded migration is not Imown. The influence o f phosphorylation on the electromobility 
o f PDE4D3 suggests that this may be the case.
Sixty eight percent of recombinant PDE4B4 activity is found in the soluble (S2) fraction o f 
disrupted COS-1 cells. This distribution is similar to other PDE4B isoforms as 71%, 61% 
and 58% o f expressed activity is found in the S2 fraction o f recom binant PDE4B1, 
PDE4B2 and PDE4B3 lysates respectively [233]. O f the remaining activity the majority 
(23%) was localised to the PI fraction (fig3.2.2). It is possible that in an over-expressed 
system, the membrane-binding sites were saturated and excess enzyme was left free in the 
cytoplasm. However the integrity of the method for demonstrating particulate association 
has been shown for other enzymes such as RD I [240]. While western blot analysis does 
not suggest any im m unoreactive PDE4B4 outwith the S2 portion, activity analysis 
demonstrates PDE4 activity in the PI fraction. PI fraction integrity was confirmed by LDH
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assay analysis, described in appendix 1. PI fractions used in both western blot and PDE4 
activity analysis were prepared in the same way. It is not clear why this discrepancy exists, 
but confocal microscopy o f real time subcellular distribution o f PDE4B4 would help to 
clarify this issue.
The kinetic analysis o f PDE4B4 is summarised in table 3.4, with previously reported 
kinetic variables for other PDE4B isoforms presented. As can be seen the Km value for 
PDE4B4 lies close to the range set by the other PDE4B isoforms. Soluble PDE4B4 Vmax 
relative to soluble PDE4B1 Vmax is greater by 9 fold. Association with the particulate 
fraction P I reduces this difference to a third. Differences in kinetic variables associated 
with particulate association have previously been reported for PDE4A4 [76]. In this study 
particulate PDE4A4 had a relative Vmax that was 56% that o f the soluble enzyme. This 
study also described a difference in the IC50 for rolipram between particulate PDE4A4 and 
soluble PDE4A4. Such a distinction was also demonstrated in my study for PDE4B4, 
where a P I IC 50 rolipram of 0.16pM, was double the S2 fraction (0.08p.M).
Differences between the Km and Vmax values for different PDE4B isoforms may not 
seem large. Small differences in regulatory properties between PDE4B isoforms may allow 
tight control of cAMP concentrations. Thus PKA activation of PDE4 isoforms increases 
activity by 50%. I f  the local concentration o f cAMP is set to around the activation 
threshold o f PKA, then small increases in concentration w ill result in PKA 
phosphorylation o f PDE4 isoforms. The resulting increase in cAMP PDE activity will 
lower cAMP, limiting the scale and duration of the effect. Differential expression of PDE4 
isoforms with small differences in Vmax may then be used to regulate the response to 
cAMP.
Particula te association m ight influence PDE4 isoform  activity , by altering the 
conformation o f the protein. Protein-protein interaction sites on the N-terminal regions of
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PDE4 isoforms have been described [72]. Interaction o f SH3 domains on src family 
tyrosine kinase enzymes and proline rich domains in the N-terminal region of RNPDE4A5, 
HSPDE4A4 and PDE4D4 have been demonstrated [82, 83, 241]. Altered conformation of 
the PDE4 isoforms was demonstrated by a change in the sensitivity to rolipram. Thus 
interaction o f PDE4B4 with as yet undeterm ined protein partners may explain the 
differences in PI and S2 kinetics.
Regulation o f PDE4 isoforms by protein kinase enzymes results in cross talk between 
different cascades. Thus PKA activates PDE4D3 by phosphorylation at Ser54 [238], while 
ERK2 inhibits long form PDE4s by phosphorylation [66, 67]. PDE4B4 contains the 
common UCRl PKA STR at Ser53, equivalent to Ser54 o f PDE4D3, a residue shown to be 
essential for PKA activation o f PDE4D3 [238]. I have dem onstrated that elevating 
intracellular cAMP with IBMX/forskolin treatment o f COS-1 cells activated PDE4B4 as 
would be expected by the structural homology with other long form PDE4 isoforms. I have 
further suggested that Ser53 is the residue responsible for this activation as Ser53-Asp 
mutants had increased activity over wild type PDE4B4, while S e ri4-Asp mutants exhibited 
reduced activity. Unfortunately the confirmatory Ser53-Ala mutant experiment was unable 
to be performed due to toxicity and loss o f cellular viability.
Conclusion
The novel PDE4 isoform PDE4B4 has been cloned and characterised. It is a long form 
PDE4B isoform with largely soluble localisation in overexpressing COS-1 cells. Km and 
IC50 closely resemble the other long form PDE4B isoforms, while the soluble Vmax was 9 
times greater than PDE4B1. Particulate association reduced the sensitivity of PDE4B4 to 
rolipram and lowered the Vmax relative to PDE4B1. PKA activation increased PDE4B4 
activity and mutation o f PKA STR amino acids suggested this was due to phosphorylation
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of Ser56. Phosphorylation o f Serl4  resulted in electrophoretic mobility changes, but no 
apparent change to enzyme activity.
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Chapter4 PDE4 isoform expression during U937 
differentiation
4.1 Introduction
Tissue macrophages derive from circulating blood monocytes and transform through a 
series o f stages to the mature cell,[145]. Macrophages are involved in disease progression, 
chronicity and resolution so understanding the biochemical changes associated v^ith this 
phenotypic switch may suggest therapeutic targets. Hunninghake et al for instance showed 
that PKCp expression was dram atically reduced when m acrophage differentiation 
occurred, [147].
Cyclic AMP is a crucial second messenger in macrophages and monocytes. It is involved 
in regulating apoptosis [242], maturation and motility [243] o f these cells. The role of 
cAMP in the regula tion o f cytokine expression is becom ing increasingly clear. For 
example T N F a and IL-12 production are inhibited when lipopolysaccharide treated 
macrophages are exposed to agents that increase cAMP [244] [194]. On the other hand 
elevating cAMP increases LPS induced IL-10 production [245].
In 1976 Thompson et al demonstrated that PDE4 represents the greatest cAMP hydrolysing 
activity in inflammatory cells [221]. Subsequently, many groups have shown 60-70% 
inhibition o f cAMP PDE activity by rolipram in monocytes taken from peripheral blood 
[119, 246]. W hereas Thompson found little PDE3 in monocytes [221] others have 
consistently found that PDE3 comprises the greatest proportion o f the remaining cAMP 
PDE activity. Estimates o f its contribution range from 9 - 4 0  %. While the majority o f 
PDE3 activity in monocytes was found to be associated with particulate fractions 90 -  100
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% of PDE4 is soluble. This physical compartmentalisation suggests PDE isoforms are 
targeted to specifically regulate cAMP in these fractions.
Gantner et al demonstrated that PDE isoform expression profile changes upon monocyte to 
macrophage maturation [119]. While many groups have examined the PDE subfamily 
profiles o f inflammatory cells, few have investigated the individual PDE4 isoforms. This 
may be related to the low abundance o f these enzymes in cells combined with the 
relatively poor yields associated with cell isolation. W here PDE4 isoforms have been 
investigated RT-PCR has generally been employed revealing the presence o f PDE4A, 
PDE4B and PDE4D [223, 246]. Due to the potential for post-transcriptional degradation of 
mRNA it has been previously advised that cellular profiling should include analysis o f the 
enzyme protein itself [50].
Attempts to study macrophage development are hampered by the low abundance of tissue 
available for study. A ttempts to measure PDE4 isoform activity in cells isolated from 
sputum proved unrew arding due to the small number o f cells and the difficulty in 
achieving uncontaminated pure-lineages (see Appendix 2). Monocytes from human blood 
cultured on plastic have been shown to phenotypically represent tissue macrophages, but 
the small numbers o f cells produced makes analysis of low abundance signalling proteins 
difficult [119]. Increasing use o f cell lines representing monocytes has shown that they can 
be made to take on the characteristics o f macrophages [154].
The U937 promonocytic cell is a suspension cell line that under certain conditions can 
take on the characteristics o f macrophages [154]. This model has been used to identify the 
key stages in macrophage differentiation and the signalling systems involved [154, 156]. 
Previous investigators have studied the PDE4 activity o f U937 cells [226, 247, 248]. 
Before using such a model to investigate a specific aspect o f biochemical behaviour, it is
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essential to verify that the model approximates the original with regards to the behaviour to 
be analysed.
I hypothesised that tight regulation o f PDE4 iso form expression would occur during the 
development o f mature macrophages. Understanding how PDE4 isoform expression 
changes might offer insights into the roles each isoform plays in cellular behaviour. I also 
wanted to verify the U937 cell model with regards to PDE activity by comparing it to an 
ex-vivo model of macrophage development.
Results
Section 4.1 U937 differentiation
Previous reports have suggested that treatment o f U937 cells with 4nM PMA (U937pma) 
results in a phenotypic switch similar to that undergone by monocytes cultured on plastic 
[154]. One o f the earliest changes to occur on transfer o f peripheral blood monocytes to 
plastic is surface adhesion[l 19]. To assess the capacity o f U937 cells to mimic this 
behaviour I incubated suspension monocytic U937 cells in flasks containing gridded glass 
cover-slips, with or without PMA and counted adherent cells after 96 hours. Cells from 
both adherent and suspension compartments were lysed and the protein quantified. The 
relative proportion o f total cell lysate protein in the suspension and adherent populations 
was quantified and used to examine the expression of various surface phenotypic markers, 
signalling molecules and PDE activities.
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4.1.1 PMA increases the adherence index o fU 937pro  monocytic cells
Table 4.1.1 demonstrates that U 9 3 7 p m a  cells are 10 fold more adherent. Total protein is 
increased in U 9 3 7 p m a  cells by a factor o f 3 . 8 .  The proportion o f the total protein found in 
the adherent compartment in treated cells (71%), is greater than that in control U937 cells 
(2%). Thus treatment o f U937 cells with 4nm PMA leads to greater surface adherence than 
in control cells. Visually, U 9 3 7 p m a  looked larger and more spread out than control cells.
4.1.2 PMA causes the increased expression o f  f - 2  integrin (CD~11)
In view of the increased adherence and previous reports that cultured monocytes express a 
macrophage like profile o f adhesion molecules, I assessed the expression of the P2 integrin 
CDl lb[155, 156]. Figure 4.1.2 demonstrates expression of GDI lb  protein in U 9 3 7 p m a  but 
not U937 cells.
4.1.3 PMA reduces the expression o f  P K C f and increases the expression o f
To assess the effect on functional markers of macrophage behaviour I chose to examine 
PKCp and COX-2. PKCP has been shown to be down-regulated with alveolar macrophage 
development [147], while COX-2 is believed to be expressed primarily by macrophages in 
human lung .The expression o f both o f these proteins is represented in fig 4.1.3. In 
U937pMA cells, PKCp expression was dram atically reduced w hile COX 2 was 
transcriptionally activated.
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Control U937 U937pMA
No of Cells per hpf 39+/- 20 468 +/- 98
Total Protein (pg/ml) 47 +/- 4 178 +/- 14
Percent Solution (%) 97 28
Percent Adherent 2 71
(%)
Table 4.1. PMA treatment increases the surface adhesion o f  U937 
cells.
U937 cells were incubated for 96 hours with 4nM PMA, in flasks 
containing circular coverslips. After incubation coverslips were 
removed washed three times with ice cold PBS. Adherent cells were 
counted in 4 high power fields (hpf) per coverslip using a standard 
haemocytometer. Culture medium was removed from each flask and 
cells in suspension were collected by centrifugation these were 
washed and lysed in buffer containing 0.1% TritonXlOO. Remaining 
adherent cells w ere w ashed  and sim ilarly  lysed. P ro tein  
quantification was carried out and the total protein calculated for 
each flask. Number o f adherent cells per treatment is presented as a 
m ean (n=4). Total protein  represents the com bined protein 
quantification o f adherent cells and cells in solution. Proportion of 
the protein from each compartment is presented.
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Fig 4.1.2 PMA induces the expression o f (32 integrins in U937 cells.
U937 cells were treated with 4nM PMA for 96 hours and non adherent 
cells were removed. Remaining cells were washed and lysed in 3T3 lysis 
buffer. Untreated U937 cells were lysed and used as control cells. 
Proteins were separated using SDS-PAGE ensuring equal protein 
loading in each lane. Western blot analysis was performed on the cell 
lysates and nitrocellulose was probed with anti CD-I lb  monoclonal 
antibody. Lane 1; U937pma, lane 2; U937 cells. As can be seen, 96 
hours of 4nM PMA induces CD-I 1 integrin expression in U937 cells.
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Fig 4.1.3 Changes in the expression of PKC(3 and COX -2 with differentiation
U937 cells and U937pma were lysed and equal amounts of protein were separated 
by SDS-PAGE. Western blot analysis was performed and proteins identified 
immunologically with antibodies raised against PKC(3 and COX-2. Lanel; 
control U937 cells, lane2; U937pma. Fig 4.1.2.A, demonstrates that a striking 
reduction in PKCp expression occurs with macrophage differentiation. Fig 
4.1.2.B, shows that COX 2 expression is induced with differentiation. Both 
changes correspond to previously reported changes with macrophage 
development and are believed to contribute to the phenotype stability.
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4 .L4  C hanges in P D E  isoform  a c tiv ity  occur w ith  macrophage 
differentiation
I compared the effect o f PMA induced differentiation of U937 cells on PDE3 and PDE4 
activities. PMA treatment results in a fall in the total cAMP phosphodiesterase activity (fig 
4.1.3A,B). While the proportion o f PDE3 to the total activity rises from 11 to 28% on 96 
hours of PMA treatment that o f PDE4 falls. There is also a significant fall in the actual 
PDE4 activity in U 9 3 7 p m a  cells, from 132pmol/min/mg to 66pmol/min/mg. To ensure that 
this conformed to the peripheral blood monocyte model we compared the same parameters 
in cultured monocytes from human volunteers. Fig 4.1.3C demonstrates that while PDE3 
activity rose from 20 pmol/min/mg to 5 Ipmol/min/mg with 5 days o f culture, PDE4 
activity fell from 73pmol/min/mg to 47pmol/min/mg. Plastic cultured monocytes therefore 
reflect the PDE isoform changes seen in U937pMA celldevelopment.
4.1.5 Changes in PDE isoform activity in U937pma cells on a per cell basis
The data presented above suggests that PDE4 activity falls in line with total cAMP PDE 
activity. These data were calculated on a total protein basis as has previously been reported 
for macrophage differentiation studies [119]. I have also shown that the cellular protein 
content changes with U 9 3 7 p m a  development. To measure the changes in PDE isoform 
activity at a cellular level I recalculated the activity making a correction for cellular protein 
content to give activity on a per cell basis. Figure 4.1.4 shows that while total PDE4 
activity falls on per mg protein basis, it rises when calculated on a cellular basis. Both 
PDE3 and PDE4 activity rise in a similar fashion.
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Cyclic AMP PDE U937 U937pM.\
activity (pmol/min/mg) (pmol/min/mg)
Total 149+/- 38 92
PDE3 18.0 +/- 3.0 26 +/- 4
PDE4 132 +/- 6 66 +/- 5 **
g U 9 3 7  
gg U937 pma
PDE3 PDE4
80
60
I13 40
208
monocytes Day 5 cultureU937 U 9 3 7 pma
Fig 4.1.4 Effect o f PMA on PDE isofonn expression in U937 cells and 
plastic differentiation on ex-vivo monocytes.
U937 cells and ex-vivo monocytes, were differentiated as described in 
materials and methods. U937 cells and U937PMA were counted and 
lysed in KHEM buffer. PBMC from normal volunteers were cultured on 
plastic for up to 5 days and washed and lysed in KHEM buffer. Total 
cAMP PDE activity was measured at IpM cAMP. PDE3 and PDE4 
activities were measured using the specific PDE inhibitors cilostamide 
Xpm (PDE3) and rolipram 10pm (PDE4) and subtracting the resulting 
activity from total activity. A, table expressing the Total PDE, PDE4 
and PDE3 activity for U937 and U937p\u. Protein per cell was 
calculated and used to adjust the activity per unit protein. Both activity 
per unit protein and activity per million cells are presented (n=3); B, 
graphic representation of changes in each cAMP PDE activity with 
differentiation; C, graphic representation of the percent total activity 
represented by both PDE3 and PDE4 in both U937/U937p\iv\, and ex- 
vivo monocytes/macrophages (n=l ). (**, P = 0.002 Student’s paired T Test).
125
Cyclic AMP PDE C937 C937 U937Pma C937pvia
activity (pmol/min/nig) (pmoi/min/lO^cells) (pm oi/m in/n^) (pmol/min/lO^cells)
Totsà
PDE3
PDE4
149+ /. 38  
17.7 +/- 2.6  
1 3 2 + /-6
6 .8 + / -  1.8 
1 + / -  0.2 
6.2 +/- 0.5
92 
26 +/- 4  
66  +/- 5
16.5 
4.6  + /-0 .2  
1 2 + /-0 .9
lJ937pma
Ü937
PDE4 PDE3
Fig 4.1.5 Activity o f cellular PDE4 and PDE3 activity in U937 and 
U937pma cells.
U 937 cells and U 9 3 7 pma were counted and lysed in KHEM buffer. 
Total cAMP PDE activity was measured at IpM cAMP. PDE3 and 
PDE4 activities were measured using the specific PDE inhibitors 
cilostamide Xpm (PDE3) and rolipram 10pm (PDE4) and 
subtracting the resulting activity from total activity. Protein per cell 
was calculated and used to adjust the activity per unit protein. A; 
both activity per unit protein and activity per million cells are 
presented (n=3); B; graphic representation of the PDE3 and PDE4 
activity per million cells in both U 9 3 7 /U 9 3 7 pma (n=3).
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Discussion Section 4,1
Cell lines have been used previously to reflect mature inflammatory cells, [154] [155, 249]. 
U937 differentiation to U 9 3 7 p m a  reflects changes o f  m onocyte to m acrophage 
differentiation. I developed this model to measure changes in PDE4 isoform expression. To 
verify this model I measured adhesion index by comparing protein content and cell count 
in the suspension and adherent compartments o f cultured U937 and U 9 3 7 p m a  cells. 
Increased adhesion to plastic is a recognised behaviour o f both directly isolated and ex- 
vivo differentiated macrophages [119, 145]. Observing U 9 3 7 pm a  cells demonstrated 
significant phenotypic changes typical o f m acrophages. In com parison with their 
progenitor cells U 9 3 7 p m a  are flat large cells. Such an increase in the plasma membrane 
may be associated with an increase in the protein content. I used the data described above 
to calculate the amount o f protein per cell and found a significant increase in this index 
with differentiation. (47 +/- 4 Vs 179+/- 14 per 10^ cells). Again this reflects the ex-vivo 
model described by Gantner et al who reported an increase from -5 0  to -150  pg/ 10  ^ cells 
[119]. It is likely that such an increase in protein and membrane reflects, among other 
things, the expression o f cell surface molecules associated with cell adhesion [250, 251].
CD l lb  expression reflects macrophage development and is a surface adhesion molecule 
important in cell-cell interactions in developing inflammation [149, 251]. In combination 
with CD 18 it forms the complex integrin Mac-1. H ass’ group have demonstrated that 
surrogate cell lines induced to differentiate to macrophage like cells express increased 
C D l lb  [154]. This group have recently demonstrated that elim inating expression of 
CD l lb, using antisense oligo-nucleotides, prevents the full expression o f the differentiated 
phenotype, [156]. Fig 4.1 shows increased expression o f CD l lb  in U937pMA.consistent 
with a macrophage phenotype. Hunninghake et al showed reduced PKC(3 expression in
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AM compered to progenitor monocytes and I have dem onstrated a similar change in 
U937pMA compared to U937 cells (Fig 4.1.2) [147]. Thus key signalling molecules other 
than PDE isoforms that are known to change during macrophage development also change 
during U 9 3 7 p m a  development. Finally COX-2 expression takes plaee as macrophages 
mature [242, 252]. It has been proposed that COX-2 products such as PGE2 and TXA2 
maintain the phenotype o f mature AM. I have demonstrated that in U937 cells no basal 
expression of COX-2 is present while in U 9 3 7 pm a  COX-2 expression is seen.
The markers used above to confirm the developmental stage o f U937 cells on the 
granulocytic lineage were all effectively “on-off’ markers. Using such markers protects to 
some extent against bias related to protein content. Thus comparing equal quantities o f 
protein from each cell type may bias the result if  each cell type contains different amounts 
o f protein per cell. In fact by comparing two markers o f maerophage activation I have 
weighted the bias in favour o f the null hypothesis, that no significant change has oeeurred. 
That is iOOpg o f U937 protein reflects almost four times as many cells as 100p.g o f 
U 9 3 7 p M A  cell protein. This strengthens my results in favour o f U 9 3 7 p m a  cells reflecting 
macrophage biochemistry.
Having demonstrated that the U937pMA model accurately reflects macrophages I compared 
PDE3 and PDE4 activity in each stage o f development. This follows Gantner et al, who 
found a fall in PDE activity with a co-incident fall in PDE4 and a rise in PDE3 activities 
with AM development [119]. Other reports have also demonstrated that monocytes have 
different PDE profiles than maerophages [126, 127]. Excitingly Fig 4.1.3 demonstrates that 
PDE3 activity rises while PDE4 activity falls on the background o f falling total PDE 
activity with the development o f U 9 3 7 p m a - These data refleet the activity derived for 
expressed protein in cell lysate. As U 9 3 7 p m a  contain more protein per cell I recalculated 
the activities for total cell number (fig 4.1.4). Interestingly total PDE4 aetivity per 10  ^cells 
does not fall as noted above. To confiim that this reflected the previously reported work by
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Gantner et al I re-calculated their data as presented and found that they too found an effect 
o f protein eontent. Doing this shows a fall in PDE4 aetivity from -  lOOpmol/min/mg in 
monocytes to -2  Op mo 1/m in/mg in day 6 differentiated macrophages. This converts to 6.2 
pm ol/m in/10^ cells and 4.5 pmol/min/10^ cells respectively. Thus in both cell marker 
expression and signalling molecule aetivity the U 9 3 7 p m a  model appears to reflect the 
changes taking place when macrophages develop. I could now examine which PDE4 
isoforms changed in activity or expression.
Section 4.2 Changes to PDE4 isoforms when U937 cells 
differentiate with PMA.
To compare the expression and activity o f various PDE4 isoforms I used western blot, RT- 
PCR and immunoprécipitation to isolate specific PDE4 families.
4.2.1 PDE4A activity is increased by PMA treatment o fU 937  cells
Our group previously reported that PDE4A4 is present in resting U937 cells [247]. 
Immunoprécipitation using antiserum raised against the common PDE4A C-terminal 
allows isolation o f all active PDE4A isoforms expressed. The PDE4 activity o f these 
immunoprecipitates can be measured to compare the relative activities between control 
U937 cells and U 9 3 7 p m a  cells. Figure 4.2.1 A, shows PDE4A contributes a greater (81%) 
proportion o f the total cellular PDE4 activity in U 9 3 7 p m a  cells than in U937 cells (2%) 
when activity is equalised for protein concentration. This increase in activity does not 
reflect the reduction in total PDE4 activity seen in section 4.1, as actual PDE4A aetivity is 
seen to increase from 1.1 pmol/min/mg to 53pmol/min/mg, (fig 4 .2 .IB). The change in
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protein content with U 9 3 7 p m a  cells would tend to limit any increase in PDE4A activity per 
cell, as PDE4A iso forms are “diluted” by other proteins. Calculating the activity per lO*’ 
cells, however shows the increase in PDE4A activity to be preserved with U937 cells 
having 0.02 pmol/min/10^ cells and U 9 3 7 p m a  cells having 9.6 pmol/min/10^ cells.
4.2.2 Change in PDE4A expression in U937pma
To test if  the increased PDE4A activity was related to a change in enzyme content, I 
examined protein expression by western blot. Fig 4.2.2 clearly shows that a band identified 
by PDE4A C-terminal anti-Sera is increased in U937pma cells. Figure 4.2.2A, compares 
equal cell numbers, while Fig 4.2.2B compares increasing amounts o f U937 and U937pma 
lysate protein. Both blots demonstrate an increase in the intensity o f the protein band 
developed with anti-PDE4A antiserum and this is quantified by densitometry in fig 4.2.2C. 
This demonstrates a profound increase in the intensity of staining for PDE4A consistent 
with the activity data described in 4.2.1.
4.2.3 Novel appearance o fP D E 4A I0  mRNA in U 9 3 7 p m a
Unfortunately two long forms o f PDE4A, PDE4A4 and PDE4A10 both run at a similar 
weight on SDS PAGE. To attempt to identify which isoforms are being expressed I 
performed RT-PCR using RNA from each cell type as template. Primers designed to 
complement the unique N-terminal regions o f PDE4A4 and PDE4A10 were used and 
conditions and sequences are presented in materials and methods section 2.1.4. Figure 
4.2.3, shows that PDE4A10 is only expressed in U 937pma cells while PDE4A4 is 
expressed in both cell types. This suggests that PDE4A10 expression is transcriptionally 
activated with maturation. Interestingly an intense RT-PCR product band is found in U937 
cells although relatively little protein is identified on western blot or immunoprécipitation.
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Fig 4.2.1 Changes in PDE4A activity when U937 cells and monocytes 
differentiate towards macrophage like cells
U937 cells were differentiated for 4 days with 4nm PMA. Adherent human 
monocytes were differentiated on plastic for 5 days. Control cells (Day 0), and 
differentiated (U937p^^  ^ Day 5 monocytes) cells were lysed and PDE4A 
iso forms were i mmunoprec ipitated using an anti-sera raised against the 
PDE4A C terminal. Immunpoprecipitates were assayed for PDE4 activity. Fig 
4.5 A demonstrates that the proportion o f PDE4A to the total PDE4 activity 
rises dramatically from 1.94% to 81%. Fig 4.5 B demonstrates that in both the 
U937 model and in ex-vivo monocytes the PDE4A activity increases. (** P = 
0.002, Student’s T test).
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Fig4.2.2 Differentiation is associated with an increase in expression of 
PDE4A protein
U937 and U937pma cells were lysed in 3T3 lysis buffer and lysate protein 
was resolved by SDS-PAGE, followed by western blot analysis using 
antisera raised against the C-terminal of PDE4B. Fig4.2.2A,protein from 
1*10^5 cells was loaded in each lane: Lane 1 PDE4A4; Lane 2 PDE4A10; 
Lane 3 U937pma; Lane 4 control U937. Fig 4.2.2B, equal quantities of 
protein was loaded in each lane: Lane 1 PDE4A4; Lanes 2 - 4  100, 60 and 
40pg of protein from U937pma cells; lanes 4 - 7  equivalent protein 
quantities from control U937 cells. Both PDE4A4 and PDE4A10 run at the 
same weight making them difficult to distinguish on a western blot. Figure 
4.2.2C, autoradiographs were subjected to densitometric analysis, and the 
intensity of PDE4A bands relative to control U937 cells are presented 
(n=3). Note that consistent with previous activity data, PDE4A protein 
expression is significantly increased on differentiation. (P = 0.007, Student’s T 
test).
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Fig4.2.3 Differentiation is associated with an increase in transcription o f  
PDE4A10.
RT-PCR analysis of RNA isolated from U937 cells and U 9 3 7 p m a . Equal 
amounts of RNA was isolated and cDNA was prepared as described in 
materials and methods. This cDNA was used as template for PCR using 
primers directed against the specific N terminal regions of PDE4A4 and 
PDE4A10. Lanel contains markers, lane 2 - 5  contain the PCR product 
following per using PDE4A10 primers, lanes 6 - 1 0  contain per products 
from reactions using PDE4A4 primers. Lanes 2 ,  6 and 7 contain template 
cDNA from control U937 cells, while lanes 3 and 8 contain template from 
U 9 3 7 p m a  cells. Lanes 5  and 9  are positive controls and lanes 4 and 10 are 
negative controls. As can be seen while PDE4A4 is expressed under both 
control and differentiation conditions PDE4A10 expression appears only 
after 4 days of treatment with 4nM PMA.
133
4.2.4 Peripheral blood monocytes show increasedPDE4A activity with plastic  
differentiation
Imm unoprécipitation o f active PDE4A was performed on cell lysates derived from 
peripheral blood monocytes eultured for increasing periods o f time on plastic. Figure 4.2.4 
demonstrates that a similar inerease in aetivity as seen with U 9 3 7 p m a  development occurs 
in plastic cultured ex-vivo monoeytes suggesting that these changes normally occur in 
macrophage maturation.
4.2.5 PDE4D expression fa lls upon macrophage differentiation
Cell lysates derived from U937 and U 9 3 7 pm a  were analysed by western blot, with antisera 
raised against the C-terminal o f PDE4D. Figure4.2.5A, shows that while PDE4D3 and 
PDE4D5 are expressed in control U937 cells 4 days of incubation with of 4nM PMA leads 
to a fall in the expression o f both isoforms. PDE4D3 is absent from U 9 3 7 p m a  cell lysate, 
while PDE4D5 can be found only when large quantities o f protein are resolved. Figure 
4.2.5B, expresses the PDE4D5 data in terms o f intensity o f protein band using U937 cells 
as a reference point. This shows that PDE4D5 expression in U 9 3 7 p m a  cells is 18% of U937 
cell expression.
4.2.6/4.2.6.1 PD E4D  activity fa lls  with U 9 3 ? p m a  ^ n d  day Smacrophage 
development
In contrast to the increased activity o f PDE4A, immunoprécipitation o f PDE4D isoforms 
demonstrates a fall in activity of this family in U 9 3 7 p m a  cells. Figure 4.2.6A shows that as 
a proportion o f total PDE4 activity PDE4D falls from 60% to 25%, while fig 4.2.6B 
expresses this in terms o f actual activity showing a fall from 80 +/- 14 pmol/min/mg to 17 
+/- 7 pmol/min/mg in U 9 3 7 p m a  cells. With the change in cellular protein content a fall in
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Fig 4.2.4. PDE4A activity in ex-vivo monocytes.
PBMC from normal volunteers were cultured on plastic for 
2 hours then non-adherent cells were washed off. 
Differentiation on plastic was allowed to progress for a 
range of periods. Cells were then washed and lysed in 
KHEM buffer. PDE4A isoforms were isolated by 
im munoprécipitation using antisera raised against the C 
terminal of PDE4A. PDE4 assays were performed on the 
immunoprecipitates. It can be seen that progressive culture 
resulted in the increasing expression o f  PDE4A activity.
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Fig 4 .2.5 The changes in PDE4D expression in Ü937 cells differentiated with 
4nM PMA
U937 cells and LJ937pma cells were lysed in 3T3 lysis buffer and equal 
amounts of protein were resolved by SDS-PAGE and analysed by western blot 
Fig 4.2.5A: Lane 1 positive control recombinant human PDE4D3 & 5; Lanes 2 
and 3 correspond to lOOpg and 60pg of control U937 cell lysate; Lanes 4 and 
5 contain the same protein quantities from U 9 3 7 p.\ia cells. As can be seen 
differentiation causes the com plete disappearance of PDE4D3 from U937 
cells, while PDE4D5 undergoes a significant but smaller drop in expression. 
Autoradiographs from these western blots were subjected to densitometry and 
the amount of detectable PDE4D5 relative to control U937 is presented (fig 
4.2.5B). As PDE4D3 completely disappeared no value is presented for this 
isoform, however PDE4D3 expression in U937 cells was equivalent to 
PDE4D5. As can be seen there is a dramatic reduction in the expression of 
PDE4D isoforms with macrophage differentiation.(**, p = o.(X)7, Student’s T icsi )
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Fig 4.2.6A The changes in PDE4D expression in U937 cells differentiated 
with 4nm PMA
U 937 cells and U 9 3 7 pma were lysed KHEM buffer and a volume o f  lysate 
representing 600pg protein was subjected to immunoprécipitation using 
antiserum raised against the common C terminal o f  PDE4D. 
Immunoprecipitates were analysed for PDE4 activity at IpM cAMP. Figure 
4.2.5A, the proportion o f  PDE4D activity relative to total PDE4 activity is 
presented. As can be seen the relative contribution o f PDE4D to total PDE4 
activity falls from 60% to 25% in U 9 3 7 pma Figure 4.2.5B, The actual PDE4D 
activity per unit protein is presented reflecting a substantial fall in overall 
PDE4D activity (n=3). Fig 4.2.5C, The PDE4D activity per million cells is 
presented. Again activity per cell also falls. ( ** P=0.049, * p >0.5 , Student’s 
Paired T Test)
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Fi^ 4.2.6. J The changes in PDE4D expression in p lastic adherent peripheral 
blood monocytes
Monocytes were cultured on plastic for up to 5 days. Day 1, day 3, day 5 and
undifferentiated monocytes were lysed in KHEM buffer and a volume of
lysate representing 600pg protein was subjected to immunoprécipitation using
anti serum raised against the common C terminal of PDE4D.
Immunoprecipitates were analysed for PDE4 activity at IpM cAMP. PDE4D
activity fell with time spent in culture from a initial activity of 17.1
pmol/min/mg to 2.7 pmol/min/mg. This reflects the changes seen with U937 
cell differentiation.
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activity could represent a dilution effect of other proteins, thus 1 recalculated the activity 
on a per 10^ cell basis. Figure 4.2.6C, shows that the reduction in activity seen on per mg 
protein basis is less marked at a cellular level. This is inconsistent with the western blot 
data on p ro te in  expression . F igu re 4.2.6.1 expresses the PDE4D  activ ity  
immunopreciptiated from lysates prepared from fresh peripheral blood monocytes and 
monocytes cultured on plastic. PDE4D activity again falls confirming the physiological 
relevance of the U 9 3 7 p m a  model.
4.2.7 PDE4B expression increases with U93 7pma development
Cell lysates from U937 and U 9 3 7 p m a  cells were analysed by western blot and PDE4B 
isoforms identified using antisera raised against the C-terminal of the PDE4B family. As 
previously reported only PDE4B2 is expressed in U937 cells and remains present in 
U 9 3 7 p M A  cells (fig 4.11) [247]. Differentiation to U 9 3 7 p m a  is associated with a substantial 
increase in the intensity o f the band shown in fig 4.2.7A. Three experiments are presented 
in a disordered sequence to improve densitometry. This analysis is presented in fig 4.2.7B, 
and clearly shows a 180% increase in the intensity o f the PDE4B2 band with U 9 3 7 p m a  
development.
4.2.8 PDE4B activity increases with U937pma development
Figure 4.2,8 presents data derived from immunoprécipitation o f PDE4B iso forms and 
subsequent PDE4 assay on the immunoprecipitates. Figure 4,2.8A and 4.2.8B, demonstrate 
that both the activity o f PDE4B and the contribu tion to total PDE4 activity rose 
considerably with U 9 3 7 p m a  maturation. Thus in U937 cells PDE4B activity was 8 +/- 
4pmol/min/mg representing 6% of total PDE4 activity, while in U 9 3 7 p m a  cells PDE4B 
activity was 29+/- lOpmol/min/mg, representing 44% total activity. Again the activity was 
calculated on a per cell basis and the increase in activity was preserved.
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Fig 4 .2 .7 The changes in PDE4B expression in U937 cells differentiated with 
4nM PMA
U937 cells and U937pma were washed and lysed lysed in 3T3 lysis buffer and 
equal quantities of protein from each cell type were resolved by SDS-PAGE. 
PDE4B isoforms were identified by anti-PDE4B antisera on a western blot fig  
4.2.6A. Lanes 1,4 and 5, U937pma cell lysate. Lanes 2, 3 and 6, control U937 
cells. Autoradiographs were subjected to densitometric analysis and the 
relative intensities of each PDE4B band compared to control LJ937 was 
calculated and are presented (fig 4.2.6B). Control U937 cells express only 
PDE4B2, of the PDE4B family. Differentiation with PMA causes a substantial 
increase (+180%) in the band for PDE4B2 in U937pma ( ** P = 0.02, Student’s 
Paired T test)
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Fig 4.2.8 Changes in PDE4B activity in U937 cells differentiated with 4nM  
PMA.
U937 cells and U937pma cells were counted and lysed in KHEM buffer. A 
volume o f  cell lysate equal to ôOOpg was subjected to immunoprécipitation 
using antisera raised against the common C terminal o f  PDE4B. These lysates 
were analysed for PDE4 activity. Fig 4.2.7A, a pie chart representing the 
proportion o f  total PDE4 activity represented by PDE4B before and after 
differentiation. Fig 4.2.7B, The absolute activity per unit protein is presented 
+/- standard error (n=3).Fig 4.2.7C, The activity per million cells is presented. 
As can be seen an absolute increase in PDE4B2 activity is seen both in terms 
o f  absolute activity and activity per cell.( * P = 0.09, Student’s Paired T test)
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4.2.9 Densitometric analysis o f  western blot
Throughout this detailed profiling o f the PDE4 isoform content o f U937 and U937pma 
cells, I have presented data showing both activity per cell and activity per mg protein. This 
reflects the changes in cellular protein content found w ith differentiation. The 
densitometric analysis o f band intensity from western blot was performed on equal 
quantities o f protein, however and may result in bias. Figure 4,2.9 presents the 
densitometry data as optical density units with additional calculation o f expected band 
intensity for equal cell numbers. As can be seen where an increase in expression occurs, as 
with PDE4A and PDE4B comparing equal numbers o f cells would increase the difference 
described in my work. Thus it is likely that a greater quantity o f PDE4A and PDE4B are 
expressed in U937pma cells than my data suggest. In terms o f PDE4D, my data again 
underestimates the changes at a cellular level. Thus although PDE4D content of U937 cells 
is higher in my experiment than predicted for a per cell analysis, the fall is less marked. 
Thus it is likely that actual PDE4D expression at a cellular level in U937pma cells is lower 
than suggested in this work.
Discussion section 4.2
Having shown that U 9 3 7 p m a  cells represent mature macrophage development I measured 
the changes in PDE4 isoform expression. U937 cells expressed PDE4D3, PDE4D5, 
PDE4B2 and small quantities o f PDE4A4. This is in agreement with MacKenzie et al 
[247]. I demonstrated a large increase in PDE4A activity and expression in U 9 3 7 p m a - 
Increases in activity and PDE4A expression were found at both total protein and cellular 
level and were not an artefact of the changing protein content o f cells. This increase was at 
least in part due to new expression o f PDE4A10 a recently described long form PDE4A
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Fig 4 .2.9 Expression ofP D E 4 isoforms in U937 and U937pma cells
U937 and U 9 3 7 pma were lysed and western blot analysis was performed on 
equal quantities of lysate protein (lOOpg). Proteins were visualised with 
antisera raised against the C-terminal regions of PDE4 isoforms. 
Quantification of isoform expression was performed using Kodak Digital 
Science ID densitometry software. Data presented here demonstrates the 
difference between the density observed using equal quantities of protein and 
that predicted by expression per cell number. As can be seen the patterns of 
expression per cell number exaggerate the relative expression expressed per 
lOOpg protein.(n=3 per experiment (arb units = arbitrary units).
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isoforin [234]. As a novel gene expressed with a phenotypic switch PDE4A10 may play a 
role in macrophage specific regulation. On the other hand it seems likely that PDE4A4 is 
also increased in U 9 3 7 p m a  cells over U 9 3 7  cells.
Wang et al suggested that in human monocytes PDE4B2 was the key cAMP PDE isoform 
in controlling inflammatory behaviour[253]. Another group found a linear correlation 
between the ability o f a range o f cyclohexyl amine compounds' to selectively inhibit 
PDE4A or PDE4B as opposed to inhibiting PDE4D and their capacity to limit T cell 
proliferation or T N Fa production in response to house dust mite antigen [253, 254]. Using 
a knock out mouse model Jin et al dem onstrated the im portance o f PDE4B2 in 
inflammation by demonstrating failure to produce T N Fa in knock out mice exposed to 
EPS,[255]. I demonstrated a trebling o f the PDE4B2 content and activity in U 9 3 7 p m a - 
These data is consistent with the reports described above and strengthens the likelihood of 
PDE4B2 having important immunomodulatory roles.
In contrast to PDE4A isoforms and PDE4B2, PDE4D3 and PDE4D5 expression falls in 
U 9 3 7 p m a - This finding was consistent in all western blot analyses performed. The level of 
reduction in expression was greater than the fall in PDE4D activity found using 
immunoprécipitation o f U 9 3 7  and U 9 3 7 p m a  lysates. Although the trend was for a fall in 
PDE4D activity it was not consistent with the western blot data. Increasing the stringency 
of the washing steps of the immunoprécipitation, led to a complete loss in all PDE4 
isoform activity, and thus could not be used to coinect PDE4D activity. The western blot 
data was more consistent than the immunoprécipitation data. In the latter greater variability 
was found between experiments suggesting more error. The same antibody was used for 
both forms o f analysis and it seems unlikely that the error lies with the antisera. The 
immunoprecipitated PDE4D may have been isolated along side another PDE4 isoform in a 
molecular complex that then contributed to the activity recorded. No such additional PDE4 
isoform was found when immunoprecipitates were blotted with antisera raised against the
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other PDE4 isoforms. I believe the data from the western blot is a more correct reflection 
o f the cellular changes that occur with U 9 3 7 pm a  development due to the consistency o f 
these data.
To confirm that the findings in U 9 3 7 p m a  reflected changes seen in peripheral blood 
monocytes my colleague Dr George Baillie examined the activity and expression profiles 
o f ex-vivo monocytes differentiated on plastic. He demonstrated that PDE4A isoforms 
increased alongside PDE4B2 while PDE4D3 and PDE4D5 were reduced in expression. 
Again my U937 model closely reflected the ex-vivo model.
Section 4,3 A switch in long form/ short form dominance has 
functional significance in ERK 1/2 signalling.
PDE4B2 is a short form PDE4 and its activity is increased by ERK2 phosphorylation[67]. 
PDE4D3 and PDE4D5 are long forms and their activity  is reduced by ERK2 
phosphorylation [66, 67], The changes outlined in section 4.2 demonstrate a switch from 
long form PDE4D dominance to a short form PDE4B2 dominance with U 9 3 7 p m a  
development. I hypothesised that PDE4 regulation by ERK2 would be altered by this 
change in isoform expression.
4.3.1 Changes in PDE4 response to EGF
Figure 4.3.1 demonstrates that when control U937 cells are treated with EGF the total 
PDE4 activity falls implying a long form-dominant response. U 9 3 7 p m a  cells however show 
an increased PDE4 activity consistent with a short form-dominant response.
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Fig 4.11 PDE4 responses to EGF treatment varies with 
PMA treatment
Control and PMA treated U937 cells were exposed to EGF 
for increasing periods of time. Cell were washed and lysed 
and the PDE4 activity measured. As can be seen EGF 
caused a rapid 26% decrease in the PDE4 activity of U937 
cells. In PMA treated, differentiated cells however a rapid 
increase in activity was recorded. This difference probably 
corresponds to the ability of EGF to rapidly activate 
MAPKinase series of signal transduction kinases. These are 
known to exert opposite effects on the long and short 
isoforms of PDE4.
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Fig 4.3.2 PDE4 responses to salbutamol in U937 and U937 
PMA cells
Control and pma treated U937 cells were exposed tolOpM 
salbutamol for up to 25 minutes. Cell were washed and 
lysed and the PDE4 activity measured. A. U937 PDE4 
activity rose by around 10% by 5 minutes and returned to 
normal by 25 minutes. B. U937pma cell PDE4 activity 
continued to rise unchecked. The presence of the MEK 
inhibitor PD98059 leads to an increased elevation in 
activity and demonstrates that MAPkinase may become 
activated by salbutamol.
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4.3.2 Changes in response to P2 agonists
Figure 4.3.2 shows the PDE4 activity in response to treatment with salbutamol in U937 
and U937pMA cells. Although representing only two experiments these data suggests that 
PDE4 activity in U937 cells initially increases then falls while in U937pma the activity 
continues to rise.
Discussion Section 4.3
I used EGF to activate ERK2 in U937 cells because other pro-inflammatory signals such as 
EPS or T N F a activate ERK by multiple different pathways. Such ‘dirty’ signals might 
have changed PDE4 activity by other pathways that are hard to isolate in a living system. 
My data suggested that a switch in long form-dominance to short form-dominance was 
reflected by a change in crosstalk between ERK2 and cAMP signalling. This exciting 
result suggested that PDE4B2 could play a significant role in the development o f 
inflammatory signals. Cyclic AMP is believed to have anti-inflammatory behaviour on cell 
signalling and my data suggests that increased PDE4B2 activity will reduce local cAMP 
levels and permit signalling to progress.
Conversely I measured the activity o f PDE4 in response to a p2 agonist. These are 
important therapeutic agents in asthma. It is known that salbutamol increases PDE4 
activity in monocytes [226]. This may result in reduced activity o f the receptor in a process 
called heterologous desensitisation. P2 agonists are G-protein coupled receptors that 
activate adenylyl cyclase by release o f G as. It is believed however that prolonged receptor 
occupancy results in a switch in downstream signalling to a G ai activation of ERK 1/2. 
Thus I was interested to observe changes in this complex receptor system in terms of PDE4 
activity. Initial results showed an early an increase in PDE4 activity in U937 cells perhaps 
reflecting PKA phosphorylation o f PDE4 isoforms. Following activation, however a
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gradual decrease in activity occurs. Whether this represents a dephosphorylation event or a 
ERK2 related inactivation is not clear. In U 9 3 7 p m a  however activation continues 
unchecked. This suggests that a subsequent activation o f ERK2 downstream of the P2 
receptor may cause short form activation in differentiated macrophages.
Conclusions
In this chapter I have demonstrated that while tissue fixed macrophages are hard to acquire 
in vivo, the U 9 3 7 p m a  model is a useful surrogate for the study of phosphodiesterase 4  
activity. M acrophage differentiation is associated with significant changes in the 
expression and activity of PDE4A, PDE4B2 and PDE4D, In particular the new expression 
of PDE4A10 may offer a “cell specific” PDE4 isoform to target therapeutically. PDE4B2 
is also highlighted as an important PDE4 in macrophages. The overall switch from a long 
form dominant to a short form dominant profile of PDE4 may have important implications 
for our understanding of crosstalk in inflammation based signalling cascades involving 
cAMP.
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Fig 4.3.3 Diagram representing the effect o f  macrophage 
development on cAMP crosstalk with MAP Kinase
Monocyte Macrophage
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Chapters Lipopolysaccharide regulation of PDE4 
isoforms and PDE4 inhibition in activated RAW 264.7 
cells
Introduction
In chapter 4 I demonstrated differential regulation o f PDE4 isoforms in macrophage 
development suggesting that different PDE4 isoforms might regulate specific functions. 
Support for PDE4 dependent regulation o f macrophage function comes from studies 
demonstrating specific inhibition o f PDE4 alters macrophage behaviour. For example 
PDE4 inhibitors have been shown to prevent LPS stimulated T N F a and IL-12 production 
[256, 257]. The association of rolipram with PDE4 occurs with two distinct kinetics, a high 
affinity rolipram binding site (HARBS) and a low affinity rolipram binding site (LARBS) 
[223] leading to a proposal that different conformations o f PDE4 isoforms interacting with 
rolipram in specific ways [91]. Inhibition of T N Fa production by rolipram occurs with 
kinetics more akin to PDE4 activity inhibition than H^rolipram displacement from 
HARBS, suggesting that different conformations o f PDE4 may have different roles in 
regulating cellular cAMP [223]. Mackenzie et al demonstrated in U937 cells that cAMP 
dependent phosphorylation o f CREB (PCREB), showed stepwise increases with rolipram 
dose [247]. This work suggests that rolipram may inhibit PDE4 with multiple kinetics and 
thus regulate cell function in an isoform or conformation specific fashion.
By what mechanism cAMP inhibits LPS stimulated TN Fa production is unclear although 
indirect inhibition by IL-10 has been proposed. Cyclic AMP can increase the production of 
the “anti-inflammatory” cytokine IL-10 [245] and removing with anti-IL-10 antiserum,
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prevented the inhibition o f T N Fa by rolipram [163]. Procopio et al, on the other hand 
demonstrated that in an IL-10 knock out mouse model, cAMP was still capable o f 
preventing LPS stimulated T N Fa arguing for an alternative method o f inhibition [194]. 
While Kambayashi et al did not find a change in T N F a mRNA levels from rolipram 
treatment alone, many groups have found cAMP dependent T N F a regulation occurs at 
transcriptional and post translational stages [206]. Cyclic AMP inhibition of LPS induced 
TN Fa production therefore may occur in a direct or indirect manner.
Many groups studying rolipram inhibition o f cytokine production have found that the 
effect is enhanced by the presence o f a cAMP elevating signal. Thus while rolipram alone 
will not elevate intracellular cAMP the addition o f for example, a (32 adrenergic agonist or 
PGE2 along with PDE4 inhibition causes changes in cellular behaviour [258]. Whether 
LPS can provide such a cAMP stimulus is not clear[244].
LPS activates ERK 1/2 [259, 260] and cAMP is known to inhibit the classical Ras-Raf-1 
pathway o f ERK 1/2 activation by PKA mediated phosphorylation o f Raf-1 [261]. Cyclic 
AMP generated by PDE4 inhibition is therefore well placed to prevent LPS generated 
ERK 1/2 activation if  LPS uses the Ras-Raf-1. Gutheridge et al demonstrated that both LPS 
and constitutively active Raf-, activated ERK 1/2 in RAW 264.7 cells [262]. LPS however 
did not cause Raf-1 activation. Indeed both LPS and Raf-1 were mutually antagonistic. 
Other groups have demonstrated Raf-1 independent activation o f ERK 1 in myeloid cells 
[263]. Controversial work recently presented proposes that R apl can activate B-Raf and 
thus activate ERK 1/2 [264, 265]. Rap 1 is activated by a number o f second messengers 
including cAMP [266]. A family o f guanine nucleotide exchange factor (GEFs) called 
EPAC have been shown to activate Rapl in a cAMP dependent, PKA independent fashion 
[38]. Rapl could resolve the puzzle posed by Gutheridge et al, in that if Rapl was activated 
by LPS then it might activate ERK 1/2 in a Raf-1 independent manner (Fig 5.1). Carron et
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al recently showed that LPS induces (3 integrin induced macrophage spreading in a process 
that involves rapl activation [204].
Although many studies have investigated the effects o f inhibiting PDE4 on cytokine 
generation few have looked at LPS modulation o f PDE4 activity. 1 hypothesised that 
cAMP regulation would take place in a PDE4 isoform specific manner and that this might 
influence inflammatory behaviour. Thus I proposed to measure the response o f PDE4 to 
LPS and look for functional outcomes o f PDE4 inhibition. Finally 1 investigated what role 
if any Rap-1 might play in transducing the cAMP signal generated by PDE4 inhibition
LPS receptor
DAG
Cyclic AMP
Raf-1
Fig 5.1 Proposed mechanism of cAMP crosstalk in LPS activation o f MAPkinase.
(Ca^\ calcium; DAG, diacyl glycerol; )
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Results
Section 5.1
5.1.1 Lipopolysaccharide activates PDE4 but reduces PDE3 activity
I hypothesised that increases in cAMP phosphodiesterase activity would be required to 
“permit” pro inflammatory signals to be transduced. lOng/ml LPS was used to activate 
RAW 264.7 cells and PDE activities were measured over 90 minutes exposure (Figure 
5.1.1) (n-2). PDE4 activity climbs from 10 minutes, peaks at 50 minutes with normal 
activity regained by 90 minutes (figure 5.1.1.A). In con trast PDE3 activity, which 
contributes around 30% o f cAMP PDE activity in resting cells, is rapidly reduced 
following LPS stimulation.
LPS stimulates the production o f various mediators from macrophages. To avoid a 
secondary autocrine effect, I selected an early time point to analyse the activation further 
(figure 5.1.LB). By 30 minutes I found a significant increase o f 39.8% +/- 4.2% activation 
of PDE4 (n=4). The data presented is pooled from various experiments and percent change 
is quoted to minimise the effect o f cellular variability between experiments.
5.1.2 Wortmannin and PKA inhibitors significantly reduce LPS activation o f  
PDE4
Gene transcription and phosphorylation by PKA and ERIC2 can regulate PDE4 activity. I 
employed a battery o f signal transduction inhibitors to try and identify the pathways 
leading to PDE4 activation by LPS. Actinomycin 3p,g/ml, did not significantly affect the 
activation o f PDE4 suggesting that new protein production does not underlie the increase 
in activity at 30 minutes. Inhibition o f the MEK-ERK axis reduced PDE4 activation by
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Fig 5.1. /. LPS increases PDE4 activity while reducing PDE3 activity
Raw 264.7 cells were incubated with lOng/ml LPS for various 
periods. Cells were harvested, lysed in KHEM buffer and PDE3 or 
PDE4 activity was measured. Fig5.1.1A demonstrates that while 
PDE3 activity is rapidly reduced, PDE4 activity is preserved and 
increases from around 25 mins until 50 mins (n=2). Fig5.1.1 B 
presents data from repeated experiments looking at 30 minutes o f  LPS 
stimulation (n=4). LPS appears to increase PDE4 activity by 40% +/- 
4% after 30 minutes. (** indicates P = 0.05, calculated by paired T 
test o f  treated and non treated cells).
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Fig 5.1.2 The effects o f  various compounds on the increase in PDE4 
activity produced by 20 minutes treatment with LPS.
Raw 264.7 cells were pre-incubated with various signal transduction 
inhibitors for 30 minutes, prior to 20 minutes incubation with lOng/ml 
LPS. Cells were lysed in KHEM buffer and the PDE4 activity to I pM 
cAMP was measured. The data is presented as percentage change in 
the treated cells compared to the untreated cells. As can be seen little 
difference is recorded in the presence o f actinomycin (3pg/ml). MEK 
inhibition only inhibits 16% o f the activation seen with LPS. The 
greatest effects were seen in the presence o f H89 (lOpM) and the 
myristylated PKA inhibitor peptide (lOpM ) and wortmannin (lOpM). 
These molecules abolished PDE4 activation by LPS and reduced 
resting PDE4 activity.
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50%. The greatest inhibition o f PDE4 activation by LPS was seen with wortmannin and 
H89, both o f which reduced PDE4 activity overall.
5.L3 RAW  264.7 cells contain PDE4A1, PDE4A6, PDE4B2 and PDE4D3 
and PDE4D5
On the basis o f inhibitor studies it appeared that MEK was involved in the activation of 
PDE4 by LPS. ERK2 can activate short form PDE4 isoforms and inhibit long forms and so 
I investigated which long and short forms exist in these cells using western blot analysis. 
PDE4D5 is expressed to a greater degree than PDE4D3. The short form, PDE4B2 is the 
only member of the PDE4B family to be expressed. Two representatives o f the PDE4A 
family, rPDE4Al and rPDE4A6 are seen.
5.1.4 Lipopolysaccharide activates PDE4B2
Next I used immunoprécipitation to isolate PDE4 isoforms before and after LPS treatment 
and measured the PDE4 activity in the resulting im m unoprecipitates. Figure 5.1.4 
demonstrates that while PDE4A and PDE4D im munoprecipitates did not appear to 
increase in activity PDE4B activity rose by around 50%.
5.1.5 Inhibition o f  PDE4B in LPS treated RAW  264.7 cells
Using a range o f signal transduction inhibitors I identified the pathways involved in 
activating PDE4B. While the SB203580 compound inhibiting P38 MAPKinase, did not 
affect the activation o f PDE4B, U 0126 does abolish the activation completely. Again 
actinomycin does not alter the activation arguing against a gene transcription event.
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Fig 5.1.3. PDE4 isoform expression in RA W 264.7 macrophage cells.
Raw 264.7 cells were lysed in either 3T3 lysis buffer (A and C) or 
KHEM and subjected to high speed fractionation (B) and proteins 
were resolved on SDS-PAGE. Nitrocellulose membranes were probed 
with antibodies raised against the common C-terminal o f PDE4 gene 
families. Within each experiment equal amount o f lysate protein were 
loaded onto each lane. Fig 5.1.3A. PDE4A isoforms. Two immuno- 
bands appear co-mi grating with rat PDE4A1 and PDE4A6. Fig 
5.1.3B, PDE4B isoforms. One band co-mi grating with PDE4B2 
appears in both soluble and particulate fractions fraction. Fig 5.1.3C, 
PDE4D isoforms. Two bands co-mi grating with PDE4D3 and 
PDE4D5 appear. There is a clear excess o f PDE4D5.
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Fig 5.1.4 PDE4B 
macrophages
is activated following LPS treatment o f RAW
RAW 264.7 cells before and after treatment for 20 minutes with lOng/ml 
LPS treatment were lysed in KHEM buffer. PDE4 isoforms were isolated by 
immunoprécipitation using antiserum raised against PDE4A, PDE4B and 
PDE4D. PDE activity o f immunoprecipitates was measured (n=3).Fig 
5.1.4A, the majority of PDE4 activity in RAW 264.7 cells is accounted for 
by PDE4D, while 5%  is accounted for by PDE4B. Fig 5.1.4B, LPS increases 
PDE4B activity but does not increase PDE4A or PDE4D activity (n=3). (**, 
P = 0.00, Paired T test o f immunoprecipitates before and after LPS treatment).
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Fig 5 .1.5 Inhibition o f  the activation o f PDE4B
Serum starved RAW 264.7 cells were pre-treated with various inhibitors 
of signal transduction cascades, prior to incubation for 20 minutes with 
1 Ong/ml LPS. PDE4B was immunoprecipitated from cell lysates and the 
PDE activity of these extracts was measured. LPS increased PDE4B 
activity by 42%. As can be seen gene transcription does not appear to 
explain the increase in activity of PDE4B as actinomycin has no 
significant effect on PDE4B activation. MEK inhibition by the U 0126  
compound results in a loss of activation. Inhibiting P38 MAPkinase with 
the SB203580 compound does not alter PDE4B activation. (**, P < 0.05, 
Student’s paired T test o f the difference between LPS and LPS + inhibitor from base).
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Discussion Section 5.1
Lipopolysaccharide’s capacity to activate o f RAW 264.7 murine macrophage has been 
shown to equate with toxicity in vivo [267]. An extensive literature exists on pathways 
downstream o f the LPS receptor complex yet surprisingly little is known about the effect 
o f LPS on PKA activity or intracellular cAMP levels [259, 268]. Indirect studies using 
inhibitors o f PKA on LPS stimulated macrophages suggest that PKA is not activated [269]. 
Other groups have shown PKA inhibition to reduce LPS responses. H89, a PKA inhibitor, 
can inhibit the activity o f MSK 1 and Caivano et al have demonstrated that some effects 
attributed to PKA on the basis o f H89 inhibition may be due to bystander effects on this 
kinase [216].
I have shown that LPS causes an increased PDE4 cAMP hydrolysis in macrophages. This 
increase in activity would be expected to lower intracellular cAMP levels, as 1 
hypothesised. PDE3 and PDE4 show contrasting responses to LPS in a similar fashion to 
other examples o f funetional conipartmentalisation. Ahmad et al, demonstrated that while 
GM-CSF, an important macrophage survival factor was capable o f activating PDE3 and 
PDE4, IL-3 specifically activated PDE4 [102]. Dousa demonstrated in kidney mesangial 
cells, PDE3 inhibitors inhibit proliferation, while PDE4 inhibitors prevent oxide radical 
release [98]. Thus biochemical compartmentalisation may explain distinct functional 
responses to anti-inflammatory agents.
The greatest effects on PDE4 activation came with PI3Kinase and PKA inhibition. 
Baseline PDE4 activity was decreased implying that a degree o f constitutive activation o f 
PDE4 is present in these cells. PKA ean activate PDE4 isoforms and PI-3Kinase has was 
shown to activate PDE4A in pre-adipocytes through a p70S6 Kinase mediated pathway
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[112, 238]. LPS is known to activate PI-3kinase in macrophages [231]. I have also found 
partial reduction in PDE4 activity with MEK inhibition. ERK2 has been shown to affect 
PDE4 isoform activity in an isoform specific manner [67]. I wished to try and tease out 
which isoform was being activated as this might suggest which pathway was dominant in 
the LPS activation.
RAW cells express one PDE4B and two PDE4A isoforms (fig 5.1.3). This pattern reflects 
the mature maerophage phenotype described in chapter 4. PDE4D5 is also expressed 
differing from our U937 model. It is possible that this isoform reflects the immortalisation 
process. Immunoprecipitated PDE4A activity did not change with LPS treatment of RAW 
264.7 cells. This argues against a direct role for the PL3kinase -  p70S6 kinase pathway 
described in preadipocytes. I f  PDE4D was the predom inant isoform responsible for 
controlling the inflammatory response LPS would be expected to inhibit PDE4 activity by 
MAPkinase activation. Thus MEK inhibition would activate PDE4. This was not seen, and 
immunoprecipitated PDE4D did not respond to LPS.
PDE4B2 is the only ‘short-form’ PDE4 isoform present in RAW cells making it the likely 
subjeet o f ERK 1/2 activation downstream o f LPS [67]. Immunoprécipitation studies 
support this hypothesis as PDE4B2 is activated. The contribution o f PDE4B2 to total 
PDE4 activity is not sufficient to explain the change in PDE4 activity recorded. This may 
reflect an artefact o f im munoprécipitation where iso forms are stripped from their 
molecular partners, altering their eonstitutive function. Again MEK inhibition reduces the 
activation of PDE4B2 further supporting its contribution to the overall activation o f PDE4 
seen.
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Section 5.2
Evidence for m ulti-m olecular signalling complexes is accum ulating [79], Physical 
compartmentalisation o f individual PDE4 isoforms may explain some o f the differences 
between the response o f FDE4B2 and PDE4D5 to EPS described above. This suggests 
differential activation o f that ER K l/2 physically associated with PDE4B2, but not that 
associated with PDE4D.
Evidence for the incorporation o f PDE4 isoforms in multi-molecular complexes is lacking. 
Yarwood et al demonstrated that RACK-1 binds PDE4D5 tightly [84] and RACK-1 was 
shown to be important in determining macrophage integrity [270]. Corsini et al have also 
shown that senility in murine macrophages could be overcome by replacing reduced 
RACKl expression [230].
I next attempted to identify roles for PDE4B2 and PDE4D5 by demonstrating a direct 
physical relationship between PDE4 isoforms and components o f the B-Raf -  ERK 1/2 
pathway and RACK 1.
5.2.1 PDE4B2 appears to co-immunoprecipitate with Phospho - ERK1/ERK2 
and B~Raf
I attempted to demonstrate physical association between PDE4B2 and activated ERK 1/2 
by co-immunoprecipitation. I used PDE4B antiserum to isolate PDE4B2 and performed 
western blot analysis o f the immunoprecipitate. These were probed with antibodies raised 
against the phosphorylated residues o f activated ERKl and ERK2. Figure 5.2.1.A shows 
that a band co-migrating with phospho-ERK2 appears associated with PDE4B2. As it is 
believed that the members o f the MAPkinase signalling pathway form multimolecular 
complexes, 1 predicted that other members o f this pathway should co-localise with
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Fig 5.2.1 Co-immunoprecipitation o f IP-Band signalling proteins of the ras- 
ERKl/2 pathway
Raw 264.7 cells treated with Ips for various times were lysed and 
Immunoprécipitation was performed from Img of lysate protein using 
antiserum raised against PDE4B (Schering, UK). Immunoprecipitates were 
resolved by SDS-PAGE. Immunobands were developed with antibodies raised 
against B-raf and phospho-ERKl/2 proteins. Fig 5.2.1 A, ERK 1/2: lane 1 
molecular weight markers and ERK 1/2 control; lane 2 1P-PDE4B from 
untreated cell lysate, lanes 3 and 4 1P-PDE4B from raw cells treated with Ips 
(lOng/ml) for 10 and 20 minutes respectively. Lane 5 positive ERK 1/2 control. 
Fig 5 .2 .IB, B-raf blot. Lanes 1 - 4 immunoprecipitates from lysates of control 
and Ips treated RAW cells. Lanes 6 - 9  contain pre-dear ‘pull-down’. It can be 
seen that although initially promising, the results of the pre-dear studies 
suggest non-specific association of B-raf and anti-serum is taking place.
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PDE4B2. Figure 5 .2 .LB demonstrates an equivalent im munoprécipitation experiment 
probed with antibodies against B-Raf. Unfortunately the right side o f this blot shows B-Raf 
appearing in the Serum taken from pre-immunised rabbits that were subsequently used to 
raise the PDE4B antibody. Thus the validity of the co-immunopreeipitation studies is poor.
Despite altering the stringency o f the washing stages of immunoprécipitation I was unable 
to produce conditions where B-Raf did not appear in the preclear supernatant.
5.2.2 Back phosphorylation o f  Immunoprecipitated PDE4B2
I used a back phosphorylation method to time the phosphorylation o f PDE4B2. PDE4B 
im munopreeipitates were used as substrates for ‘ho t’ phosphorylation studies using 
reeom binant active-ERK 2 and radiolabelled phosphate (^^P) as a label. PDE4B2 
endogenously activated by phosphorylation will resist further phosphorylation and inactive 
PDE4B2 will be labelled. Figure 5.2.2 dem onstrates that although a weak band 
coiTesponding to PDE4B2 can be made out, the degree o f phosphorylation is too slight to 
distinguish it above background ‘noise’.
5.2 .3/5 .2J PDE4D5 and RACK-1 in EPS treated RAW  264.7 cells
I investigated a physical association of PDE4D5 and RACK-1. Figure 5.2.3 demonstrates 
expression o f both these molecules in RAW 264.7 cells. In each case high speed 
fractionation was performed and Fig 5.2.3A, demonstrates that PDE4D5 is distributed to 
all fractions with a greater proportion in the particulate than the cytosolie fraction. Figure 
5.2.3B demonstrates that RACK-1 is excluded from the cytosolic compartment, with the 
majority being found in the nuclear fraction. To investigate if activation of Raw 264.7 cells 
altered RACK-1 or PDE4D5 distribution, they were treated with EPS for up to 30 minutes. 
Figure 5.2.4 shows that no significant shift o f either protein from the PI compartment to 
the S2 takes place within this time frame.
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Fig5.2.2 Back phosphorylation of immunoprecipitated PDE4B2 
from EPS treated RAW 264.7 cells
RAW 264.7 cells treated with EPS (lOng/ml) for a range of times 
were lysed and antiserum raised against PDE4B was used to 
immunoprecipitate PDE4B2 from lysates. Immunoprecipitates 
were incubated with recombinant active ERK kinase fragment in 
the presence of ^^P-ATP. Immunoprecipitates were resolved by 
SDS-PAGE, and acrylamide gels were transferred to a 
nitrocellulose membrane and exposed on a phosphoimager (Bio 
Rad LTD, UK). The resulting image is presented. Lane 1 phospho- 
markers, molecular weight markers (Amersham-Pharmacia);Lane 2 
No treatment; Lanes 3-6 and Lanes 7-10, EPS lOng/ml for 2, 5, 10 
and 20 minutes respectively. The level of PDE4B2 is marked on 
the image, but as can be seen only a faint band is detectable. 
Insufficient protein is therefore present to make an estimate of the 
degree of phosphorylation compared to basal conditions.
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Fig 5.2.3 PDE4D5 shares a similar distribution as RACK 1 in RAW 264.7 
cells
RAW 264.7 cells were harvested and subjected to high speed fractionation 
as described in materials and methods. Fraetions were resuspended in 
equal volumes and PDE4D5 and RACK 1 were visualised by western blot 
analysis. Equal volumes o f fraetion, equivalent to 40pg S2 lysate protein, 
were loaded in each lane. Fig 5.2.3A PDE4D5: lane 1 +ve eontrol; lane 2 
PI fraction; lane 3 S2 fraction and lane 4 P2 fraction. Fig 5.2.3B RACK 1 : 
lane 1 +ve control; lane 2 P2 fraction; lane 3 S2 fraction and lane 4 PI 
fraction. As can be seen the majority o f both PDE4D5 and RACK 1 is 
distributed between the particulate fraetions with a greater proportion in 
the PI fraction. RACK 1 appears to be excluded from the S2 compartment 
while a small fraction o f PDE4D5 appears here.
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Fig 5.2.4 Activation does not affect PDE4D5 or RACK 1 distribution in 
RAW 264.7 cells
RAW 264.7 cells were incubated with lOng/ml LPS for given time periods. 
Cells were subjected to high speed fractionation and PDE4D5 and RACK 1 
were visualised in the S2 and PI fractions, by western blot. Equal volumes 
of cell fraction were loaded on each lane, equivalent to 40pg of S2 protein. 
Fig 5.2.4A PDE4D5: lane + and 6 +ve control; PI fraction lanes 1 - 5, Ips 
lOng/ml 0, 1, 5,10, 30 minutes respectively; S2 fraction lanes 7 - 1 1 ,  Ips 
lOng/ml 0, 1, 5,10, 30 minutes respectively.Fig 5.2.4B RACK 1 PI fraction 
lanes 1 - 6, Ips lOng/ml 0, 1, 5,10,15, 30 minutes respectively; S2 fraction 
lanes 7 - 12, Ips lOng/ml 0, 1, 5,10,15, 30 minutes respectively. No 
significant changes in distribution occurred with Ips treatment. This does not 
rule out a translocation between particulate fractions.
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Discussion Section 5.2
These studies were carried out in order to investigate PDE4B2 activation by ERK 1/2 
following LPS treatment o f macrophages and to identify a role for PDE4D5 in macrophage 
activation. Although I was able to demonstrate physical association between PDE4B2 and 
both Erk 2 and B-Raf molecules, I also found these molecules associated with pre-immune 
Serum. Figure 1.3 illustrates that two ERK2 docking domains exist in PDE4D3.1 predicted 
that direct association between long form PDE4 and ERK2 would take place. While this 
invalidates the experiment it does not refute the hypothesis that the molecules do associate. 
My next attempt to demonstrate ‘back-phosphorylation’ of immunoprecipitated PDE4B2 
failed due to low signal-noise ratio. This probably reflects the low abundance of PDE4B2 
isoforms in RAW  264.7 cells in common with m ost PDE4 isoforms. Again this 
unsuccessful experiment does not refute my hypothesis that E R K l/ ERK2 activates 
PDE4B2 and that this requires physical association. In order to demonstrate this activity I 
would have liked to develop stable RAW 264.7 cell lines over-expressing PDE4B2. By 
increasing the substrate for ERK 1 /2 ,1 would hope to improve the sensitivity of both these 
experim ents. U nfortuna tely time restraints coupled w ith difficulty  in successful 
transfection o f these cells meant this work was not completed.
To demonstrate a role for PDE4D5 in activated RAW 264.7 cells I looked for co­
localisation o f PDE4D5 and the scaffold protein RACK-1. Both molecules localised to the 
nuclear compartments o f lysed RAW 264.7 cells. RACK-1 was completely excluded from 
the cytosolie compartment. This co-localisation was exciting and led me to attempt co- 
immunoprecipitation experiments. Unfortunately this work was inconclusive. The nuclear 
distribution of RACK-1 in RAW 264.7 cells was intriguing as it has previously been 
described as a cytosolic protein [84]. One explanation for the nuclear distribution o f 
PDE4D5 is stimulation by components o f the serum in cell culture medium causing
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proliferation o f RAW 264.7 cells. To investigate this serum starvation o f these cells was 
performed, however this failed to cause any change in the distribution.
Lipopolysaccharide is known to activate macrophages and inhibit proliferation. To see if  
LPS stimulation led to a shift of PDE4D5 or RACK-1 out of the nucleus RAW 264.7 cells 
were treated with LPS. While LPS did not increase the S2 content o f either PDE4D5 or 
RACK-1 (Fig 5.2.4), a movement between the particulate eompartments cannot be ruled 
out. To further clarify this I would have liked to measure the PDE4 content o f each 
compartment over the time course. To further clarify the role o f PDE4D5, I would have 
liked to treat RAW 264.7 cells with other activators o f E R K l/ ERK2. It may be that 
restricted pools o f E R K l/ ERK2 are activated by different agents. Valledor et al showed 
that timing o f M APKlnase activation was linked to different outcomes [271]. Thus 
physical com partm entalisation o f PDE4D5 and E R K l/ ERK2 means that different 
activators may lead to different PDE4 isoforms being affected and that different 
downstream effects may result.
As my attempts to clarify EPS’ action on PDE4 were unsuccessful, 1 chose to investigate 
the result o f PDE4 inhibition on cellular behaviour. Thus 1 measured RAW 264.7 
inflammatory responses to LPS in the presence and absence o f rolipram.
Section 5.3 
Functional outcomes of PDE4 inhibition on LPS stimulated 
RAW cells.
5.3.1 PDE4 inhibition increases LPS stimulated iNOS expression
To assess what role PDE4 plays in regulating macrophage behaviour 1 examined the 
expression o f various inflammatory mediators and proteins in the presence o f rolipram. As
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rolipram potently inhibits the production o f T N Fa in LPS stimulated macrophages and 
both T N Fa and iNOS are described as being present in asthmatic airways I examined 
iNOS expression in the presence o f rolipram. Figs 5.3.1 A, demonstrates that iNOS 
expression is increased by PDE4 inhibition in the presence o f LPS at a dose o f rolipram 
between 10-50pm. To confirm that this was a PDE4 specific phenomenon, I compared the 
effect o f cilostamide with rolipram. As can be seen in fig 5.3. IB, inhibition of PDE3 failed 
to increase the expression o f iNOS to the same degree.
5.3.2 Indomethacin abolishes the increased iNOS expression
Next I co-incubated the stimulated RAW cells with indomethacin (lOOnM) to exclude a 
prostanoid driven cAMP effect. As can be seen in fig 5.3.2, Indomethacin abolished the 
increase in iNOS expression caused by rolipram.
5.3.3 Rolipram causes an increase in LPS stimulated COX-2 expression
Figure 5.3.3 shows that resting RAW 264.7 macrophages express little COX-2, but when 
exposed to LPS an immunoband corresponding to COX-2 appears. When the cells are co­
incubated with rolipram and LPS this expression is dramatically increased. Fig 5.3.3 B & 
C shows rolipram’s effect is dose dependent.
5.3.4/5.3.5 Rolipram enhanced COX-2 expression is resistant to indomethacin 
and results in increased PGE2 production
COX-2 expression is under partial cAMP control. To exclude a positive feedback o f PGE2 
derived cAMP on COX-2 I included indomethacin in the medium. Fig 5.3.4 demonstrates 
that the increased COX 2 expression occurs despite the presence o f indomethacin 
(lOOnM). Rolipram appears to be exerting a direct effect on COX-2 transcription. To 
ensure that the effect of rolipram on LPS induced COX 2 expression was translated into a
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Fig 5.3. ] Rolipram enhances the transcriptional activation o f  iNOS by LPS in 
RA W 264.7 cells.
Raw 264.7 cells were incubated for 16 hours in serum free DM EM with LPS 
(lOng/ml) with or with out rolipram or cilostamide. Cells were lysed and 
western blots prepared from these cell lysates were probed with iNOS 
monoclonal antibody. Equal amounts o f protein were loaded in each lane. Fig 
5.3.1 A Lane 1 +ve, Lane 2 - 6 LPS + rolipram 0.1 pM, 1 pM, lOpM, lOOpM, 
ImM respectively. This experiment clearly showed the dose dependent 
increase in iNOS expression that occurred when rolipram was co-incubated 
with LPS in RAW cell cultures.Fig 5.3.IB. Lane 1 +ve eontrol, Lane 2 
Rolipram lOpM alone. Lane 3 cilostamide 2pM alone and Lane 4 LPS + 
cilostamide 2pM. This data demonstrates that neither rolipram or cilostamide 
alone is capable o f causing the transcription o f iNOS alone in serum free 
medium. Cilostamide, a PDE3 inhibitor, does not enhance LPS stimulated 
iNOS expression similar to Rolipram.
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Fig 5.3.2 Indomethacin reduces rolipram’s augmantation o f iNOS 
expression in the presence o f  Ips.
Raw 264.7 cells were incubated in the presence o f LPS, 
rolipram(lOpM) and indomethacin (lOOnM). Cells were lysed and 
equal amounts of protein were resolved by SDS-PAGE. 
Nitrocellulose membranes were immunoblotted using antiserum 
raised against iNOS. Lane 1 no treatment, lane 2 Ips alone, lane 3 
Ips + Rolipram. Lanes 4 - 6 as lanes 1 - 3 with the addition of 
indomethacin. While rolipram enhances LPS iNOS expression the 
addition o f indomethacin abolishes the inerease in iNOS 
expression eaused by rolipram.
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Figure 5.3.3 Rolipram but not cilostamide increases LPS stimulated cox-2 
expression.
Raw cells were incubated with LPS (lOOng/ml) +/- a range of rolipram 
concentrations, +/- cilostamide lOpM +/- forskolin lOOpM. Cell lysates were 
prepared and subjeeted to western blot analysis with 40|ig o f protein loaded 
in each lane. Blots were probed with monoclonal antibody raised to COX-2. 
Fig 5.3.3A, Rolipram does not cause COX-2 expression and enhances LPS 
induced COX-2 expression. Cilostamide has no effect on LPS mediated 
COX-2 expression. Forskolin, does not mimic the effects of rolipram alone, 
(lane 1 no treatment, lanes 2-4 rolipram lp.M, 5|liM and 10p.M respectively, 
lane 5 LPS lOOng/ml, lanes 6-7 cilostamide IpM  and lOpM respectively, 
lane 8 LPS + cilostamide lOpM, lane 9 LPS + rolipram 10|uiM, lane 10 
forskolin lOOpM. Fig 5.3.3B Rolipram increases LPS stimulated COX-2 
expression in a dose dependent manner, (lanes 1 to 10 LPS lOOng/ml + 
rolipram 30pM, 10 p-M, 3 p-M, 1 p,M, 0.3 pM, 0.1 |iM , 0.03 pM, 0.01 pM, 
0.003 pM, 0.001 pM, respectively. Lane 11 LPS lOOng/ml, lane 12 no 
treatment). Fig 5.3.3C Band intensity was measured from representative blots 
illustrated in fig 5.3.3B and a graph of intensity against Log 10 rolipram 
concentration was plotted.
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Figure 5.2.4 Rolipram enhances COX-2 expression in an indomethacin 
resistant fashion
Raw 264.7 cells were incubated for 16 hours in the presence or absence of 
LPS (lOOng/ml) +/- rolipram (lOpM) +/- indomethacin (lOOnM). Cell 
lysates were prepared and equal quantities o f protein were resolved by 
SDS-PAGE. Immunobands were visualised using antiserum raised against 
COX-2. Lane 1 no treatment, lane 2 LPS alone, lane 3 LPS + rolipram, lane 
4 indomethacin alone, lane 5 LPS + indomethacin, lane 6 LPS + 
indomethacin + rolipram. This figure demonstrates that the enhanced 
expression of COX-2 by rolipram does not represent an exaggeration of a 
autocrine feedback loop by PGE2.
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Fig 5.2.5 Rolipram dose dependently increases PGE2 production by 
RAW 264.7 macrophages.
Raw 264.7 cells were incubated with LPS and rolipram in increasing 
concentrations for 16 hours. PGE2 El A was performed on cell free 
medium. Rolipram causes a dose dependent increase in PGE 2 
production.
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functional effect I demonstrated an increase in PGE 2 production. Fig 5.3.5 clearly shows a 
dose dependent increase in PGE2 production when macrophages are activated by LPS in 
the presence o f rolipram.
5.3.6 Indomethacin does not alter the ability o f  rolipram to inhibit TNFa.
COX-2 derived PGE2 could exert anti-inflam m atory activity and partially explain 
rolipram’s negative control of TNFa. Fig 5.2.6 demonstrates that Raw 264.7 cells produce 
large amounts o f  T N Fa when activated by lOng/ml LPS. Rolipram  reduces this 
significantly, confirming that my model system behaves in a similar fashion to other 
groups’. Indomethacin introduced to the system has no significant effect on the ability of 
rolipram to inhibit T N Fa production, implying that this effect is not driven by PGE2.
Discussion Section 5.3
PDE4 is believed to have pro-inflammatory activity by virtue o f its ability to reduce 
intracellular cAMP and the anti-inflammatory activity o f rolipram. I have demonstrated 
increases in iNOS and COX-2 expression in the presence o f rolipram. This apparently 
paradoxical work suggests that NO and PGE2 may exert anti-inflammatory behaviour. 
Increasing evidence supports this view and my work offers further explanations for 
rolipram’s anti-inflammatory role [167, 244, 272, 273]. Several groups have shown these 
proteins to be under transcriptional control by cAMP [274] although both transcriptional 
activation and repression have been reported [275]. Inducible nitric oxide synthase 
regulation by rolipram was secondary to COX-2 activation, suggesting either PGE2 or 
TXA2 increases iNOS expression. Thus, COX-2 causes a PGE2 autocrine activation of 
adenylyl cyclase and cAMP production. In the presence of rolipram this cAMP is enhanced 
and a powerful signal to iNOS expression is produced.
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F/g 5.3.6. Indomethacin does not prevent rolipram inhibiting LPS 
induced TNFa in RA W macrophages.
RAW cells were cultured as described in the presenee o f LPS, rolipram 
lOpM and indomethacin (lOOnM). Cell free medium T N F a content was 
measured by ELISA. Column 1 no treatment, column 2 LPS lOng/ml, 
column 3 LPS + rolipram, column 4 indomethacin alone, column 5 LPS + 
indomethacin and column 6 LPS + indomethacin + rolipram. As can be 
seen rolipram powerfully inhibits LPS stimulated T N F a production. 
While indomethacin appears to slightly reduce T N F a production from 
LPS stimulated macrophages, it has no significant effect on rolipram.
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The indirect effect o f rolipram on iNOS through COX-2 is reminiscent of its reported 
indirect effect on T N F a through IL-10. I have demonstrated that indomethacin did not 
affect the increased expression of COX-2 in the presence of rolipram. Rolipram appears to 
affect the expression o f COX-2 in the absence o f an additional positive cAMP stimulus. 
This suggests that PDE4 normally exerts a negative regulatory effect on COX-2 expression 
following LPS stimulation. Rolipram may then act in this circumstance by elevating cAMP 
slightly, possibly in a local region of the cell, or simply preventing the negative effect of 
increased PDE4 activity following LPS stimulation. PDE4 activity increases then falls 
following LPS exposure, lowering cAMP then restoring it. This dip could allow cAMP 
inhibited signals to propagate transiently. The effect of rolipram on COX-2 expression is 
not therefore straight forward and requires further investigation. It is o f note that 
cilostamide did not cause the same effect on iNOS expression as rolipram, which may 
seem unlikely given a non-PDE source o f cAMP such as PGE2. I propose that the 
reduction in PDE3 activity seen with LPS treatment leads to the abolition of any PDE3 
inhibitor activity.
In view o f the increase in PGE2, a cAMP elevating stimulus, following rolipram I 
hypothesised that PGE2 might be responsible for T N F a inhibition. Figure 5.3.6, clearly 
demonstrates that COX-2 activity is not responsible for T N Fa inhibition by rolipram in 
RAW cells. The precise role o f cAMP in regulating T N F a production is not clear, with 
some groups disputing IL-lO’s role and suggesting a post-translation effect instead. The 
anti-inflammatory behaviour o f PGE2 and rolipram requires further investigation.
Section 5.4
LPS is a pow erful activator o f ERK 1/2, a signal transduc tion pathway that is 
characteristically inhibited by cAMP. I was surprised by the apparent ability of rolipram to 
increase LPS signalling in terms o f COX-2 expression. I hypothesised that rolipram, by
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increasing cAMP was enhancing the signal transduction cascade downstream of LPS. This 
counter-intuitive theory suggests that differential activation of signal transduction elements 
could take place. I chose to investigate rolipram’s effect on LPS activation o f the E R K l/ 
ERK2 family o f molecules.
5.4.1 LPS activates a restricted pool o f  ERK 1/2 in RAW  cells
To confirm that LPS activated MAPkinase I stimulated RAW cells with various activators 
o f ERK l/2. Using monoclonal antibodies raised against the phosphorylated residues of 
activated ERK 1/2 I compared immunoblots o f activated versus total ERK 2. Fig 5.4.1 
shows the effects o f different compounds on ERK-1/2 phosphorylation. As can be seen 
PMA causes a substantial and early (1 minute)s activation o f ERK 2 while TN Fa and LPS 
cause a sequentially less profound and delayed activation.
5.4.2 Rolipram increases the phosphorylation o f  E RK  2 over LPS alone
I measured the effect o f LPS on ERK-2 phosphorylation in the presence and absence of 
rolipram. Fig 5.4.2 shows that the presence o f rolipram leads to an earlier and more 
profound phosphorylation. Fig 5.4.2, B uses figures derived from densitometry to calculate 
the effect o f rolipram on the activation of ERK 2.
5.4.3 Rolipram activates CREB in an H89 sensitive manner
So far I have demonstrated apparently paradoxical effects o f rolipram on RAW 264.7 cells. 
To confirm that PDE4 inhibition can function in a classical manner in these cells, I 
examined the role o f rolipram on the transcription factor CREB. CREB activation 
conforms to its phosphorylation status, and fig 5.3.4 demonstrates that rolipram increases 
CREB phosphorylation in a PKA dependent manner.
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Fig 5.4.1 Different compartments o f ERK 1/2 are activated by different 
stimulators o f RAW 264.7 cells
Raw 264.7 cells were incubated in the presence of three different 
agents for varying lengths of time. Lysates were prepared and equal 
quantities of lysate protein were resolved by PAGE and subjected to 
western blot analysis. Immunodetection of activated ERK 1/2 was 
achieved using phospho-ERKl/2 antibodies. Lanes: Lanes 1, 7 and 
11, no stimulation; Lanes 2 - 5 PMA 4pM  for 1, 3, 5 and 10 minutes; 
8 - 1 0  TN Fa 10 pM 5, 10 and 20 minutes; lanes 12-13 LPS lOng/ml 
5, 10 and 30 minutes. As can be seen while all agents are known to 
activate ERK 1/2, they do so in different time frames and to different 
degrees.
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Fig 5.4.2 Effect o f  rolipram on LPS induced ERK 1/2 phosphorylation.
Raw 264.7 cells were incubated with LPS (lOng/ml) with (lanes 7-12, 40 
protein per lane) or without (lanes 1-7 60 pg protein per lane) rolipram lOpM, for 
various times. Lanes 1 + 7 0  minutes, lanes 2 + 8 Sminutes, 3 + 9 1 0  minutes, 4 + 
10 20 minutes, 5 + 1140 minutes, 6 + 12 60 minutes. As can be seen LPS causes 
the phosphorylation o f ERKl by 20 minutes. In the presence of Rolipram, 
however this activation event occurs more rapidly and to a greater degree. The 
eft'ect is particularly marked in ERK2. Fig 5.3.2.B shows ERKl staining to 
demonstrate protein loading. Slightly more protein was loaded in the lanes without 
rolipram to allow a reasonable visualisation. This would be inclined to bias the 
experiment against showing any significant difference with rolipram. Fig 5.3.2.C, 
shows the results o f this experiment subjected to densitometric analysis (n=2). 
This data confirms the more rapid and greater phosphorylation that occurs in the 
presence o f rolipram. Fig 5.3.2D Demonstrates that no effect on ERK 
phosphorylation was seen in the presence o f rolipram alone, (lane 1 Ctrl, lanes 2 - 
6, 5, 10, 15, 20 and 25 mins respectively).
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Fig5.4.3. LPS phosphorylates CREB in a MEK dependent manner, 
while rolipram acts through PKA.
Raw cells were treated with various compounds and the cell lysates 
were subjected to western blot analysis, using an antibody raised 
against the phosphorylated residue of activated CREB transcription 
factor. Lane 1 no treatment. Lane 2 LPS iOng/ml, Lane 3 LPS + 
rolipram 10/iM, Lane4 LPS + rolipram + H89 lOjuM, Lane 5 LPS + 
H89, Lane 6 rolipram alone, Lane 7 cilostamide 10/xM alone, Lane 
8 cilostamide + LPS + H89, Lane 9 LPS + U 0126 10 pM  and Lane 
10 U 0126 pM  alone. This data shows that LPS causes 
phosphorylation of CREB in a U 0126 sensitive fashion. This 
confirms Cohen et al’s work, that demonstrated MSK dependent 
activation of CREB. In their hands H89 inhibited MSK, but here 
H89 did not affect LPS phosphorylation of CREB. On the other 
hand H89 did reduce the marked phosphorylation caused by 
rolipram in the presence or absence of LPS. This suggests firstly 
that rolipram is capable of activating Pka in RAW cells, but also 
that a basal level of PDE4 activity is generally controlling the level 
of intracellular cAMP.
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Discussion Section 5.4
To demonstrate that ER K l/2  can be differentially activated in RAW 264.7 cells I used 
various agonists, chosen to elicit different functional effects. Valledor et al working with 
RAW 264.7 cells demonstrated the outcome o f ERK l/2 activation varied with the timing 
[271]. While M-CSF, PMA, GM-CSF and IL-3 cause proliferation o f macrophages and 
induce a very rapid (5min) maximal activation o f ERK l/2, LPS reduced proliferation with 
a slower (15min) peak activation. It is interesting to speculate if  this differential response 
depends on spatial as well as temporal compartmentalisation. I confirmed this using 
phosphorylation o f ER K l/2  as a surrogate marker o f ERK 1/2 activation. Thus LPS 
treatment o f resting RAW 264.7 cells causes delayed activation o f a restricted pool o f 
ERK l/2 when compared to PMA, consistent with its recorded anti-proliferative activity. 
Such differential activation supports the notion o f compartmentalised pools o f signalling 
molecules. Next I demonstrated that rolipram alters the manner in which ERK activation 
occurs. Thus in the presence o f rolipram phosphorylation occurred earlier and to a greater 
degree than in its absence. If differential ERK activation affects cell behaviour differently 
then rolipram would alter the response to LPS and may suggest a mechanism for some of 
the anti-inflammatory effects seen with rolipram.
Having demonstrated a number o f unexpected effects o f rolipram on RAW 264.7 cell 
function I ensured that more ‘classical’ activity was taking place. I measured the effect of 
elevating cAMP by rolipram on the phosphorylation o f the transcription factor CREB. I 
demonstrated H89 inhibited this pathway and thus confirm ed that the mechanics o f 
‘classical’ cAMP signalling were present in RAW 264.7 cells.
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Section 5.5
PDE4 inhibition led to increased COX 2 expression and altered ER K l/2 activation I next 
looked for a mechanism to explain these effects. A new GEF called EPAC has recently 
been described that allows cAMP to activate the small G protein R ap-1 [276]. Rap-1 has 
been controversially reported to cause ERK 1/2 activation by B-Raf [277]. Rap-1 has been 
shown to be important in macrophage behaviour, with Carr on etal showing a role in 
macrophage response to P-integrin binding [204]. Using activation and regulation mutant 
forms o f Rap-1 transfected into RAW 264.7 cells I looked for changes in inflammatory 
mediator production.
5.5.1 Successful transfection o f  RAW  264.7 cells using Superfect (Qiagen)
Attempts to transfect RAW 264.7 cells using the DEAE/Dextran method proved difficult 
and I used the Superfect (Qiagen) system to successfully express the Rap-IA  mutants. 
Figure 5.5.1 demonstrates that although transfection efficiency varies between mutants, 
each transfection expresses more Rap-IA  than mock transfected cells.
5.5.2 Over expression o f  R ap-1A activation mutants does not alter rolipram  
inhibition o f  LPS-stimulated TNFa
To investigate if  rolipram activates Rap-IA  to inhibit LPS stimulated T N Fa production, I 
created temporary transfections o f mutant Rapl constructs in RAW 264.7. These have 
previously been described [204] and are designed to represent the conformation o f active 
(GTP-bound, SeiT2/Val mutation) or constitutively inactive ( Dominant negative, GDP- 
bound, ThiT7/Asn mutation) Rapl confomiations. Cells were treated with lOng/ml LPS in 
the presence and absence of lOjiM rolipram. I measured the T N F a production in each 
case. Fig 5.5.2 suggests that constitutively active Rap-IA  transfects produced less TN Fa
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Fig 5.5.1 Success o f superfect transfection o f RAW 264.7 cells
Raw 264.7 cells were transfected using the superfect method 
(Qiagen). Activation and PKA phosphorylation mutants of rap-1A 
were prepared and transfected. Equal quantities of cell lysate were 
loaded on each lane and resolved by PAGE. Immuno-detection of 
recombinant Rapl was achieved using antisera raised against 
Rapl protein. M=Mock transfections. Fig 5.5.1.A: lanes 1 and 4, 
Wild type; lanes 2 and 5, Dom Neg; lanes 3 and 6, Cons Active. 
Fig 5.5.1.B: Lanes 1-3, Wild type; lanes 4-6 Aspartate mutants; 
lanes 7-9, Alanine mutants. As can be seen transfection efficiency 
varied between cells, but in each case rap-1A expression in 
transfected cells exceeded non-transfected ‘mock’ cells. (Dom 
Neg, dominant negative mutation. Cons Act, Constitutively active 
, Aspartate mutants. Alanine mutants )
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Figure 5.5.2 Rap-IA activation mutants alter the effect o f rolipram on Ips 
induced TNFa production
Raw 264.7 cells transfected with Rap-IA activation mutants were treated 
with lOng/ml Ips and the TN Fa production was measured in cell free 
medium by ELISA. Cons Active = Constitutively active: Serl2/Val 
mutation; Dom Neg = Dominant negative: Thrl7/A sn mutation. As can be 
seen constitutively active mutants led to reduced T N Fa production at base. 
No significant differences were seen* between the different mutants in 
terms of Ips or rolipram on TN Fa production. Note in all transfections the 
inhibitory effect of rolipram was lost by transfection. No difference was 
seen with cilostamide I OpM (Cil). (*PairedT test of differences between treatment 
groups and control).
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than controls in a resting state. No significant difference was seen, however between 
different activation mutants when treated with LPS. In each case a substantial increase in 
TN Fa was found. Rolipram failed to inhibit LPS stimulated T N Fa in any o f the cells 
regardless o f the mutant form transfected. I have previously shown a significant reduction 
o f T N Fa production in the presence o f rolipram and these data suggests that transfection 
itself may subvert the mechanics o f rolipram inhibition.
5.5.3 Over expression o f  Rap-IA  activation mutants affects rolipram induced  
increase in COX-2 expression and PGE2 production
Next I used the same transfects and measured PGE2 production and COX-2 expression 
when LPS was administered in the presence and absence o f rolipram. Fig 5.5.3 shows than 
dominant negative rap -lA  appears to abolish the effect o f LPS on these cells. When 
transfected with constitutively active mutants LPS was able to cause an increase in PGE2 
production but no additional effect o f rolipram was seen. In wild type transfects LPS 
effects were abolished, but rolipram caused activation o f the COX-2 gene. In each 
transfection no significant difference was seen in the level of COX-2 protein expression. 
There was greater expression of COX-2 between transfected cells and mock transfected.
5.5.4 Protein Kinase A activation mutants effect on TN Fa production in LPS  
stimulated RAW  264.7 cells
As the effects o f Rap-IA  activation mutants were equivocal, I reasoned that cAMP may 
involve Rap-IA  by the more classic PKA route. Our laboratory had previously made 
constructs o f Rap-IA  mutated at the PKA phosphorylation domains. Thus a SeiT80/Asp 
has a ‘phosphorylated’ conformation while a S e ri80/Ala results in a ‘non-phosphorylated
Cox-2 — H
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Fig 5.3.3 Ejfect o f RAP-1 activation mutants on COX - 2 expression and 
PGE2 production by LPS stimulated RA W cells.
Raw 264.7 cells were transfected with various RAP-1 activation mutants. 
(Dom Neg, Dominant Negative Thrl7/Asn; Cons Active, Constitutivly 
active Serl2/Val.) Fig 5.3.4A. Western blot analysis of equal protein 
quantities for COX-2 expression when various activation mutants are 
treated with Ips (lOng/ml) and rolipram 10/xM. (Lanes 1-1-5 mock 
transfection, 2+ 6 wild type,3 constitutively active, 4 wild type, 7 dom 
neg.) Fig 5.3.4B, PGE2 production from various treatments of the above 
transfected RAW cells. No consistant patterns are seen. No significant 
effect of either Ips or Rolipram are evident. This data may suggest an 
important role for RAP-1 or may illustrate experimental difficulties when 
using transfected cell models.
188
IpaI
3oa
2 5 0
M
■ control
□ Ips
□ Ips + Rolipram
Mock Wild Type S to A S to D
Figure 5.5.4 Rap-IA PKA phosphorylation mutants ejfect on Ips 
stimulated TNFa production
Raw 264.7 cells were transfected with rap-1A mutated for the PKA 
phosphorylation domains. Wild type represent non-mutated over-expressed 
Rap-IA, S to A, Seri 80/Asp activation mutants and S to D, Seri 80/Ala 
phosphorylation negative mutants. Cells were treated with lOng/ml Ips and 
TN Fa was measured in cell free culture medium by ELISA. As can be 
seen wild type rap-1A transfects behave similarly to non-transfected cells. 
In both the gain of function and loss of function mutants Ips behaved 
normally, however rolipram did not inhibit this effect to the same degree.
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non-phosphorylatable’ mutant. I made RAW 264.7 cell transfects over expressing these 
mutants and treated them as above. Fig 5.5.4 shows the effect o f rolipram in mock 
transfections to be maintained with a significant reduction in T N Fa production. The effect 
of PKA mutants however is again less clear. While the peak T N Fa produced by wild type 
transfects is muted, the effect of rolipram is retained, suggesting transfection alone may 
alter LPS signalling.
Discussion Section 5.5
I decided to investigate the role o f the novel cAMP signalling pathway EPAC-RaplA in 
transducing rolipram ’s effects in macrophage inflammation. There are two strategies 
available to measure Rap-IA  activity in cells. Firstly activated Rap-IA  is a powerful ligand 
for its partner ral in a GTP bound form (ral-GDS). Ral GDS can be synthesised in fusion 
with GST allowing R ap-IA  to be ‘fished’ out of lysate using this construct as ‘bait’. 
Several reports have suggested difficulty with this technique in immune cells [278], The 
other technique relies on G-protein’s being activated by conformational change when 
bound to GTP. This active conformation can be mim icked by mutation and thus 
conformationally active and in-active forms can be made for most G proteins. Over 
expressing these mutants and measuring the effects biochemically in comparison to each 
other allows some inferences to be drawn. Our lab received mutant forms o f Rap-IA  as a 
gift from J. Bos et al, and we made a Series of PKA domain mutants by Quickchange 
(Qiagen). I successfully developed a method o f transfecting these immune cells that have 
traditionally been difficult to manipulate.
I have not seen consistent effects of Rap lA  mutants on either LPS or rolipram’s effect on 
RAW 264.7 cells. If rolipram functioned through Rap-IA  I would expect constitutively 
active mutants to cause a diminished response to LPS and an exaggerated response to 
rolipram. Thus LPS would cause a smaller TN Fa effect and a larger COX-2/PGE2 effect.
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On the other hand dominant negative R ap-IA  mutants should take the brake off T N Fa 
production and prevention o f rolipram inhibition. Neither o f these effects was consistantly 
seen.
There are several possible methodological problems with my strategy. Firstly transfection 
efficiency varied between experiments. I attempted to split all transfections into triplits 24 
hours before treatment to avoid internal variation o f transfection efficiency. Adjusting for 
Rap-IA  expression based on western blot density did not alter the results. Transfection 
efficiency is less than 100%. This means normal cells remain that are capable of normal 
responses to LPS and rolipram. If  these normal cells constitute a large proportion o f the 
population any effects o f mutant transfection will be swamped. My data does not conclude 
that this is occuring, as the effects seen in transfected cells do not match that seen in mock 
transfections. To avoid this problem in the future, pure stable cell lines should be created 
using cytotoxic selection strategies to produce pure strains o f over-expressing cells.
Transfection o f foreign material into a cell can be a toxic proceedure to cells. Cells 
responses vary, but a pro-inflammatory effect in macrophages would not be surprising. 
Such a response would certainly invalidate my data. Including mock transfections, positive 
and negative controls partially get round this problem but not entirely.
Conclusion
I have extended my studies of PDE4 in macrophage cells by investigating biochemical and 
functional roles o f PDE4 isoforms and PDE4 inhibition. I have demonstrated increased 
PDE4 activation following LPS stimulation o f RAW cells. The complex signalling 
mechanisms activated by LPS make this global effect on PDE4 difficult to interpret. 
Certainly the effects o f signalling inhibitors suggest that constitutive activation of PDE4 
occurs in RAW cells and thus changes to total PDE4 activity is likely to reflect the balance
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of activation and de-activation o f individual isoforms. I have shown that PDE4B2 is 
activated by LPS stimulation and MEK inhibitors reduce that this. This agrees with Wang 
et al, who showed PDE4B2 to be the key isoform regulating monocyte behaviour in ex- 
vivo cells[253]. Unfortunately I have not been able to consistently demonstrate a physical 
association between PDE4B2 and members of the MAPKInase signalling pathway.
Rolipram is an anti-inflammatory compound and its behaviour varies with its ability to 
elevate cAMP and I have demonstrated two new anti-inflammatory behaviours. Firstly in 
the presence of rolipram LPS generates increased amounts o f iNOS and COX-2 protein. 
These are functionally active enzymes producing nitric oxide and PGE2 respectively. The 
role o f these mediators has come under scrutiny recently and it has been postulated that 
they may reflect an attempt to dampen an inflammatory response in diseased airways. That 
the increase in iNOS expression is dependent on COX-2 production o f PGE2 suggests that 
this latter is the key anti-inflammatory molecule. Thus I have demonstrated a new 
secondary pathway for rolipram’s physiological activity. I have also shown that this is not 
responsible for inhibition o f TN Fa production.
The second anti-inflammatory effect is a change in macrophage response to LPS. Rolipram 
causes an increased and early phosphorylation o f ERR 1/2, an event that closely correlates 
with activation. The pattern o f ERK 1/2 phosphorylation changes in the presence o f 
rolipram from an ‘activated’ profile to a ‘proliferative’ one as described by valledor et al. 
This would significantly alter the cells response to LPS and may effect the inflammatory 
outcome.
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Fig 5.5.5 Revised proposal fo r  cAM P/ERKl/2 crosstalk: Incorporation o f  rolipram
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Chapter 6  The synthesis of HIV-Tat fusion protein 
PDE4D3 and PDE4B2
Introduction
I have demonstrated regulation o f PDE4 isoform expression in macrophage development, 
and suggested certain isoforms may have function-specific roles in inflamm atory 
signalling. Compartmentalisation suggests that such specificity may reflect spatial isolation 
of individual isoforms to restricted areas o f the cell or to multi-protein signalling modules. 
Protein-protein interactions governing such physical organisation also underpin kinase and 
kinase target association essential in functional regulation. Producing ‘m ock’ peptides 
mimicking the protein interaction sites on PDE4 isoforms may thus inhibit both targeting 
and regulation by enzymes. These mock peptides must occur in the correct context to 
reduce “bystander’ effects on proteins with similar modules.
There is no entirely ‘clean’ way to introduce peptides into cells. Transfection o f DNA 
coding for the desired regions may lead to changes in cell behaviour as seen in chapter 5, 
while infection o f immune cells with adenovirus containing coding DNA has similar or 
more devastating effects. In any case both of these strategies have proven difficult in 
macrophages, which are professional phagocytic cells and very resistant to the introduction 
o f active foreign material.
Various methods o f transducing protein into intact cells have been attempted. Tagging 
peptides with lipid groups has been shown to allow small molecules to enter cells, but in a 
very variable manner. In 1999 Schwarze et al [279] described a novel method for delivery 
of a fully active enzyme into all cells o f a live mouse. This group utilised the property of
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the N-terminus of the HIV twin arginine transactivation enzyme (Tat) that allows it to pass 
through bi-lipid membranes. This small portion o f the enzyme is known as HIV-Tat, and 
Schwarze et al showed that recombinant, denatured full length P-galactosidase protein in 
fusion with H IV-Tat was not only delivered into cells, but was renatured and active once 
internalised.
My aim was to synthesise four such fusion proteins coding for full length and N-terminal 
fragments o f PDE4 isoforms linked to HIV-Tat. I chose PDE4B2 since I had previously 
shown this molecule to be important in the development o f inflammatory signalling, and 
PDE4D3 as this molecule was shown to be absent from these cells and would function as a 
negative control. A lthough unsuccessful in my attem pt this process was a useful 
methodological experience.
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Results
Section 1 
Strategy employed
Following standard protocols reported in materials and methods, I planned to produce full 
length and N-terminal PDE4 isoform-HIV tat fusion proteins. A schematic illustration of 
the method I employed is shown in figure 6.1.1. The sequence for HIV-TAT was retrieved 
by interrogating the complete HIV genome as published in the NCBI genome database, 
using the sequence published by Schwarze et al as a search tool [279]. This peptide 
sequence was connected to the PDE4 fragment o f choice by a poly-glycine linker region. 
This allows free rotation o f the combined proteins once synthesised preventing inhibitory 
interaction. A seven amino acid length sense primer for the PDE4 was added to the glycine 
linker. An antisense primer for the C-terminal region o f the PDE4 sequence to be cloned 
was created. Figure 6.1.2 describes the various elements o f the primers used. Each cDNA 
had reciprocal open restriction enzyme sites ends encoding the complimentary sequence of 
a restriction site o f the poly-linker region o f Pgex precision plasmid vector. I used Not-1 
sires for the majority of these constructs. This vector contains the sequence o f GST and a 
peptidase target domain allowing recombinant proteins to be purified on sepharose beads 
then cleaved off. By using this plasmid I untended to utilise the Kozak initiation sequence 
included. While simplifying the method, this strategy requires careful planning to ensure 
that the subsequent fusion protein ‘insert’ cDNA lies in-frame for that Kozak.
Prior to ligation the vector plasmid was linearised by incubating with a restriction enzyme 
designed to cut the plasm id within the poly-linker region. The insert cDNA was then 
ligated into the linearised poly-linker region. A plasmid was identified by RLFP and 
sequence analysis was performed to ensure correct alignment and the integrity of the DNA
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Fig 6.1.1 Schematic representation o f  PDE4D3 N terminal HIV tat fusion protein
PCR primers designed to recognise N  terminal sequence o f PDE4D3 and coding for 
HIV-tat and restriction enzyme binding sites were used in PCR reactions with pre­
cloned PDE4D3 in pcDNA3 plasmid vector, A. The resulting cDNA was used as an 
insert for a ligation reaction into the poly-linker region o f  Eco-Rl linearised P-Gex 
5X expression vector, B. These expression clones were transformed into standard E 
Coli for amplification and screening, C. Screening was performed by restriction 
digest using pst-1 with three resulting cDNA fragments confirming correct 
sequence cloning, D. Formal confirmation was made by sequence analysis
continued..............
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D/ Restriction digest screening
E/ Growth and stimulation
IPTG 
------► GST PX tat PDE4D3NT
F/ Isolation o f protein
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Recombinant PDE4D3NT-GST protease
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G / PDE4D3-N Term inal -HIV tat fusion protein
PDE4D3-NT - GlyGlyGly - HIV tat
Fig 6.1.1 Continued.
A clone with confirmed sequence was selected and plasmid isolated and purified. 
This was transformed into BL 21 E Coli, a strain selected for its ability to produce 
recombinant proteins. A successfully transformed colony was identified on 
ampicillin selection media. This colony was cultured at optimised temperature and 
stimulated to produce the fusion protein by the addition o f IPTG, E. Bacteria were 
harvested by centrifugation and lysed. Protein rich supernatant from lysed bacteria 
were incubated with sepharose coated beads, F. Sepharose binds the GST o f the 
fusion protein allowing purification from the supernatant. Finally precision protease 
was used to cleave the recombinant PDE4D3-N Terminal - HIV tat fusion protein 
from the GST which was removed by bead centrifugation, D. Finally a cartoon 
representation o f  the desired fusion protein, E.
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TATGGCAGGAAGAAGCGGAGACAGCGACGAAGA 
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Anti-sense primer - ms 3
GATCTACATCATGTATTGCACTGGCr”
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Fig 6.1.2 sequence o f the PDE4D3 N-Tenninal HIV tat fusion primer
Schematic representation of the primers used to generate the insert from a 
cloned stock PDE4D3 full length sequence. Sense primer codes the fusion 
peptides to be included in the cloned sequence. These are detailed as HIV- 
tat and the poly-glycine linker. A region coding for the specific N-terminal 
of PDE4D3 is included in the sense sequence. For other PDE4 isoforms the 
specific N-terminal sequence could be substituted at this point. Two anti­
sense primer sequences are described. MS2, codes N-terminal truncated 
PDE4D3 while ms3 encodes the generic C-terminal PDE4D. By including 
this latter sequence full length PDE4D3 fusion protein could be 
synthesised. Finally a schematic diagram demonstrating how these primers 
related to full length sequence is provided.
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sequence. A plasmid containing verified coding sequence for HIV-tat-PDE4 was amplified 
and purified as described. This was transformed into the BL-21 E Coli expression system. 
These bacteria were stimulated to synthesise protein, using IPTG. Harvested bacteria were 
solubleised and the protein extracted from the supernatant fraction using beads coated with 
sepharose. Finally precision protease was used to cleave the peptide from the beads to 
produce a purified peptide.
I attempted to make HIV tat fusion proteins for a variety o f  PDE4 isoforms. Unless 
otherwise noted I will describe PDE4D3-N-terminal fusion protein to illustrate the 
problems encountered. Figure 6.1.2 illustrates the primers I designed to code for HIV-tat 
PDE4D3-Nterminal fusion.
Section 2 
Optimising the method
6.2.1 Optimising PCR methods HiFi Vs Taq
I set out first to compare a variety of PCR agents as successful ligation depends on having 
optimum quality cDNA product. Optimal PCR conditions were assessed by varying the 
cycling temperature and times over a range of values. Optimum cycling conditions based 
on these experiments are presented in table 2.3, (materials and methods). Figure 6.2.1 
demonstrates two agents, Taq (Promega), High Fidility (Roche) and High Fidelity2 
(Roche, with a mix containing twice the template DNA). Taq is a thermostable DNA 
polymerase, while the high fidelity mixes Taq and Pwo DNA polymerases. These latter 
enzymes contain intrinsic 3 ’-5’ proof reading capacity that increases the fidelity o f the 
PCR product. In this experiment I used HIV-tat-PDE4D3 N-terminal sense primer and a 
PDE4D3 C-terminal primer, thus cloning a full length PDE4D3-HIV tat fusion coding for
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Fig 6.2.1 Optimisation o f PCR technique
Primer pairs encoding the HIV-tat-N-terminal PDE4D3 fusion [ 
GAGCTCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGACGGCGGCGGC 
GGCGGCGGCGGATGATGCACGTGAATAATTT] and the extreme C- 
terminal of PDE4D3 [GATCTACATCATGTATTGCACTGGC] were 
incubated using a variety of PCR reagents. An cDNA of -1848 bp was 
expected. Lane I molecular weight markers, lane 2 High 
Fidelity (Roche), Lane 3 Taq (Promega) and Lane 4 High Fidelity 
(Roche, double template DNA). As can be seen the conditions selected 
were satisfactory for use with High Fidelity, PCR reagents and this was 
selected for further experiments.(values molecular size, bp: base pairs)
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Fig 6.2.2 Restriction fragment (rFLP) analysis o f ligated plasmids
PGEX 5.3X plasmids into which cDNA encoding PDE4D3 N- 
terminal - HIV tat fusion protein had been ligated using a range of 
molar ratios of insert to plasmid, were incubated with pstl restriction 
enzyme as described in materials and methods. The cDNA was 
resolved on a 1% agarose gel containing ethidium bromide and 
visualised under UV light. Lanes 1 -4 vector/insert (v/i) ratio of 1/7, 
5-8 v/i ratio 2/7 and 9-13 v/I ratio of 3/7. Expected fragments of 
5040Kba, 1049Kba and 883Kba were seen in lanes 1, 2, 3 and 12. 
These plasmids were selected for further analysis by commercial 
sequenceing.
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1.8 Kba. On the basis o f this early optimisation I used HiFi (Roche) for all further PCR 
steps.
6.2.2 Screening fo r  transformed vectors — restriction digest
Complimentary DNA encoding a PDE4 sequence fused to H IV-tat was purified from 
agarose gel and quantified by spectrophotometry. This cDNA became the “insert” DNA 
for plasmid ligation. Ligation of insert cDNA was completed as described in the materials 
and methods, and different ratios o f insert to plasmid were compared to ensure optimum 
ligation. Successful ligation o f insert into most linearised plasm id led to some re- 
cireularised plasmid that did not contain the insert and possibly some inverted sequence 
insertion. This led to false positive resistant colonies when transformed E-Coli were grown 
on selection media. To avoid selecting bacteria with non-ligated or misaligned plasmids, 
restriction digest was performed on purified plasmid from randomly selected samples from 
bacterial colonies. Figure 6.2.2 demonstrates the successful incorporation of insert in only 
4 o f 13 colonies selected. Three of the 4 successful clones were ligated with a ratio o f 
insert cDNA to vector plasmid o f 1/7 based on molarity. When other ratios were used the 
resulting number of colonies on selection media was small. Thus for future ligations this 
ratio was used. Clones suggested by digest screening were commercially sequenced to 
confirm their integrity.
6.2.3 Optimising expression
Following successful cloning and amplification o f the expression vector containing fusion 
cDNA I transformed the plasmid into BL 21 E Coli. This strain is used as an expression 
vehicle as it is less likely to make inclusion bodies with recombinant proteins than other E 
Coli. These complexes o f bacterial proteins form when ‘foreign’ proteins are improperly 
processed by bacteria and are prepared for destruction [280]. Growing the bacteria under
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Fig 6.2.3 Optimisation o f expression o f PDE4D3-NT-tat in BL 21 E Coli
BL21 E Coli transformed with PDE4D3-N Terminal-HIV tat cDNA P 
Gex vector were grown to optimum density (0.7 abs units) and IPTG 
added. 4 colonies were selected and incubated at different temperatures. 
Bacteria were harvested, lysed and particulate free lysate was boiled in 
2XSDS sample buffer. Lysate was applied to an 8% SDS-PAGE gel as 
follows: Lanes 1-4, 37°C; 5,6,8 and 9, 22°C; 10-13,4°C and lanes 7 and 
16 non-stimulated E Coli. Gels were stained with coomassie blue stain 
and dried. As can be seen different colonies appear to express protein 
optimally at different temperatures. Further analysis was performed on 
colonies represented in lanes 6 and 8, grown at 22°C.
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conditions favouring slow production of protein reduces the formation o f inclusion bodies. 
Different growth conditions were tested to optimise protein production free from IB, by 
resolving particula te free eytoplasm on SDS-PAGE. Figure 6.2.3 demonstrates that 
different colonies produced protein optimally under different conditions. This is well 
recognised and means that for any given recom binant protein optimising growing 
conditions is necessary. It was still clear that a large proportion o f the expressed protein 
existed in inclusion bodies. This may be explained by the tendency o f PDE4 N-termini, to 
form oligomers by UCRl -  UCR2 interaction. It is also known that GST can form dimeric 
forms, thus large complexes o f peptides may develop within the E Coli. I next attempted to 
vary the lysis buffer to improve solubility o f peptide in the supernatant.
6.2.4 Optimising isolation
To optimise the solubility o f the expressed peptide I attempted to lyse the BL 21 E Coli in 
a range of lysis buffers. These included two different lysozyme buffers (Lyl and Ly2 -  
section MM) and a sucrose buffer (Sul). Figure 6.2.4 demonstrates that lysozyme based 
bacterial lysis results in a greater proportion o f protein in the supernatant fraction. I next 
attempted to isolate the soluble protein on sepharose beads to maximise purification. 
Unfortunately despite achieving a high supernatant to pellet protein ratio I was unable to 
isolate the fusion protein on sepharose beads. Various conditions were tried, to enhance 
sepharose binding but the protein remained in the supernatant following collection o f beads 
by centrifugation. This suggests that little active GST was present to bind and that soluble 
protein was not an active fusion protein. I assumed therefore that most of the expressed 
protein was contained in the form o f inclusion bodies (IBs).
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Fig 6.2.4 Optimisation of bacterial lysis
BL21 E Coli transformed with P Gex plasmid containing the fusion 
cDNA coding for PDE4D3N-Terminal-HIVtat, were treated with IPTG 
and grown at 22°C for 6 hours. Bacteria were harvested and lysed in a 
range of lysis buffers Ly 2, Lyl and su 1 (section Materials Methods). 
Supernatant and pellet fractions were boiled in 2X SDS sample buffer 
and resolved on an 8% SDS-PAGE gel. Gels were stained with 
coomassie blue stain and dried. Lane 1 and 2 Ly 1, lane 3 and 4 Ly 2 
and 5 and 6 Su 1. Lanes 8 and 9 represent full bacterial cells boiled in 
lysis buffer. Even lanes supernatant fractions while odd lanes pellet 
fractions. Lysozyme (Ly) based buffers were selected for further 
analysis as a greater proportion of expressed protein is found in the 
supernatant fraction.
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6.2.5 Sarkosyl detergent based lysis o fB L  21 E  Coli
In an attempt to denature IB during bacterial lysis, I used a strategy involving the ionic 
detergent Sarkosyl. This causes IB disruption by denaturing protein-protein interactions. 
The supernatant collected from centrifugation o f bacteria lysed in 10% sarkosyl contained 
a relatively high supernatant/pellet recombinant protein ratio, (fig 6.2.5.1). In lane 6, it is 
clear that no association between sepharose beads and recombinant GST-fusion protein 
took place. It is likely that the 10% sarkosyl buffer used to produce protein dénaturation 
and inclusion body solubilisation also denatures GST causing failure to associate with 
sepharose.
To combat this problem I attempted to minimise the concentration o f sarkosyl in the lysis 
buffer (fig 6.2.5.2). As can be seen, although recom binant protein appears in the 
supernatant from low dose sarkosyl lysed bacteria (fig 6.2.5.2,A) little difference was seen 
at reducing sarkosyl concentrations when protein was collected on sepharose coated beads 
P2 (fig 6.2.5.2, B). I attempted to re-nature GST by adding the ionic detergent triton X- 
100. As can be seen (Fig 6.2.5.3) while some re-natured protein was collected on beads 
(P2), a large proportion remains in the supernatant (S2).
6.2.6 Urea dénaturation o f  inclusion bodies
Inclusion bodies can be denatured in 8M urea, and I attempted fusion protein isolation with 
this method. Lysozyme lysed bacterial pellet fraction (PI), was solubilised in 8M Urea and 
gradually renatured by osmotic replacem ent o f Urea using dialysis. Figure 6.2.6 
demonstrates a significant concentration effect of sepharose beads suggesting that dialysis 
based re-natu ration o f  GST has allowed successful isolation o f fusion protein. 
Unfortunately lane 4, shows loss o f fusion protein with peptidase cleavage o f P2.
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Fig 6.2.5.1 Comparison o f ‘GST-pull down' to pellet fraction in sarkosyl 
lysed transformed E Coli
BL 21 E Coli transformed with P Gex containing the fusion cDNA coding 
for PDE4D3N Terminal-tat, were treated with IPTG and grown at 22°C for 
6 hours. Bacteria were harvested and lysed in 10% sarkosyl lysis buffer 
(section MM). Pellet fraction (P I) and supernatant SI were collected by 
centrifugation. Sepharose coated beads were added to SI and incubated at 
4"C for 2 hours. Beads were collected and washed and collected by 
centrifugation. Collected beads (P2) and wash buffer (W l) were retained. 
All fractions were boiled in 2XSDS sample buffer and applied to an 12% 
SDS-PAGE gel as follows: lane 1 and 2 S I, Lane 3 molecular weight 
markers, lane 4 P I, lane 5 W l and lane 6 P2. Despite a significant amount 
of recombinant protein appearing in the PI fraction none appears to be 
collected on the beads. This is likely to be due to the denaturing effect of 
10% sarkosyl on GST.
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Fig 6.2.5.2 Ejfect protein solubilisation and GST dénaturation o f minimising 
sarkosyl concentration
BL 21 E Coli transformed with P Gex containing the fusion cDNA coding 
for PDE4D3N Terminal-tat, were treated with IPTG and grown at 22°C for 
6 hours. Bacteria were harvested and lysed in buffer containing a range of 
sarkosyl concentrations (section MM). Supernatant SI was collected by 
centrifugation. Sepharose coated beads were added to SI and incubated at 
4°C for 2 hours. Beads were collected and washed and collected by 
centrifugation (P2). P2 and S 1 were boiled in Laemelli buffer and applied to 
an 12% SDS-PAGE gel as follows: lanes 1 - 8, 0.025, 0.05, 0.1, 0.15, 0.2, 
0.3, 0.4 and 0.5 % respectively. Significant quantities of protein were found 
in the SI fraction from buffers containing 0.05 - 0.2 % sarkosyl, A. No 
significant sepharose bead isolation of GST fusion protein was seen at any 
concentration of sarkosyl. Thus minimising the concentration of sarkosyl 
did not prevent the inhibition of GST function.
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Fig 6 .2 .53  Ejfect on GST function o f adding triton X 100 to sarkosyl 
lysed E Coli.
BL 21 E Coli transformed with P Gex 5X containing the fusion cDNA 
coding for PDE4D3N-Terminal-tat, were treated with IPTG and 
grown at 22°C for 6 hours. Bacteria were harvested and lysed in 
buffer containing 1% sarkosyl to which 1% triton was added (section 
MM). Supernatant SI was collected and sepharose coated beads were 
added and incubated at 4°C for 2 hours. Beads were collected and 
washed by repeated centrifugation (P2), while remaining supernatant 
from bead pull down (S2) was retained. P2 and S2 were boiled in 
Lamelli buffer and applied to an 12% SDS-PAGE gel as follows: S2 
lanes 1 and 2; P2 lanes 3 and 4. S2 contains the majority of expressed 
recombinant protein, while a proportion appears associated with the 
P2 bead fraction. This proportion appears little different when triton X 
100 is included compared to no triton buffers.
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Fig 6.2.5.4 Urea dénaturation o f inclusion bodies allows more efficient 
extraction o f  recombinant protein
BL 21 E Coli transformed with P Gex 5X containing the fusion cDNA 
coding for PDE4D3N-Terminal-tat, were treated with IPTG and grown at 
22°C for 6 hours. Bacteria were harvested and lysed 8M Urea at 4"C 
(section MM). Supernatant SI was collected and dialysed through 
graduated osmotic saline solutions. Sepharose coated beads were added to 
the reconstituted lysate and incubated at 4°C for 2 hours. Beads were 
collected and washed by repeated centrifugation (P2). Half P2 was 
retained while half was incubated with precision protease to cleave the 
recombinant protein from the beads. Beads were collected by 
centrifugation (P3) and the remaining protease buffer was denatured 
using protease inhibitors. This supernantant (S3), contains the full length 
recombinant fusion protein. All fractions were boiled in Lamelli buffer 
and applied to an 12% SDS-PAGE gel as follows: lanel SI; lane 2 P2; 
lane 3 S3 and lane 4 wash 1. P2 demonstrates the concentration of 
renatured GST-fusion protein bound to sepharose beads. S3 is 
contaminated by other protein bands suggesting an impure collection.
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Chapter 6: Discussion
The ability to transduce proteins or peptide fragments into live mammalian cells offers the 
opportunity to interfere with protein activity in a highly specific fashion. In this way 
information about the functioning o f individual members o f the PDE4 family could be 
gained. I f  successful, such work would allow development o f rational therapeutic targets 
engineered to inhibit individual members of the family and hopefully reduce adverse 
effects associated with non-speeific inhibitory action. Unfortunately mammalian cells are 
highly resistant to internalising sueh foreign material. The development o f HIV-tat fusion 
proteins and allied strategies appears to offer an opportunity to overcome cells’ natural 
resistance to invasion.
Various strategies are available when synthesising fusion proteins. A full-length insert 
encoding cDNA for the entire fusion protein ean be made as I have done. Alternatively 
small sections can be made independently and inserted by ligation. The advantage o f the 
latter is that the cDNA fragments are relatively short and easier to synthesise and ligate, 
however the main disadvantage is the number of ligation reactions required. My strategy 
requires careful planning in advance to ensure all the protein remains in frame, but requires 
only one ligation step. The main disadvantage of this method is that the primers required to 
produce the fusion cDNA are very large. This makes PCR more difficult to perform due to 
the development o f secondary structure and leads to more errors as primers are less 
inclined to bind target DNA due to the large areas of ‘overhang’.
I selected a Glutathione S-Transferase (GST) fusion system to ease isolation. GST is a 
short 26Kda peptide originally isolated from Schistosoma Japonicum. It reversibly binds 
sepharose containing matrices allowing elution in increasingly ionic buffers. I used PGex
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5.3 X which contains a protease cleavage domain sensitive to the precision protease from 
Pharmacia.
In designing primers to synthesise the fusion insert cDNA, I had to bear in mind 3 
important principles. Firstly, bacterial expression of proteins requires the presence of 
upstream sequences of initiation called Kozak sequence [281]. This sequence provides the 
start o f transcription and all downstream sequence including the HIV tat, PDE4 sequences 
and the terminal stop codon must be in frame with this sequence. By using the pre­
engineered plasmid PGex 5.3 I already had a Kozak sequence present. Secondly the choice 
of restriction sites for insertion is critical to allow correct alignment for transcription to 
continue and to prevent the unintentional production o f new restriction sites. Finally 
because the length o f overhang will reduce the strength o f binding o f the primer to the 
plasmid sequence I tried to make the shortest possible primers. This process is complicated 
by the need to have a long overlap section for binding to firmly attatch to the plasmid. 
Thus these two factors mean that the optimum length o f primer is hard to assess prior to 
performing PCR. A final aspect o f length is that long primers tend to form secondary 
structure or primer oligomers, which reduces the efficiency o f PCR. In the process of 
optimising the PCR reaction briefly detailed in results section 6 .2 .1 ,1 encountered some of 
the problems associated with primer design and PCR. The final proof o f successful insert 
synthesis comes with protein production thus poor primer design can waste considerable 
time and resources before becoming apparent.
Optimising conditions of reaction are critical to successful recombinant protein production. 
Optimum protein expression requires optimal cDNA synthesis, successful ligation, 
efficient transform ation and bacterial growth conditions. Each o f these aspects has 
competing factors which require careful consideration. PCR requires optimal primer 
design, and correct melting and annealing temperatures. Different Taq systems cope better 
at different temperatures and under different conditions and errors can be incorporated into
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cDNA when using long primers. I optimised the PCR system used and the reaction 
conditions over several weeks to produce the purest and greatest quantity o f insert cDNA 
possible. High Fidelity PCR reagent (Roche), has a ‘proof-reading’, capacity that seeks 
errors in cDNA sequence. I found that this system produced the purest PCR product, and 
subsequent sequence analysis confirmed the integrity of the reaction. Ligation requires the 
correct plasmid to insert ratio to increase the chances o f insertion and correct orientation. 
Again I spent some time assessing the conect ratios to use and chose 1 insert/7 plasmid 
molar ratios. Most importantly the successful production of recombinant protein in bacteria 
requires consideration be given to conditions o f growth, replication, nutrient supply, 
stimulation and time for protein production. I have detailed the conditions I experimented 
with during this phase of protein production.
The greatest problem I encountered while attempting to synthesise recombinant fusion 
proteins was the development of inclusion bodies (IBs). In mammalian systems a complex 
system o f chaperones and proteases exist to eliminate misfolded proteins. When this 
system breaks down am yloid plaques form. These are highly organised fibrillar 
proteinaceous complexes that lead to degenerative disease especially in the central nervous 
system. Inclusion bodies represent the bacterial equivalent o f amyloid plaques. These 
complexes contain proteases and over expressed proteins along with proteolytic fragments 
and chaperones. Canio et al recently demonstrated that IB are highly organised and contain 
active enzymes, including proteases and often the recom binant protein artificially 
expressed [280]. It was initially assumed that GST fusion proteins would be soluble, 
however it has been widely reported that even short peptides often form inclusion bodies 
[282]. Slowing growth conditions by reducing the incubation temperature or the dose o f 
IPTG have all been tried with varying success. I tried manipulating the growing conditions 
to improve the solubility o f the fusion protein but these strategies largely failed.
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The standard lysis buffers used in the purification of soluble protein contain the non-ionic 
detergent Triton-X 100. This detergent allows the GST to maintain its activity and bind 
sepharose. Unfortunately it has been shown that these do not enhance the solubility of IBs. 
I attempted to use different buffers to maximise the solubility o f the over expressed 
protein. Although I met with some success when using buffers containing lysosyme, I 
found that the resultant soluble protein was not active in terms o f  sepharose binding. 
Frangioni et al reported that the ionic detergent sarkosyl could solubilise IB proteins 
containing GST and described renaturation. Thus I decided to pursue a method o f IB 
purification solubilisation and renaturation. I initially used high percentage ( 10%) sarkosyl 
buffers and confirmed both the solubility of IB protein and the dénaturation of GST when 
sepharose binding was attempted. I attempted to minimise sarkosyl concentration and 
found that equivalent solubilisation was possible at between 0.05 and 0.5% sarkosyl. These 
concentrations are less than reported by Franglioni (~ 1%), but GST-Sepharose binding 
was still inhibited. Next I included 1% Triton X-100 in the buffer and demonstrated some 
isolation on sepharose beads, but this proportion was still small compared to the unbound 
protein.
Finally I attempted a method described by Wey-Jinq Lin et al [283]. They used 8M urea to 
solubilise isolated IB s and renatured them slowly by gradual dialysis in salt buffers. While 
this produced the purest samples of sepharose bound protein the quantity of product was 
too small to use in experimental analysis.
While I was unsuccessful in producing sufficient quantity o f pure fusion protein, I learned 
a lot from the attempt. The main problem encountered after conditions o f plasmid 
production had been optimised was inclusion body formation. This problem has previously 
been described by Richter et al who attempted to make His tagged PDE4A truncates for 
enzyme analysis [284]. They showed that C-terminal truncates formed dimeric forms, 
while if  the C termini were included larger aggregates were formed. This tendency for
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oligomeric aggregation may well increase the tendency for IB formation. Beard et al 
dem onstrated that UCR 1 and UCR 2 regions tend to form multimeric units when 
expressed [69]. Thus even though I was working with N-terminal fragments I may have 
produced multimeric IB complexes.
In the future various alterations to the method might be tried to prevent this happening. 
Firstly the choice o f purification may have increased the tendency to form inclusion 
bodies. Thus GST tends to form oligomers which will compound the problems described 
above. To get round this problem other tags could be used. Successful recombinant PDE4 
isoforms have been made in fusion with M(?? majo basic protein) by using the P MAL 
vector. This can then be isolated by virtue o f binding to beads coated with. The original 
authors o f the HIV tat fusion protein system described isolating their proteins by tagging 
them with HIS tag. Richter et al also successfully used His tagging in PDE4A truncate 
preparation, [284]. The tendency o f the UCR-1 and UCR-2 regions o f PDE4 N-terminals 
to form protein protein interactions results in another source o f oligomer formation. 
Curtailing the region o f PDE4 in fusion with HIV tat may reduce the efficacy o f the final 
protein product as an inhibitor, but may increase the probability of successful production.
I did not experiment with the full range o f expression bacteria available. It may be that 
some are more inclined to form IBs with certain recombinant proteins than others. In the 
future I would include an optimisation step using other E Coli such as the JM 21 strain.
Although Schwarze et al reported that proteins isolated in a denatured state were renatured 
in live cells, it is possible that alternative strategies o f transducing DNA into cells may 
provide a better solution [279]. Thus the development o f reverse transcriptase containing 
viruses capable o f transfecting immune cells may aid DNA transduction.
216
Conclusion
I attempted to synthesis a series of PDE4 isoform HIV-tat fusion proteins. 1 encountered 
various problems. Eventually time was the primary limiting factor. Careful planning of 
each stage improved the success at each point. Optimising conditions for each reaction 
helped ensure a successful outcome.
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Chapter 7 Discussion
Given the evolutionary pressure for conserving resources it is remarkable that nature has 
developed families of signalling proteins whose family members each express the same 
activity. Cyclic AMP phosphodiesterases are one such family and PDE4 constitutes one 
subfamily o f enzymes exhibiting this behaviour. The PDE4 family itself consists of an 
extensive range of enzymes with around 16 family members. Studying PDE4 is o f interest 
to biological scientists, as understanding the reasons for such variety within one enzyme 
family may shed light on basic principles of cellular regulation [4]. PDE4 enzymes are also 
o f considerable interest to medicine, and pulmonaiy medicine in particular, as inhibitors of 
PDE4, by virtue o f elevating cAMP levels, act as both anti-inflam m atory and 
bronchodilatory agents [117]. Understanding the functions of individual PDE4 isoforms 
may help to illuminate the reason for such molecular diversity and suggest specific 
therapeutic targets whose inhibition will lead to precise changes in cellular behaviour with 
a low incidence o f adverse effects. A large volume o f current PDE4 research is therefore 
aimed at identifying specific roles for individual PDE4 isoforms.
Macrophages are a useful model for investigating PDE4 isoform specific function as they 
exhibit well-characterised behaviour that is relatively easily measured. As key cells in the 
regulation o f both the innate and specific immune systems they present a target for 
therapeutic manipulation to control inflammatory disease. As a result macrophage signal 
transduction has been intensively investigated in the hope that therapeutic targets will be 
discovered [285]. PDE4 regulation o f macrophage cAMP levels has frequently been found 
to alter cellular function with important consequences for inflammation [195, 286].
I have here firstly characterised the properties o f a novel PDE4 isoform and subsequently 
investigated the importance o f individual PDE4 isoforms to macrophage function in order 
to identify possible therapeutic targets. In analysing macrophages I began by monitoring
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the changes in PDE4 isoform expression with macrophage development from monocytes 
and by measuring the response o f individual PDE4 isoforms to macrophage stimulation. In 
order to investigate the molecular mechanisms behind PDE4 inhibitor regulation o f 
inflammation I investigated the outcome o f rolipram treatment on activated macrophages. 
To illuminate these molecular mechanisms I investigated crosstalk between PDE4 and 
ERK l/2 systems and the effect o f the small GTPase Rapl on rolipram manipulation o f 
macrophage function. Finally I attempted to develop reagents that could be administered to 
cells to disrupt specific isoform function.
7.1 The new PDE4B isoform PDE4B4
The complexity o f PDE4 gene regulation means that further PDE4 isoforms are likely to be 
discovered. An understanding of the structure o f PDE4 genes coupled with the sequence o f 
rodent and primate genomes will allows new isoforms to be found. Identification can be 
done using bio-informatics approaches, looking for conserved 5' regions across species that 
may reflect exons o f novel PDE4 isoforms. Also molecular techniques can be used 
employing probes that recognise regions o f homology between members o f PDE4 gene 
families. These can be used to interrogate cDNA libraries in order to identify novel 
molecules sharing this sequence. The attractive aspect o f this strategy is that by using 
cDNA derived from expressed cellular mRNA it is likely that the cDNA identified will 
encode an expressed and therefore functional protein. Such a strategy was used in the 
discovery o f the new FDE4B isoform PDE4B4.
A region of the common domain UCR2 from the PDE4B gene sequence was used to probe 
a rat cerebral cortex library and thus identify a molecule o f different molecular size to 
other known PDE4B isoforms. It is rather surprising that no human homologue to this 
species has been identified given the high degree o f cross species conservation that exists 
between other PDE4 isoforms [50]. However inspection of the murine genome indicates an
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authentic exon encoding the unique 5' region of PDE4B4, supporting the notion that this is 
a genuine PDE4B isoform found in rodents. Other PDE4 isoforms for which such 
conservation has yet to be identified include rnPDE4A6, but whether this is a species 
specific phenomenon or a gap in our understanding is not clear [50].
K inetic analysis o f PDE4B4 reveals a cAMP hydrolysing enzym e with sim ilar 
characteristics to other PDE4B iso forms that are summarised in table 3.4. Thus the 
sensitivity to inhibition by rolipram (IC50) and an approximation o f the affinity for cAMP 
(Km), for PDE4B4 lie within a range that includes other PDE4B isoforms. The apparent 
Vmax for PDE4B4 derived from a range of observations of activity at 1|llM cAMP, relative 
to PDE4B1 is however 9 times greater. The actual activity that this represents at a cellular 
level will depend on the levels of expression, but such a range o f Vmax for one species o f 
PDE4 family demonstrates the capacity to control cellular response to cAMP by varying 
expression levels. The effect o f regulation on PDE4 isoforms may shed light on this. 
Phosphorylation o f PDE4 enzymes by PKA leads to around a 50% increase in activity (refs 
check), while phosphorylation by ERK2 reduced PDE4D3 the activity by 75% [66]. These 
changes in cAMP hydrolysing activity is achieved by increasing Vmax while leaving Km 
unaltered [68]. By setting the intracellular cAMP concentration close to the threshold for 
PKA activation a cell can control the propagation o f a cAMP dependent signal by 
controlling PDE4 isoform activity within these relatively tight limits. Having different 
PDE4 isoforms with similar affinities for cAMP but different activities may allow 
differential expression to control cAMP signals in a cell specific manner.
Particulate bound PDE4B4 Vmax differs from soluble PDE4B4 (Table 3.4). Thus while 
soluble PDE4B4 Vmax was 9 times that o f soluble PDE4B1, particulate bound PDE4B4 
Vmax was only 3 times higher. This is similar to the difference in Vmax between 
particulate and soluble fractions of PDE4A4 expressed in COS-1 cells [76]. It is suggested 
that conformational changes associated with particulate fraction binding lead to a change in
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the kinetic characteristics o f PDE4 isoforms, evidenced by the increased sensitivity o f 
particulate PDE4A4 to rolipram [82], This change in ÏC50  was mimicked by association 
with Src tyrosine kinase isoforms and lost when the Src binding domain was deleted from 
PDE4A4 [232]. PDE4B4 displays the opposite characteristic as the IC 50 for rolipram is 
greater in the PI fraction than the S2 fraction and therefore PDE4B4 is similar to other 
long form PDE4B isoforms, but differs from the short form PDE4B2 [233]. It may be that 
the interaction o f UCRl and UCR2 described by Beard et al, alters the effect of particulate 
binding in a PDE4 family specific manner [69] such that PDE4B isoforms behave in a 
different way to PDE4A isoforms. Alternatively particulate association o f PDE4B long 
forms may involve different regions o f the molecule that lead to specific conformational 
changes resulting in a different conformational switch to that described for PDE4A4. It is 
interesting that Baroja et al described association o f a PDE4B isoform with the T cell 
antigen receptor molecule CD3e [287], confirming the ability o f PDE4B isoforms to 
associate with specific membrane proteins.
Analysis o f the cDNA sequence o f PDE4B4 reveals coding regions for UCRl and UCR2 
revealing it to be a third long form PDE4B isoform along side PDE4B1 and PDE4B3 
[233]. Long form status confers certain regulatory properties on PDE4B4. For example, a 
recent observation that PKA activation o f long form PDE4 isoforms was due to 
phosphorylation of a Serine residue in the UCRl region was investigated in the context of 
PDE4B4 [239]. I have shown that Ser53 o f PDE4B4 is critical for the PKA dependent 
activation o f this molecule. Thus PKA activation led to a 57% increase in activity while the 
Ser53-Asp mutant displayed a 45% increase in activity. This degree o f activation is similar 
to that seen with PDE4D3 where Ser54 is the equivalent Serine Target Residue (STR) [68].
Finally exam ination o f the unique N-terminal region o f  PDE4B4 reveals structural 
homology to the long form PDE4 isoform PDE4D3. O f particular interest is the 
conservation o f a PKA STR around S eri4 o f PDE4B4. The equivalent residue in PDE4D3
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can be phosphorylated by PKA, but the function o f this modification is not Icnown. One 
observation in PDE4D3 that is conserved in PDE4B4 is that PKA phosphorylation results 
in retarded mobility on SDS-PAGE. It has been suggested that S e ri3 in PDE4D3 (S eri4 
PDE4B4) is responsible for this mobility shift. Consistent with data described for PDE4D3 
Seri4 in PDE4B4 does not appear to be important for PKA dependent activation.
I have investigated the kinetic characteristics o f a new long form PDE4B isoform. It shares 
many properties with other long form PDE4B family members and differs from other 
PDE4 isoforms. It displays remarkable N-terminal homology with PDE4D3 (fig3.1.1). 
This region is believed to allow association between PDE4D3 and AKAP450 and MAKAP 
and it would therefore be interesting to see if  PDE4B4 also displays protein interactions 
with these targeting molecules.
7.2 PDE4 inhibition in macrophages
M acrophages have served as a useful model for exam ining PDE4 inhibition in 
inflammatory systems. Two important principles have been described. Firstly inhibitors of 
PDE4 by virtue o f causing elevations in intracellular cAMP have anti-inflammatory 
activity [118]. Secondly the cAMP generating capacity o f PDE4 inhibition is increased in 
the presence o f a positive stimulus for cAMP such as PGE2 or a (32 agonist such as 
isoprenaline [142, 223]. The functional outcome o f PDE4 inhibition is also partially 
dependent on adenylyl cyclase stimulation. This was dem onstrated by Seldon et al in 
monocytes who found that although PDE4 inhibition elevated cAMP in a synergistic 
fashion, with both PGE2 and albuterol, increased T N Fa suppression was only seen with 
PGE2 [142]. This work suggests a degree o f functional compartmentalisation o f monocyte 
cAMP and it raises the possibility that different pools o f cAMP may control different 
cellular functions. As previous reports have found PDE4 inhibitors are effective in 
preventing EPS stimulated cytokine production from macrophages I was interested to
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investigate how LPS, which is not known to activate adenylyl cyclase could combine with 
rolipram to cause macrophage inhibition.
I elected to investigate macrophage production o f inducible nitric oxide synthase (iNOS) 
along side T N F a as this is the enzyme responsible for nitric oxide (NO) production at sites 
o f inflammation [288]. Nitric oxide and iNOS have been found to be increased in the 
airways o f active and quiescent asthmatics [219, 289], and macrophages have been shown 
to be responsible for a large proportion o f lung NO production in response to inhaled 
endotoxin [290]. Inducible NOS is thus an interesting marker for macrophage activation 
and is o f relevance to diseases of the lung. Together with this iNOS expression has recently 
been found to be under partial control by cAMP. The response o f the iNOS gene to 
elevations in cAMP, however appear to depend on the cell type and the source of adenylyl 
cyclase activation. For example Pang et al, found that forskolin and PGE2 both suppressed 
EPS induced iNOS transcription in J774 macrophages [275], Nusing et al, however found 
that db-cAMP potentiated the expression o f iNOS in response to interferon y (IFNy) in 
microglial cells [220].
7.2.1 Rolipram increases LPS stimulated iNOS expression in RAW 264.7 cells
I have found that rolipram dose dependency increases the expression o f iNOS in LPS 
treated RAW 264.7 macrophages (fig 5.3.1 A) while cilostamide, an inhibitor of PDE3 did 
not (fig 5 .3 .IB). PDE3 represents substantial (-30% ) cAMP PDE activity in resting 
macrophages (figure 5.1.1) and peripheral blood monocyte derived macrophages [119], but 
I found rapid reduction in activity following LPS stimulation. Thus failure o f cilostamide 
to cause an up regulation o f iNOS may simply reflect a cAMP dose response, or may 
suggest fimctional compartmentalisation of PDE3 and PDE4. Previous studies o f alveolar 
macrophages have found that while PDE4 inhibition has displayed anti-inflammatory 
behaviour PDE3 inhibition has not [291].
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Increasing doses o f rolipram alone did not cause iNOS expression while synergism with 
LPS was found at low doses o f rolipram. It is not known if  LPS causes activation o f 
adenylyl cyclase allowing synergism with PDE4 inhibitors. Jeon et al studying the 
cannabinoid receptor CB2 in macrophages found that CB2 dependent inhibition of AC 
prevented LPS stimulated expression o f iNOS [292]. Other studies not specifically directed 
at iNOS expression have found little effect o f PKA inhibition following LPS treatment of 
macrophages. Thus circumstantial evidence points to a role for AC downstream of LPS 
stimulation in the activation o f iNOS, but the precise nature o f this role remains to be 
understood.
On the other hand LPS can cause PGE2 production from macrophages by transcriptional 
activation o f COX-2. Prostaglandin E2 can activate AC and the resulting intracellular 
cAMP has been shown previously to partly mediate the anti-proliferative effects o f PDE4 
inhibitors [202]. Indomethacin prevented the increase in iNOS transcription with rolipram 
(fig5.3.2), suggesting that a product o f COX-2 was promoting the effect o f rolipram. 
Although cAMP is laiown to upregulate iNOS expression in some cell systems and PGE2 
acts with rolipram as described above this effect was interesting, because the body of work 
detailed below suggests PGE2 does not increase macrophage iNOS expression while 
cAMP from other sources can. Thus Ru therford found in bone marrow derived 
macrophages that PGE2 did not affect nitrite production [293]. A group studying thermal 
injury using splenic macrophages found PGE2 reduced NO products from LPS treated 
resting macrophages [294] while Pang et al found PGE2 suppressed LPS stimulated iNOS 
in J774 macrophages [275]. In contrast to this Lin et al showed that while PGE2 could 
enhance LPS stimulated iNOS expression and NO production from J774 cells this effect 
was not observed in RAW264.7 cells [295]. Cyclic AMP from other sources can also 
decrease iNOS and NO production, thus Delgado et al found that pituitary adenylyl cyclase 
activating peptide prevented LPS stimulated iNOS production from RAW264.7 cells [296]. 
Finally Morris et al found that 8-bromo-cAMP prevented the LPS stimulated production of
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iNOS from RAW264.7 cells [297] and Hasko et al demonstrated isoprotenolol inhibition 
o f LPS stimulated nitrite production in RAW264.7 cells [192]. Considerable evidence 
therefore suggests that PGE2 is unlikely to cause increased iNOS expression.
On the other hand cAMP has been shown to positively regulate iNOS expression and two 
groups, one using peritoneal macrophages, [298] and one a macrophage cell line [299] 
have found exogenous cAMP to increase nitrite and iNOS expression. Kunz et al have 
investigated this further and found that while IL-1 increases nitrite production 40 fold, 
cAMP analogues elevate this 2 fold [300, 301]. This group found two pathways regulating 
nitrite production, thus while the IL-1 signal was transduced through NFkB, cAMP was 
not.
The source o f the cAMP signal and the context of that signal, therefore appear to affect the 
outcome in terms of iNOS expression. Few studies have looked at PDE inhibition on iNOS 
expression. Okado found that IBMX, a non-selective PDE inhibitor able to inhibit both 
PDE3 and PDE4 increased iNOS protein in LPS stimulated macrophages [302] and Greten 
et al found that rolipram increased nitrite production in RAW  264.7 cells but did not 
examine iNOS expression [256]. Beshbay et al however, found that rolipram inhibited NO 
production from LPS stimulated macrophages [303]. I hypothesise that the source o f 
cAMP determines the functional outcome. Thus it may be that cAMP derived from PGE2 
activation of AC is only capable o f iNOS stimulation in the presence o f a PDE4 inhibitor. 
This argument for compartmentalisation waits rigorous testing.
7.2.2 Rolipram increases LPS stimulated COX-2 production
While I have discussed how rolipram can increase PGE2 induced cAMP production, a 
second possibility was that rolipram increased PGE2 production. I have found a dose 
dependent increase in PGE2 production with PDE4 inhibition of LPS treated RAW 264.7 
cells (fig 5,3.5). I have further demonstrated an increase in the expression o f COX-2 in
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LPS stimulated macrophages treated with rolipram (fig 5.3.4). The evidence supporting a 
cAMP mediated regulation o f COX-2 expression is persuasive. Miller et al found that PKA 
phosphorylation o f CREB was partly responsible for COX-2 regulation in chondrocytes 
[217] while Hinz et al working with peripheral blood monocytes stimulated with LPS 
found PGE2 positively regulated COX-2 expression [215]. Lo et al found db-cAMP 
enhances COX-2 mRNA and PGE2 production from LPS stimulated RAW 264.7 cells. In 
contrast the study by Pang et al referred to above looked at COX-2 in J774 macrophages 
and found PGE2 inhibited expression [275]. Mechanistic studies support a role for cAMP 
and PGE2 in regulating COX-2 expression. Caivano et al found that LPS led to CREB 
phosphorylation upstream o f COX-2 activation [304] while H inz found PGE2 could 
upregulate its own synthetic enzyme through EP2/EP4 receptors [213]. No studies have 
specifically studied the role of rolipram in regulating COX-2 expression, but two have 
looked at non-specific PDE inhibitors. Hinz et al found that IBMX enhanced LPS driven 
COX-2 mRNA and PGE2 production in monocytes while Juergens et al again working 
with monocytes showed theophylline increased LPS stimulated PGE2 production [305].
It seems likely therefore that PGE2 is capable o f upregulating its own synthetic enzyme 
and that PDE4 is present to provide a braking m echanism  to prevent excessive 
overproduction o f PGE2. If  this positive feedback model is true, then I expected to find a 
similar inhibition o f rolipram enhancement o f COX-2 expression with indomethacin as I 
have described for iNOS. On the contrary, enhanced COX-2 expression was found to be 
conserved in the presence of indomethacin (fig 5.2.4), suggesting that rolipram was not 
acting in synergy with PGE2 as predicted.
The only known function o f rolipram is PDE4 inhibition, thus increased COX-2 expression 
must be related to this behaviour. One explanation is that rolipram  inhibits PDE4 
increasing cAMP and causing COX-2 expression in the absence o f LPS co-stimulation. 
Thus the increased expression in co-stimulation is an additive effect o f each compound. I
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was not able to demonstrate any COX-2 expression in cells treated with rolipram alone. 
Another explanation is that PDE4 activity provides a brake to the expression of COX-2. 
Thus PDE4 activity in LPS treated macrophages is sufficient to keep cAMP levels low and 
remove the synergistic effects of two pathways described by Kunz et al above. This would 
suggest either that resting PDE4 levels are set to keep cAMP low enough to prevent COX- 
2 expression, or that LPS elevates PDE4 activity to allow controlled expression of COX-2.
The absence of a COX-2 signal in the presence of rolipram alone suggests that rather than 
an additive effect, the cAMP produced by PDE4 inhibition is synergistic with LPS 
signalling. It is possible that a PDE4 isoform regulates the cAMP level locally to a 
signalling complex downstream o f LPS and elevations in cAMP cause enhanced signal 
transduction.
7.23 Rolipram inhibition o f  TN Fa is not COX-2 dependent
1 have dem onstrated a prostaglandin dependent increase in iNOS expression and a 
prostaglandin independent increase in COX-2 expression by rolipram in LPS stimulated 
RAW cells. Such a dichotomy has previously been observed in vascular cells where COX-
2 cAMP led to an inhibition o f GM-CSF, but not ÏL-8 production [306].
Both iNOS and COX-2 are believed to exert anti-inflammatory effects on immune cells. I 
hypothesised that in a similar manner to the indirect inhibition o f T N F a through XL-10 
proposed by Kambayashi [245], some antiinflammatory activity o f rolipram might be 
mediated through PGE2. Thus various groups have found that exogenous PGE2 is capable 
o f inhibiting LPS driven T N Fa from monocytes and macrophages o f divers origin [194, 
307, 308]. I have found that although rolipram enhances the production of PGE2 from LPS 
stimulated macrophages indomethacin did not prevent T N F a inhibition. This further
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supports the view that cAMP alters T N F a production at the level of transcription or 
translation.
I have demonstrated some effects o f PDE4 inhibition in RAW macrophages. I have shown 
that rolipram increases iNOS production by up regulating COX-2 and PGE2 production. I 
have also shown that COX-2 up-regulation appears to be mediated by PDE4 inhibition in 
the absence o f an obvious costimulation o f adenylyl cyclase. Finally I have found that 
despite an expected increase in intracellular cAMP through inhibition o f PDE4 and 
increased PGE2 production, T N Fa inhibition by rolipram is not mediated through COX-2 
activity. Having identified possible compartmentalisation o f cAMP signalling governed by 
PDE4 isoforms I wanted next to address which PDE4 isoform s are im portant in 
macrophage function. I did this in two ways, by profiling the expression and by measuring 
the effects of PDE4 isoforms to macrophage activation.
7.3 U937 differentiation
I sought to identify PDE4 isoforms o f importance to macrophage function by recording 
changes in expression with m ature cell developm ent from progenitor cells. By 
demonstrating novel or altered expression o f specific PDE4 isoforms at different stages o f 
differentiation I hoped to propose stage specific roles for these enzymes. Two caveats must 
be considered before addressing my findings.
7.3.1 Using cell lines as inflammatory cell models
Firstly I used a cell line model to profile the PDE4 isoform changes associated with 
macrophage development. This strategy has inherent problems and some advantages over 
freshly isolated “ex-vivo” tissue. These cells are transformed tumour cells and thus some
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of their properties may reflect the changes associated with immortalisation rather than 
simply the cell o f origin. Signalling processes associated with cell cycle regulation that 
would not occur in a freshly isolated cell may influence the precise behaviour in response 
to stimuli or chemical manipulation. Finally by virtue of the process o f transformation it is 
likely that certain important signal transduction elements will have been deleted or 
switched off, these might interfere with the normal behaviour o f the cell under 
investigation. Despite these caveats I feel using a cell line is justified. Although monocytes 
are relatively abundant and easy to harvest, macrophages are much less readily available. 
Macrophages derived from peripheral blood monocytes are likewise much less abundant 
than their progenitor cells. At a cellular level individual PDE4 isoforms are low abundance 
proteins. Thus although PDE iso forms can be measured in “ex-vivo” plastic cultured 
monocytes [119] individual PDE4 isoforms are less easy to measure or subsequently 
manipulate.
A wealth o f literature describes using inflammatory cell lines as models for mature cell 
behaviour and development. Hancock et al in the 1980’s used the HL-60 cell line to 
investigate the processes of IL-2 receptor expression [309]. This cell line has been used as 
a model for neutrophil development and signalling [310, 311]. It appears to be less suitable 
for studying macrophage responses however. The U937 cell was more attractive to study 
as it has been well characterised in terms o f monocyte to macrophage differentiation by 
Hass et al [154, 155]. They demonstrated that treatment o f suspension monocytic U937 
cells with low dose PMA produced an adherent cell with surface receptors that displayed a 
m acrophage phenotype. This cell has subsequently been used as a model for 
differentiation, most recently by Prudousky et al who demonstrated the importance o f 
GDI lb  expression in the maturation process [156].
Finally U937 cells have been extensively used as models for understanding the regulation 
of PDE4 activity. Torphy et al have used these cells to demonstrate PDE4 activity changes
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following salbutamol treatment [312], while DiSanto demonstrated rolipram effects on the 
phosphatidic acid sensitivity o f PDE4 isoforms [313]. O f interest to my own work on 
PGE2 regulation Alvarez et al found that PGE2 increased PDE4 activity in U937 cells 
through PKA activation o f PDE4D3 [314].
Cell lines have therefore been used to model changes in signalling molecule expression in 
inflammatory cell development, however before any inferences can be made these models 
must be verified. I have confirmed that the U 9 3 7 p m a  cell closely reflects macrophage 
development by comparing cell surface markers, signalling molecules and behaviour 
against reports in the literature. Thus as mentioned above GDI lb  is believed to reflect 
macrophage development in the context o f monocyte differentiation [156]. I have shown 
novel GDI lb  expression in U 9 3 7 p m a  developm ent from U937 cells (fig 4.1,2). 
Hunninghakes’ group demonstrated loss o f PKCP expression in the development o f the 
alveolar macrophage and I have confirmed this in U 9 3 7 p m a  cells [147]. Finally Gantner et 
al found that an “ex-vivo” model of plastic cultured monocytes became more adherent, 
increased their surface area and protein expressed per cell [119]. I have identified all these 
behavioural changes in the U937 model. Thus I have verified my U 9 3 7 pm a  model against 
historical precedent and found it closely reflects changes associated with macrophage 
development.
Gantner et al along with various other groups since Thomson in 1976 have found 
characteristic PDE isoform expression in monocytes and macrophages [119, 221]. Before I 
could use my model to measure individual PDE4 isoform expression I had to verify it 
against these precedents. In these studies o f PDE3 and PDE4 activity I compared a model 
of “ex-vivo” monocytes prepared in our laboratory. I have found the expected fall in PDE4 
activity along with the rise in PDE3 (fig 4.1.3). Unfortunately most studies compare PDE 
activities using protein quantity as a denominator. Although this is a reasonable approach 
when comparing activity levels between cells or in the same cell following a treatment it is
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not satisfactory to compare a mature phenotype with a progenitor cell. This is because as 
described above the quantity o f protein per cell can change by orders o f magnitude, 
meaning that perceived activity losses may simply reflect a dilution effect o f increased 
protein. While an elevation of PDE3 activity thus must reflect a significant rise in activity a 
loss o f PDE4 activity may or may not be an artefact o f this effect. I have demonstrated that 
changing protein content does alter the pattern o f PDE4 activity change. Thus for activity 
expressed on a cellular level PDE4 activity rises in the U 9 3 7 p m a  model, while that in the 
ex-vivo model o f Gantner et al does not fall as significantly as reported.
7.3.2 Techniques used to profile cellular PDE4 isoform content
The second caveat to these studies concerns the use o f different techniques to quantify 
PDE4 isoforms. Various techniques are available to measure the expression o f PDE4 
isoforms. Initial studies o f expression in inflammatory cells used chromatography to 
separate PDE activity by molecular size [221]. While this demonstrated that different PDE 
activities existed it did not specify individual PDE4 isoforms. RT-PCR using harvested 
mRNA has been used to profile PDE4 isoform expression in various inflammatory cells 
[223, 315]. However although gene expression is measured in this way, regulation o f 
protein expression can be achieved at a post translational stage and mRNA transcripts may 
have specific roles in themselves that do not require protein production. It was with such 
concerns in mind that Houslay et al recommended that profiling o f the expression of PDE4 
isoforms in cells should include some attempt at quan tifying protein [50]. Protein 
identification however is not straightforward. One can measure immunological activity 
based on western blot, quantifying the physical presence o f an enzyme, but this does not 
addiess isoform activity. PDE4 isoform activity is regulated by changes to tertiary protein 
structure as well as by transcriptional expression. Quantifying activity is more difficult but 
can be approximated by immunoprécipitation. This technique takes advantage o f the 
property o f IgG Fc portion which has a high binding affinity for protein A. Thus by
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incubating a solution containing a PDE4 isoform with a specific antibody, all the antibody 
can be isolated bringing bound PDE4 with it. Due to the nature o f antibody-antigen 
binding dynamics it is important to immunoprecipitate fiom the same protein concentration 
if comparisons are being made. Thus in the case o f U 9 3 7  and U 9 3 7 p m a  cells a calculation 
had to be made to accoun t for cell number. A second consideration is that 
immunoprécipitation may or may not conserve tertiary structure o f a target protein. 
Endogenous binding partners may be lost, while immunoglobulin binding might alter the 
conformation o f the protein. Bearing these considerations in mind, however it is possible to 
make comparisons o f relative activities between two different cell states for a specific 
PDE4 isoform if  the same quantity o f protein has been used with the same amount of 
antibody.
In my studies I used all three techniques available to quantify and identify different PDE4 
isoforms. Thus I used RT-PCR to distinguish between PDE4A isoforms, western blot and 
immunoprécipitation to identify all individual isoforms.
7.3.3 PDE4 isoform profile changes in U 9 3 7 p m a  cell development
7.3.3.1 PDE4A activity rises
Although the observed PDE4 activity fell in U 9 3 7 p m a , PDE4A activity rose. When 
compared at a cellular level this rise was even more substantial (Fig 4.2.1). The proportion 
of PDE4A to the total activity measured in different experiments rose from around 2% to 
81% suggesting a considerable change in the importance o f this gene family to the 
regulation o f cAMP between monocytes and macrophages. Western blot data confirms the 
rise in PDE4A transcription as no PDE4A is immunologically detected in U937, while two 
bands are easily seen in U 9 3 7 p m a - Two human PDE4A isoforms migrate at the same 
weight on SDS-PAGE, and I used RT-PCR to define which were present. Although no
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PDE4A activity was found in U937, mRNA for PDE4A4 was seen with RT-PCR (fig 
4.2.3). This is interesting and reflects the contention discussed above that the presence of 
mRNA is not a good guide to the activity o f an individual enzyme. In U 9 3 7 p m a  cells, 
considerably more PDE4A4 transcript was present, as was the novel expression o f 
PDE4A10 mRNA. Although I did not quantify the amount o f PDE4A4 mRNA, I required 
3 dilutions o f template cDNA to gain resolution on agarose gel, suggesting a substantial 
increase in mRNA.
The PDE4A4 isoform has been shown to bind to proteins o f considerable relevance to 
macrophage function. Thus McPhee et al found PDE4A4 bound to the SH3 domains o f 
Lyn tyrosine kinase, one o f the Src family of kinase enzymes [82]. The importance of Lyn 
kinase to macrophages has recently been described [231]. Lyn recruitment and activation 
has been found following LPS stimulation of macrophages [260]. Apoptosis, a key means 
o f regulating an inflammatory response involves the co-ordinated activation of proteolytic 
enzymes called caspases. PDE4A4 is a target for the essential caspase3 and cleavage as 
part o f apoptosis removes the LYN-SH3 interaction domain on the N-terminal region o f 
PDE4A4 with a resulting increase in activity [232]. Thus circumstantial evidence points to 
the possible importance o f PDE4A4 in macrophage inflammatory Rinction.
PDE4A10 is a relatively recently identified isoform [234]. It is found in brain tissue and 
this report is the first to demonstrate regulated expression upon eellular differentiation 
[316]. As yet little is known about the functional regulation or protein binding partners for 
PDE4A10, which might point to specific roles for it in regulating cell function. My study 
however points to a role in macrophage specific regulation as no mRNA was found in 
U937 cells.
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7.33.2 PDE4B2 expression is increased in U937pma cind differentiated P B M  
cells
PDE4B2 expression increases when macrophages develop in both the U937 and ex-vivo 
models. These data are consistent across both immunoprécipitation and western blot data, 
however no new PDE4B isoforms were found in differentiated cells. A role for PDE4B in 
regulating inflammatory cell function has been postulated from work in T lymphocytes, 
where PDE4B species were found to associate with the CD3e protein of the T cell antigen 
receptor [287]. A role for PDE4B in monocyte regulation was also proposed by Wang et 
al, who found that it could be increased by LPS stimulation [253]. Interestingly PDE4B 
transcription could be limited by co-stimulation o f monocytes with IL-10, reminiscent o f 
TN Fa and further supporting a pro-inflammatory role for this isoform [317]. Jin et al have 
recently used a PDE4B knock out model and demonstrated that T N F a production in 
response to LPS was absent in contrast to the wild type mouse [255]. Thus my data further 
supports the role of PDE4B2 in supporting pro-inflammatory signalling in macrophages.
7.3.3.3 PDE4D expression is reduced in U 9 3 7 p m a  cells and differentiated 
P BM  cells
Jin et al, having demonstrated that the absence o f PDE4B acted to prevent T N Fa in 
response to LPS, then compared PDE4D deficient mice [255]. They found no difference in 
response to LPS when PDE4D knock out mice were compared with wild type mice. This 
argues against PDE4D isoforms having im portant pro-inflam m atory activity. This 
d istinction  betw een  PDE4B and PDE4D  neatly  dem onstrates a func tional 
compartmentalisation between these isoforms. My data agrees with this hypothesis, as 
PDE4D expression was severely reduced when western blot data was examined (fig 4.2.5). 
Immunoprécipitation o f PDE4D did not agree with these data however. PDE4D activity 
per U937pMA cell did not fall despite a large reduction in immunologically detectable
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isoform. This difference between the two techniques is difficult to explain. The integrity o f 
the antibody has been confirmed through rigorous assessment in the laboratory and was 
used in both types of analysis and therefore does not explain the discrepancy. It is possible 
that in immunoprécipitation studies a species of PDE4 other than PDE4D was ‘pulled 
down’ along with a small amount o f remnant PDE4D artificially elevating the activity 
measured. This was not confirmed when western blot analysis o f the immunoprecipitate 
was performed. It is possible that post translational modification o f the bound PDE4D, 
however small was sufficient to artificially increase the measured activity. Thus I am 
unable to explain why a consistent discrepancy existed between the PDE4D activity found 
by immunoprécipitation and the immunological activity identified by western blot analysis. 
I believe that western blot is the more robust form of analysis and this is backed up by the 
data from peripheral blood monocyte differentiation studies.
7 .3 3 .4  A change in ERK2 regulation o f  PD E4 occurs with U 9 3 7 p m a  
development
A significant change in the relative proportions o f PDE4D and PDE4B isoforms takes 
place in both the experimental models discussed. This has important implications for 
ERK2 regulation o f PDE4 activity and therefore for ERK2 cAMP signal crosstalk. PDE4 
isoforms can be distinguished on the basis o f their response to ERK2 phosphorylation. 
Long form isoforms such as PDE4D3 and PDE4D5 present in U937 cells, but reduced in 
U937pMA cells are inhibited by ERK2 phosphorylation, while the short form PDE4B2 
which is upregulated in U 9 3 7 p m a  cells is activated [67]. The differentiation o f U 9 3 7 p m a  
cells results in a change from long form dominant PDE4 isoforms to short form 
dominance. I have shown that this has important outcomes for PDE4 regulation as in U937 
cells PDE4 activity is reduced by ERK2 activation, while in U 9 3 7 p m a  PDE4 is activated. 
ERK2 is an important enzyme in the transduction of signals downstream of cytokine and
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endotoxin receptors and thus macrophage differentiation is likely to be accompanied by 
significant changes to ERK/cAMP crosstalk [318].
7.3.4 Summary
I have advanced the understanding of PDE4 in inflammation by demonstrating a change in 
the expression o f isoforms with macrophage development. Thus PDE4A10, PDE4A4 and 
PDE4B2 were transcriptionally upregulated, while PDE4D3 and PDE4D5 expression was 
reduced. This suggests that both PDE4A isoforms and PDE4B2 are important for 
regulating cAMP in pro-inflammatory signal transduction. Cyclic AMP is loiown to inhibit 
inflammation but how it achieves this is not clear. One possibility is that cAMP activated 
PKA can prevent downstream signalling through, for example Raf-1 inhibition. Co­
ordinated PDE4 activity local to a signalling complex might therefore be permissive to 
such a signal, while inhibition by rolipram, by elevating cAMP, may inhibit the signal 
cascade. The work by Jin et al showing an distinction between PDE4 isoforms in 
regulating inflammatory signals and my work showing specific isoform expression in 
specific stages o f  macrophage maturity proposes that individual isoforms may have 
specific roles in such cAMP regulation. I wanted to further clarify the role o f different 
PDE4 isoforms by measuring their activity following LPS treatment o f macrophages.
7.4 Effect of LPS on macrophage PDE4 isoforms
Only a few studies have addressed the regulation o f PDE4 by LPS. Verghese et al found an 
LPS stimulated increase in PDE4 activity and related this to increased transcription [224]. 
PDE4B2 expression was found to be up regulated by LPS [317]. My data confinns a rise in 
PDE4 activity with LPS treatment o f RAW macrophages, however this occurs in the 
context o f a fall in PDE3 activity. Such a distinction between PDE3 and PDE4 has been 
described both in terms o f PDE activation, [319] and in terms o f function [98]. One
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explanation for the elevation in PDE4 activity is that resting intracellular cAMP 
concentration is sufficient to inhibit LPS stimulated signal transduction. Thus activating 
PDE4 reduces cAMP and permits signal transduction. An alternative explanation is that 
LPS activates adenylyl cyclase and PDE4 activation in parallel with this prevents the 
inhibitory effect o f elevated cAMP. The transient nature o f the PDE4 activation suggests 
that reaccumulation o f cAMP acts as a brake to ongoing signal transduction. This might 
support the second theory as cAMP reaccumulation will require a positive activation o f 
AC. The reduction in PDE3 activity further supports the theory o f compartmentalisation. 
Thus while cAMP controlled by PDE4 is reduced that controlled by PDE3 is elevated.
7.4.1 Regulation o f  PDE4 activation
Previous investigators have found transcriptional regulation underlies increased PDE4 
activity in LPS treated monocytes [317]. I found that the inhibition o f mRNA translation 
with actinomycin D did not prevent the increase in PDE4 activity at 30 minutes arguing 
against new protein expression (fig 5.1.2). This illustrates the need for caution when 
interpreting RT-PCR, as although increased transcript for PDE4 isoforms may be found it 
is unlikely that new protein production underlies this early phase o f activation. It may be 
that over a longer time scale, changes in the expression o f individual isoforms do occur, 
my data suggests that this is not associated with a prolonged activation of PDE4 in RAW 
264.7 cells.
Inhibitors o f PI3kinase and PKA both resulted in the abolition of LPS stimulated activation 
(fig 5.1.2). Wortmannin and H89 however reduced PDE4 activity to below the basal levels 
o f untreated cells. It is impossible on the basis o f these studies to identify a difference 
between inhibition o f  constitutive regulation in contrast with LPS stimulated activation. 
Both PKA and PDKinase have been shown to cause up regulation o f PDE4 activity [50, 
112]. The role for PB kinase in LPS signal transduction is well documented however,
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whereas the role of PKA is less well understood [320]. The effect o f MEK inhibition with 
U 0126 was interesting. This compound reduced EPS induced activation by around 50% 
(fig 5.1.2). While this could equally well represent the constitutive activation of short form 
PDE4 iso forms the effect is less profound than the previous two inhibitors. The role of 
MEK and ERK l/2 activation downstream of EPS stimulation is also well documented. The 
ERK2 dependent activation of short form PDE4 isoforms reflects the U937 data discussed 
above (section 7.3.3.4). In order to investigate the role o f ERK2 in PDE4 activation 
following EPS treatment o f macrophages I investigated the PDE4 short form activity in 
these cells.
7.4.2 RAW264.7 cells express PDE4A, PDE4B andP D E 4D  isoforms but only 
PDE4B2 is activated by LPS
The U937pMA studies described above predicted macrophages to express PDE4A and 
PDE4B isoforms. Western blot data demonstrates the presence o f PDE4D isoforms along 
with two PDE4A isoforms and PDE4B2 (fig 5.1.3). Thus although PDE4A and PDE4B 
isoforms closely match the cell model PDE4D5 and PDE4D3 appear but were not 
expected. Various differences exist between the RAW264.7 and U937 cell lines. The 
former is a rat eell line while the latter is human derived. More signifieantly RAW 264.7 
cells represent a mature cell that has been transformed whereas U 9 3 7 pm a  represent a 
differentiated immature cell line. It is possible that the expression o f PDE4D isoforms 
reflects the process o f transformation and immortalisation that are lost in the differentiation 
o f U937 cells. W eak support for this is found in the nuclear localisation of PDE4D in 
fractionated RAW 264.7 cells (fig 5.2.3).
I have already provided evidence that PDE4B isoforms are believed to play a role in 
regulating EPS signal transduction. To investigate a role for each iso form I stimulated 
RAW264.7 cells with EPS and immunoprecipitated each using PDE4 isoform specific
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antibodies. Only PDE4B2 activity increased with LPS stimulation. This agrees with Ma et 
al [317], actinomycin D however again failed to prevent PDE4B activation arguing against 
new protein transcription causing the increase. While the P38 mitogen activated protein 
kinase inhibitor SB3850-—did not affect the increase in PDE4B activity the MEK inhibitor 
U 0126 did reduce it significantly.
I have presented further evidence in support o f a role for PDE4B2 in pro-inflammatory 
signalling in macrophages. Work cited above have suggested that this enzyme is important 
in cAMP regulation in inflammation [253, 255, 317]. I have found a MEK dependent 
activation o f PDE4B2 occurring some 20 minutes following LPS treatment of RAW 264.7 
cells. MEK stimulates the activation of ERKl/2 enzymes and being a short PDE4 isoform, 
PDE4B2 would be aetivated by ERK2 phosphorylation. I was not able to demonstrate 
direct phosphorylation of PDE4B2 in LPS treated RAW264.7 cells due to low abundance 
of the protein. By using a recombinant active ERK kinase protein and ^^P-labelled ATP I 
attempted to show that PDE4B2 immunoprecipitated from LPS treated RAW 264.7 cells 
was less capable o f being phosphorylated than PDE4B2 im m unoprecipitated from 
untreated cells. I was unable to demonstrate any signal above noise, due in part to the low 
abundance of PDE4B2 in RAW 264.7 cells.
The ER K l/2  enzymes are important in the transduction o f  many cytokine stimulated 
signalling pathways and it is possible that PDE4B2 plays important regulatory roles in 
other inflammatory systems. Thus I have illustrated an example o f molecular crosstalk 
between the M EK -ERKl/2 signal cascades and the cAMP-PDE4 pathway that may have 
important implications for immune cell signalling. I have been unable to demonstrate a 
direct link between ERK l/2 and PDE4B2 however.
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7.5 Raf-MEK-ERKl/2 / cyclic AMP crosstalk
I have provided evidence for the influence of ERK l/2 signalling in regulation of cAMP in 
macrophages. Firstly I demonstrated a distinction between the effects on cellular PDE4 
activity of BGF between U937 and U937pma cells. Why less mature cells would require an 
increase in cAMP induced by an inhibition o f PDE4 is not clear. However it is possible 
that PDE4D isoforms control cAMP, which in turn regulates progress through the cell 
cycle. Several reports have described cell cycle arrest in G1 phase in macrophages 
stimulated with growth factors and treated with cAMP analogues [321, 322], On the other 
hand in mature cells where the cell cycle machinery is not active cAMP may play other 
roles in regulating pro-inflammatory signalling.
Cyclic AMP can exert both negative and positive regulation on the ras-raf-ERKl/2 signal 
transduction pathway (Houslay/Kolch). PKA phosphorylation of Ser259 of Raf-1 prevents 
its interaction with Ras and therefore downstream activation o f ER K l/2 [261]. Rap-1 is 
another ras family GTP-ase that is capable o f activating E R K l/2  by association and 
activation with B-Raf [323]. The effect o f cAMP in regulating ER K l/2 activity has been 
shown to be determined by the relative expression o f Raf-1 or B-raf in neurones [324]. 
Thus where B-raf predominates in neurones cAMP activates ERK l/2 while where Raf-1 is 
dominant in astrocytes cAMP inhibits ERKl/2 activation.
Molecular crosstalk between cAMP-PDE4 and the ERK l/2 pathways can therefore occur 
in two directions. I have provided evidence for ER K l/2 having influence over PDE4 
activity but wished to demonstrate activity in the opposite direction.
7.5.1 Rolipram increases E RK l/2  phosphorylation by LPS
ERK l/2 are protein kinases that are themselves activated by phosphorylation. Antibodies 
raised against the phosphorylated residues are thus a useful marker o f ERK l/2 activation. I
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have found that LPS treatment o f RAW264.7 cells in the presence o f rolipram leads to a 
larger and more rapid activation o f E R K l/2  than LPS alone (fig 5.4.2). E R K l/2  
phosphorylation was seen before the production of inflammatory mediators would be 
expected, suggesting that PDE4 may regulate ERICl/2 activation immediately downstream 
of LPS. Valledor et al found that timing o f macrophage ER K l/2 activation predicted the 
cellular response to stim ulation [271]. They found agents that induce macrophage 
proliferation such as PM A and CSF-1 cause an early and more substantial activation of 
ER K l/2 than LPS, which inhibits proliferation and promotes an activated phenotype. I 
confirmed that PMA and LPS could activate ER K l/2 in RAW 264.7 cells to different 
degrees and over a different time scale (fig 5.4.1). Thus rolipram, by altering the dynamics 
o f ERK l/2 activation may be expected to alter cellular response to LPS. I have only used 
phosphorylation as a surrogate marker o f ERK l/2 activation and quantified the effect by 
densitometry. I would like to confirm these data by performing ER K l/2 kinase activity 
assays.
7.5.2 Co-immunoprecipitation ofPDE4, R a f isoforms and E R K l/2
Considerable evidence is aecumulating for the formation o f complexes of signalling 
molecules bringing interacting enzymes into proximity with each other and possibly 
preventing inappropriate “over-spill” o f activated enzymes [79, 325]. I predicted that 
molecular crosstalk between PDE4 and ERK l/2 would require direct interaction between 
these moleeules. This hypothesis is supported by the presence o f kinase interaction motif 
(KIM) and FQF domains on PDE4 isoforms [65]. These motifs serve as enzyme docking 
sites for ERK2 allowing PDE4 isoforms to become target molecules for phosphorylation. 
By im munoprecipitating PDE4isoforms I hoped to isolate all the molecular binding 
partners including ER K l/2 enzymes if they were present. Although initially it appeared 
that ERK l/2 were eoimmunoprecipitated with PDE4B2, subsequent analysis o f B-raf and 
pre-immune serum suggested this could be an artefact. I was unable to increase the
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Stringency o f the eonditions sufficiently to exclude a possible experimental error in this 
work. Developing RAW264.7 cells that overexpress PDE4B2 fused to a peptide tag that 
would allow isolation without the need for immunoprécipitation might allow a “cleaner” 
isolation of PDE4B2 binding partners.
I have provided evidence for crosstalk between cAM P-PDE4 and ER K l/2  in both 
directions. That is, ER K l/2  can regulate LPS activation o f PDE4B2 thus controlling 
cAMP, while rolipram increases ERK l/2 activation suggesting a role for PDE4 isoforms in 
regulating this cascade.
7,6 Rapl mutants in RAW macrophages
One implication o f the work described above is that cAMP can activate ER K l/2 in 
macrophages. As detailed above cAMP can activate Rap-1 and subsequently ERK 1/2 by a 
B -raf dependent mechanism [264]. The im munoprécipitation studies confirmed the 
presence o f B -raf in RAW 264.7 cells which is a precondition for this pathway [324]. 
Important roles for R apl have been described in macrophage function including the 
regulation o f integrin binding [204], The essential components o f a cAMP dependent 
activation of ERK l/2 are therefore available in RAW 264.7 cells and may have important 
influence over the regulation of macrophage behaviour.
Two methods for proving a role for Rapl exist. First the GTPase binding protein Ral-GDS, 
binds only to activated rap and ras [326, 327]. By fusing this protein to a GST peptide it 
can be used to “fish” for active species of these molecules [328]. Caron et al used mutant 
Rap-1 molecules, designed to represent the active conformation or mutated to prevent 
activation [204]. These mutant Rap-1 molecules were then transfected into macrophages 
and cellular responses to stimulation were measured. Our Laboratory received plasmids 
encoding mutant Rap-1 molecules as a kind gift from J.L. Bos.
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I used RAW 264.7 cells transfected with these plasmids to measure the effect of R ap-1 
activation on T N F a and PGE2 production and COX-2 expression. Although RAW 
macrophages are difficult to transfect and are resistant to genetie manipulation, I believe 
that sufficient rapl expression was achieved. Transfection efficiency was variable between 
the mutants and all the data presented has been corrected for the relative amount o f R ap-1 
protein present.
Despite allowing for transfection differences the only signifieant effect I found was on 
PGE2 production when RAW 264.7 cells transfected with constitutively active Rap-1 were 
stimulated with LPS in the presence of rolipram. In the absence o f a significant effect of 
constitutively active Rap-1 on PGE2 production in untreated cells over either dominant 
negative or wild type mutants it is difficult to draw any conclusions from these data. It is 
interesting to note that in both the PGE2 and the T N Fa experiments transfection of wild 
type Rap-1 appeared to diminish the effect o f rolipram. I hypothesise that the act o f 
transfection results in an activated maerophage that produces many cytokines and 
mediators through alternative pathways. Finally Rap-1 may itself be a target for PKA 
mediated inhibition of activity. This is achieved by phosphorylation o f a serine residue at 
position 180 [43, 46]. I used Rap-1 constructs mutated at this residue to reflect either a 
phosphorylated conform ation or a mutant that was unable to be phosphorylated. 
Transfecting these into RAW 264.7 cells allowed me to measure a potential role for PKA 
modification o f R ap-1 in the production o f TNFa. In this case the transfection of wild type 
Rap-1 did not influence the production of T N Fa, while both mutant Rap-1 constructs 
reduced the inhibition o f rolipram. W hile this argues against the hypothesis that 
transfection alone affects the rolipram sensitivity of RAW 264.7 cells, it is hard to draw 
conclusions from the results for two opposing Rap-1 mutations having similar functional 
effects.
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7.7 HIV-tat fusion proteins
I have provided evidence o f my own backing up previous reports that PDE4B2 may have 
important roles in regulating inflammatory cell function. Proof o f such a role would come 
from the development of PDE4B2 specific inhibitors compared with other isoform specific 
inhibitors. Most PDE4 inhibitors interact with the catalytic region o f the enzyme. As this is 
the most highly conserved region o f the cell these compounds suffer from being non­
isoform specific. Developing isoform specific inhibitors remains an elusive goal.
Individual PDE4 isoforms differ from each other at their extreme N-terminal region. The 
functions o f the N-terminal regions do not lend themselves to chemical manipulation. 
These functions include targeting, protein-protein interactions and phosphorylation based 
regulation. I hypothesised that catalytically inert N-terminal domains would compete with 
the sites required to express these N-terminal functions and disrupt isoform function in a 
specific manner. Although attractive this strategy is complicated by the need to get these 
proteins into cells.
Expressing foreign proteins in eells is difficult and doing so in macrophages is particularly 
so. Various methods o f transducing genetic material into intact cells exist including 
transfection and infection. Both o f these have proven difficult in RAW cells. The recent 
description by Schwarze et al o f denatured HIV-tat fused enzymes being incorporated into 
cells and renatured offered an exciting solution to this problem [329]. In this report (3- 
galactosidase was successfully introduced into the peritoneum of rats and found to have 
penetrated every tissue of the body within 12 hours. Importantly the denatured protein was 
found to be within eells and to have been renatured. I hypothesised that catalytically inert 
PDE4B2-N-terminal peptide fused with HIV-tat would have anti-inflammatory behaviour. 
I aimed to compare RAW 264.7 cells response to such a fusion peptide with a PDE4D3 N-
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terminal HIV-tat fusion protein as this protein is likely to be less important in regulating 
LPS signal transduetion.
Unfortunately I ran out o f time to successfully isolate a fused protein but I learned a lot 
from the attempt. The various stages o f synthesis are described in the text o f chapter 6, 
however some significant lessons were learned. My main problem was the development of 
inclusion bodies consisting of recombinant proteins. This is likely to be due to the adhesive 
properties o f various molecules included in the GST fusion proteins. Firstly, the N- 
terminals o f long form PDE4 isoforms contain both U CRl and UCR2 and Beard et al 
described the physical association of these regions [69]. Although PDE4B2 N-terminal 
does not contain both o f these regions it may be that other bacterial proteins expressed 
UCR2 related proteins sufficient to cause interaction. The choice o f GST as a means of 
isolating reeombinant proteins is complicated by the tendency o f this protein to form 
oligomers. This will further encourage the formation of inclusion bodies.
In the future I would overcome these problems in a variety o f ways. Previous attempts at 
PDE4 N-terminal fusion protein synthesis have been successful using shorter sequences of 
the protein. I would try to make truncated sections of the entire PDE4B2 N-terminal 
regions in fusion with HIV-tat that would have the additional attraction that I would be 
able to pin point the source o f any inhibitory effect seen. On the other hand such a strategy 
might fail due to a lack o f appropriate tertiary protein structure. I would use different a 
isolation system. Thus rather than a GST tag I would in include a “His” tag which is 
smaller, does not form oligomers and is easily isolated by association with methionine. 
Finally I would construct a plasmid vector containing the H IV-tat sequence and His tag in 
fusion into which I could clone short sequences o f the PDE4 isoforms. In this way I could 
use smaller PGR primers increasing the integrity of the cDNA product.
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Future directions
The work presented raises several questions that should be addressed. Firstly the function, 
regulation and distribution of PDE4B4 requires to be investigated. What purpose is served 
by having three separate long form PDE4B isoforms is not clear. It may be that tissues 
express each isoform under a specific set o f circumstanees. Thus probing a variety o f 
cDNA libraries or performing northern blot analysis o f different tissues might increase our 
understanding. Identifying and investigating the regulation of the splice junction promoters 
should offer insights into how each isoform is controlled. Such studies can be done through 
promoter sequence analysis and electrophorectic mobility shift assay (EMSA). This latter 
is a functional test o f promoter activation and therefore has the additional attraction of 
being physiologically relevent. ER K l/2  phosphorylation would be expected to inhibit 
PDE4B4. I would like to confirm that this does occur and investigate the possible 
interaction of PKA phosphoiylation of S eri4 and ERKl/2 inhibition.
The U937 and U937pma cell model offers considerable scope for investigating PDE4 
regulation. As this model is verified it can be used to understand how each PDE4 isoform 
interacts in generating an inflammatory pattern of behaviour. Sufficient tissue is available 
to measure the responses o f individual isoforms to specific stimuli. Creating stable 
transfected U937 cells with o f active and dominant negative PDE4 isoforms would 
advance our understanding o f the process o f differentiation. For example it may be that if  
PDE4D isoforms are over expressed the process o f macrophage differentiation will not 
oceur. On the other hand, a RAW 264.7 cell transfected with a dominant-negative form of 
PDE4B2 may act like a rolipram treated macrophage and inflammation will be prevented.
The role of cAMP in regulating individual inflammatory mediators is complex and varies 
between cell and mediator examined. Much work is required to discover the mechanisms 
by which PDE4 regulates individual pools of cAMP that in themselves regulate specific
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cytokines. Targeting o f PDE4 requires to be better understood and discovering more 
molecular partners will illuminate this further. Yeast-2 hybrid analysis can be used to 
identify new binding partners, and understanding the expressed proteosome o f stimulated 
inflammatory cell will allow an appropriate experiment to be performed.
Molecular crosstalk holds the keys to many complex questions o f regulation of cellular 
behaviour. In particular how the M APkinase and cAMP pathways interact. I have 
highlighted various possible mechanisms that require to be illuminated. For example the 
role o f the EPA C /rapl/B -R af pathway in control o f inflammatory processes may offer 
interesting therapeutic opportunities. Using Ral-GDS to “fish” for activated rapl and using 
dominant negative EPAC mutants upstream o f inflammatory responses would shed light 
on this early field of investigation.
The development o f new molecular inhibitors o f PDE4 isoforms requires a greater 
understanding of the structure/function relationships at the N-terminals. Development of 
small peptide inhibitors sueh as HIV-tat fusion should address some o f this.
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Appendix 1 Standard curves and quantification
In chapters 3 and 5, I have used various methods to quantify proteins and chemical 
mediators o f inflammation. The solutions from which quantification was performed 
include cells lysed in KHEM buffer and cell free culture medium. Where appropriate all 
standard curves were generated using Icnown amounts of the target compound dissolved in 
the same fluid as test samples were prepared.
A ppl.l PDE4B4 quantifîcatîon
Two methods were used to quantify the relative amount o f transfected PDE4B isoforms 
when assessments o f relative activity were calculated.
App L IA  PDE4B ELISA
Firstly enzyme linked immunosorbant assay (ELISA) plates were constructed as described 
in materials and methods (section 2.4.12). Thus increasing quantities of protein from cell 
lysates prepared in KHEM were allowed to adhere to 96 well ELISA plates overnight prior 
to detection using antiserum raised against PDE4B (Schering). Antibody detection was 
carried out using HRP conjugated anti-serum raised against rabbit IgG, and visualised 
using ABTS reagent. Optical density (O.D.) of each well was counted using a multi-well 
plate reader at 405nm (Dynex technologies). Plots o f protein content against O.D. were 
constructed and the relative PDE4B isoform content of each lysate was estimated from the 
gradient of the straight line linking the plots (fig App 1.1 A).
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Figure A p p l.l  FDE4B4 relative transfection efficiency
In order to compare PDE4 activity between different transfected PDE4B 
isoforms and to compare between different treatment groups, when 
characterising PDE4B4 I used two forms o f quantitative analysis. Fig 
A pp l.l A, Enzyme linked immunosorbant assay (ELISA), was performed 
using in-house prepared ELISA plates with PDE4B anti serum (Schering). 
Increasing quantities of lysate protein was incubated in a standard ELISA 
protocol. The relative steepness o f the linear part o f the Log protein 
content/O.D. curve estimates the relative transfection efficiency. Fig 
App 1.IB, western blots were prepared for a range o f protein contents for 
each treatment group in a PKA activation analysis of PDE4B4. The 
intensity of each band was compared against a standard immunoband. Again 
the relative steepness of the gradients reflects the relative transfection 
efficiency. (O.D. Optical density; Arb Units. Arbitary density units)
249
App 1. IB  Western blot analysis
The second method used to quantify relative transfection efficiencies between different 
PDE4B transfections was western blot densitometry (section 2.4.9). SDS-PAGE was 
performed on cell lysates prepared in KHEM and a range o f protein quantities from each 
transfection was resolved on an 8% gel. Net intensity o f inimunobands visualised using 
PDE4B antiserum (Schering), HRP-conjugated anti-rabbit antiserum (Sigma UK) and ECL 
detection reagent (Amersham Pharmacia) was calculated from autoradiographs using 
KODAK I.D. software. Intensity was adjusted against a standard on each autoradiograph 
and a plot o f intensity against protein content was prepared (Fig App I.IB ). Relative 
transfection efficiency was calculated from the linear part o f each curve plotted from these 
plots.
Appl.2 TNFa quantification
Two ELISA protocols were used when quantifying the content of T N Fa from the cell free 
culture medium of RAW 264.7 cells treated with LPS with or without rolipram.
App L2A In House ELISA
ELISA plates were prepared using a standard protocol by bedding mouse TN Fa antiserum 
onto 96 well ELISA plates and incubating with sample medium and a range o f known 
TN Fa quantities dissolved in culture medium (Section 2.4.12.2), HRP-conjugated TN Fa 
secondary detection antibody was then added and finally visualisation was performed 
using ABTS solution. Optical density was measured on a Dynex micro-plate reader 
(Dynex technologies) at 405nm. A plot o f TN Fa (pg) against O.D. was prepared and 
TN Fa content of test samples was recorded from the linear part o f this standard curve.
250
.-S
S
I
0.90
0.50
0.30
0.10 
0.00  '0.10 1.0 10 100
Log 1 0  TN Fa Pg/ml
B
DI
Q
d
1.80
1.60
.40
1.20
.00
0.80
0.60
0.40
0.20
0.00
0.10 1.00 10 100 1000
Log 1 0  T N Fa Pg
Fig Appl.2 TNFa ELISA Standard Curves
To quantify the production of TN Fa by RAW 264.7 cells treated with 
LPS and various inhibitors I used two different ELISA kits. Fig 
Appl.2A, In house ELISA using commercially acquired TN Fa 
antiserum bedded onto standard 96 well ELISA plates. A standard 
non-competitive ELISA protocol was followed. Appl.2B, 
commercially acquired competitive TN Fa ELISA kit. Note in non­
competitive ELISA O.D. increases with increasing T N Fa content, 
while in a competitive protocol the reverse is true.
(O.D. Optical density, Arb Units, Arbitrary units)
251
App 1.2B Commercial competitive TN Fa ELISA
A commercial T N F a ELISA kit was also used in this study. This protocol differs from the 
in-house ELISA in being a competitive ELISA (Section 2.4.12.3). Thus pre-prepared 
ELISA plates with enbedded capture antibodies were incubated with test samples and 
standards o f known T N Fa content. Following incubation and washing, HRP-conjugated 
T N Fa was then incubated and washed off. Thus free antibody sites were occupied by HRP 
conjugate. Colour visualisation was achieved using ABTS as above. In this competitive 
ELISA a high reading at 405nm is equivalent to a low T N Fa content.
App 1.3 Prostaglandin E2 quantification
A commercial competitive assay was used to quantify the PGE2 content o f cell free culture 
medium from RAW 264.7 cells incubated with LPS with or without rolipram. This assay 
followed,a competitive protocol as described above (Section 2.4.12.4). A sample standard 
curve for this assay is presented (Fig App 1.3).
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Fig App 1.3 PGE2 ELISA Standard Curve
PGE2 content was quantified using a commercially 
acquired enzyme immunosorbant assay (EIA), (Assay 
Design Inc). This competitive assay was used to construct a 
standard curve from which to measure the PGE2 content of 
cell free culture medium from RAW 264.7 cell stimulated 
with LPS and various inhibitors.
(O.D, Optical Density. Arb Units, Arbitrary Units).
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Appendix 2 Lactate Dehydrogenase (LDH) analysis of cellular 
fractionation
A ssessm ent o f  the subcellular distribu tion o f PDE4B4 depended upon accurate 
fractionation o f the transfected cells. To confirm the integrity o f each compartment I 
measured the activity of LDH in each compartment. LDH is a cytosolic enzyme and should 
only appear to any extent in the S2 fraction. LDH catalyses the reaction;
Lactate + NADH < --------- >  Pyruvate + NAD
The course o f the reaction can be followed by measuring the decrease in absorption at 
340nm, due to oxidation o f NADH. Figure App 2.1 A describes a typical plot from such an 
experiment. The rate o f decrease in NADH absorption is proportional to the LDH activity 
and can be assessed by the gradient o f the linear part o f the curve. By comparing the 
activity o f each fraction in the absence and presence o f detergents that will lyse cells, 
allows assessment o f the integrity o f each fraction prepared in detergent free medium. 
Figure App 2 .IB, presents three such experiments and demonstrates that most activity 
appears in the S2 fraction, and that little if  any increase in LDH activity is seen when 
detergent is included (occluded). In the transfection, PDE4B4-2, significant activity is 
found in the P I fraction suggesting contamination with S2 lysate. This lysate was duly 
excluded from further analysis.
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Fig App 2.1 Lactate dehydrogenase assay to confirm cellular fractionation
Cells were lysed in KHEM buffer by passage through a fine guage needle. 
Lysates were subjected to low speed (15,000 rpm) and high speed 
(35,000rpm) centrifugation to fractionate into PI, low speed pellet; S2, high 
speed supernatant and P2 high speed pellet. To confirm the integrity o f each 
pellet the activity o f the enzyme lactate dehydrogenase (LDH) was assessed 
in each fraction. LDH is exclusively cytosolic in distribution and should 
only appear in the cytosolic (S2), fraction. LDH catalyses the reaction 
described in Fig App 2.1 A. Activity o f the enzyme can be assessed by the 
decrease in absorption o f light at 340nm resulting from the oxidation of 
NADH. This activity is proportional to the gradient o f the linear part o f the 
NADH extinguish curve (fig App 2.1 A). By comparing the activity of each 
fraction resuspended in KHEM (free) with the activity when each fraction is 
resuspended in detergent (occluded) the degree o f contamination of each 
fraction can be assessed (fig App 2.1 B). Thus in the S2 fraction if activity 
increases significantly in the occluded fraction. If there is significant 
activity in the pellet fractions it is likely that they are contaminated by S2 
fraction. In the table above PDE4B4-2 lysis shows PI contamination by S2 
fraction or uni y se d cells.
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Appendix 3 Phosphodiesterase 4 activity in induced 
sputum from normal subjects
I wished to develop an assay for measuring the PDE activity from cells isolated from 
induced sputum to compare cell type against PDE4 activity. To investigate the ability of 
the standard assay protocol to measure sputum PDE4 activity I used two different subjects 
on three different days and isolated sputum using the induction method described. Sputum 
was processed to isolate cells and these were counted. PDE4 activity was measured in 
samples of lysed cells representing the same number o f cells. I elected to use this method 
to reduce the effect o f contaminating protein from non-cellular sources.
Fig App 4, demonstrates the variability that exists within samples isolated from the same 
subject on different days. This variability has a number o f different possible explanations. 
Firstly environmental exposure to air-boume agents may influence the PDE4 activity in 
bronchial cells. Thus LPS may affect immune cells, and different quantities of LPS may be 
encountered on different days. Cellularity would not affect the data as this is controlled for, 
but the cell type may do so. It was the intention of my study to measure this aspect. FDE4 
isoforms are very sensitive to the proteolytic effect o f inflammatory proteases. Even in the 
presence o f high doses o f protease inhibitors it is likely that some degradation occurs. 
Finally the viability o f the cells was measured during the counting process, however many 
cells may be going through stages o f the apoptosis process while in the lung lumen and 
possibly during the subsequent processing. As has been described caspase 3, an essential 
apoptosis regulatory enzyme, cleaves and alters the activity o f at least one PDE4 isoform
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[232]. Thus many different factors may contribute to the intra-subject variability seen in 
induced sputum PDE4 activity.
As a result o f the degree o f variability and the requirement for involved and lengthy 
processing o f material prior to performing the PDE4 assay, I elected not to use this method 
to analyse PDE4 further. Other methods that rely less on quantitative assay, such as rcpt. 
may prove to be a better tool to measure PDE4 isoform expression in cells isolated from 
induced sputum.
Summary
While PDE4 activity could be measured in reasonable quantity in induced sputum samples, 
the quality o f the protein isolated was such that meaningful analysis was impossible at this 
stage. Other non-protein based methods may prove more useful in this tissue.
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Fig App 3: Variability in PDE4 activity from  induced sputum
Two normal subjects provided sputum samples as described. Samples 
from different days were processed, cell number counted and PDE4 
activity was measured in lysed cells. PDE4 activity is presented, 
equalised for cell number to prevent non-cellular protein 
contamination. As can be seen considerable variability exists within 
the samples from different subjects.
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